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BSA bovine serum albumin 
BTC betacellulin 
C-terminal carboxy (COOH)-terminal 
CR domain cysteine-rich domain 
DER Drosophila epidermal 
growth factor receptor 
Don-1 divergent of NRG-1 
ECD extracellular (or ecto) 
domain 
EGF epidermal growth factor 
EGFRvIII truncated ErbB-1 variant 
lacking residues 1-267 
ErbB homologue of avian 
erythroblastosis virus 
oncogene B (v-ErbB) 
ErbB-IgG fusionprotein of the ErbB 
ectodomain and the constant 
part of immunoglobulin G 
EPG epigen 
EPR epiregulin 
Erk extracellular signal 
regulated kinase 
FAK focal adhesion kinase 
Fc disulphide-linked constant 
part of immunoglobulin 
FCS foetal calf serum 
FGF fibroblast growth factor 
FRET fluorescence resonance energy 
transfer 
Gab1 Grb2-activating protein 1 
GH growth hormone 
GPCR G protein-coupled receptor 
HB-EGF heparin binding EGF-like 
growth factor 




IGF-1 insulin-like growth factor 1 
Jnk Jun N-terminal kinase 
L-domain leucine-rich domain 
MMP matrix metalloproteinase 
mab monoclonal antibody 
MAPK mitogen-activated protein 
kinase 
MGF myxoma virus growth factor 
NDF neu differentiation factor 
NMR nuclear magnetic resonance 
Nrdc N-arginine dibasic convertase 
Nrdp1 neuregulin receptor 
degradation protein 1 
NRG neuregulin 
NTAK neural- and thymus-derived 
activator for the ErbB kinase 
N-terminal amino (NH2)-terminal 
PBS phosphate-buffered saline 
PDGF platelet-derived growth factor 
PI3K phosphatidylinositol 3-OH 
kinase 
PLCγ phospholipase C γ 
PKC protein kinase C 
PTB phospho-tyrosine binding 
domain 
PTP protein tyrosine phosphatase 
RTK receptor tyrosine kinase 
SH2 src-homology domain 2 
SFGF shope fibroma virus growth 
factor 
STAT signal transducers and 
activators of transcription 
TGFα transforming growth factor α 










The fate of a given cell depends on the signals it receives from the extracellular environment, as well 
as on its unique response to those signals. Growth factors and their cellular receptors play a central 
role in the control of cell growth, survival, apoptosis, chemotaxis and differentiation during 
embryonic development, and post-natal development including that of the mammary gland. ErbB 
receptors respond to small peptide hormones such as epidermal growth factor (EGF) that are present 
in the extracellular medium. These ligands bind and activate their respective ErbB receptor by 
inducing receptor dimerisation, thereby initiating a signal transduction cascade eventually leading to a 
change in the transcription rate of target genes. ErbB receptors thus act as critical mediators that 
translate the extracellular signal across the cell membrane into a specific intracellular signal, and 
thereby determine the biological response to the growth factor. 
A loss of control over the cellular functions mediated by the ErbB network is a hallmark of 
oncogenesis, where the balance between proliferation and differentiation of cells has been disturbed. 
Several types of human cancer, including breast, colon, pancreas, ovary, brain and lung, are 
associated with deregulation of ErbB signalling. Particularly the gene amplification and 
overexpression of the ErbB members ErbB-1 and ErbB-2 have been observed frequently in breast 
cancer, and is associated with a high incidence of metastasis, poor prognosis and short patient survival 
time (1-3). In several cancer cells overexpression of these receptors is accompanied by enhanced 
ligand production due to deregulated gene expression, thus allowing autocrine stimulation (4). 
Autocrine production of EGF-like peptides contributes to cell transformation both in vitro and in vivo. 
Also mutant forms of the receptors, such as a constitutively active truncated ErbB-1 forms found in 
types of neuronal glioblastomas, may underlie neoplasias (5). The majority of this type of oncogenic 
mutant receptors interferes with the action of the normal receptor counterparts, eventually leading to 
the evolution of cells that possess a growth advantage over cells that do not carry such genetic 
alterations.  
The pivotal role of the ErbB signalling network in human cancer makes these molecules useful targets 
for therapy. At present humanised anti-ErbB-2 monoclonal antibodies (under the farmaceutical name 
Trastuzumab, or HerceptinTM) are used for treatment of breast cancer patients (6, 7). Antibodies 
directed against the normal and the truncated ErbB-1 forms are being tested in advanced clinical trials 
(reviewed in 8, 9). Moreover, distinct ATP-competitive small molecules that inhibit the tyrosine 
kinase of these receptors, such as the ErbB-1-specific 4-anilinoquinazoline derivative ErlotinibTM, and 
IressaTM (ZD1839) are currently tested in Phase III clinical trials as anti-cancer agents in patients 
suffering lung cancer (10, 11). It has also been attempted to design ErbB antagonists by the 
modification of EGF-like molecules, which are able to compete with the natural ligands for receptor 
binding, and to couple ligands to bacterial toxins to induce tumour cell-specific cytotoxicity (12-15). 
Finally, the use of EGF-related growth factors for targeted gene delivery of retroviral and phage entry 
vectors are being explored (16, 17). The design of such compounds requires detailed insight into the 
molecular mechanisms of ErbB activation and the specificity of ligand-receptor interactions.  
This chapter gives an overview of the components participating in the complex ErbB signalling 
network, and describes the processes underlying the regulation and specificity of ligand-induced 
receptor activation, with main focus on the mammalian system.  
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1 EGF-like ligands and ErbB receptors 
 
1.1.1 The EGF family of peptide growth factors  
Peptide growth factors are locally derived hormones that are involved in the regulation of 
proliferation, differentiation and survival of normal cells, but may also play a role in the pathogenesis 
of human cancer. The EGF family of peptide growth factors comprises around 15 members that all 
bind and activate members of the ErbB receptor family (18, 19). EGF-like ligands share only a limited 
amount of sequence identity, but encompass a structurally conserved domain known as the EGF 
motif, defined by three disulphide bridges. The family of mammalian EGF-like growth factors 
includes besides EGF (20) also transforming growth factor α (TGFα)(21), amphiregulin (AR)(22), 
betacellulin (BTC)(23), epiregulin (EPR)(24), heparin binding EGF-like growth factor (HB-EGF)(25) 
and epigen (EPG)(26), that all interact with the EGF receptor or ErbB-1. The neuregulin (NRG) 
subfamily of EGF-like growth factors comprises NRG-1 (27), NRG-2 (28, 29), NRG-3 (30) and 
NRG-4 (31), which can all interact with the NRG receptors ErbB-3 and/or ErbB-4.  
EGF-like growth factors are well conserved between species, and many recombinant mammalian 
ligands are also active in vertebrates such as chicken, and Xenopus laevis (frog). Also in evertebrates 
EGF-like growth factors have been described with similar characteristics as their mammalian 
homologues. In Drosophila melanogaster (fruit fly) multiple homologous EGF-like growth factors are 
found including the TGFα analogues Gurken, Keren and Spitz and the NRG analogue Vein, while in 
addition an EGF-like molecule with antagonistic activity designated Argos is present (32-35). The 
differential activities of this group of ligands have been attributed to their EGF-domains (36). Also the 
Lin-3 gene of Caenorhabditis elegans (worm) encodes an EGF-like growth factor (37). Moreover, 
various poxviruses have been shown to encode EGF-like growth factors (38). Although not essential 
for viral replication, these EGF-like growth factors appear to enhance virulence and to stimulate cell 
proliferation at the primary site of infection (39). The EGF domains of these viral growth factors, 
including vaccinia virus growth factor (VGF), Shope fibroma virus growth factor (SFGF) and 
Myxoma virus growth factor (MGF) can bind ErbB members (40). A survey of the amino acid 
sequence of the EGF domains of the various EGF-like growth factors is given in Table I. 
Most EGF-like growth factors are synthesised as heavily glycosylated transmembrane precursors, 
comprising of an extracellular region that encompasses the EGF-like domain and possible additional 
modules, a juxtamembrane region, a transmembrane segment and a cytoplasmic tail that contains 
recognition sequences for trafficking and anchoring proteins. The soluble growth factors are released 
from these precursors by proteolysis and can activate their respective receptors in an autocrine or 
paracrine manner over short distances. In addition, membrane-anchored forms of TGFα, NRG-1 and 
HB-EGF have been found to activate ErbB receptors through so-called juxtacrine interaction, 
although they appear involved in distinct signalling events (41-43). Unlike soluble HB-EGF, the 
transmembrane proHB-EGF form stimulates intercellular adhesion and regulates cell survival, and can 
serve in addition as the receptor for diphtheria toxin (42). Release of EGF-like growth factors from 
their precursors involves regulated proteolytic processing by different members of the 
metalloprotease-desintegrin (ADAM) and matrix-metalloproteinase (MMP) families. The cellular 
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expression levels of these proteases determine the release rate of the different ligands, which may 
occur constitutively or in a regulated manner (44). In particular ADAM-17/TACE is implicated in the 
cleavage of pro-HB-EGF and pro-TGFα into the mature growth factors, and it may also target other 
ErbB-1 ligand precursors during development (45-48). Furthermore, mature TGFα is released by  
 ADAM-10, while cleavage of HB-EGF is also mediated by ADAM-9, ADAM-10 and MMP-3 (46, 
49-51). Mature NRG is released by ADAM-19 activity (52). EGF is released from a large precursor 
that encompasses eight additonal EGF-repeats by a yet unidentified esterase. 
 
 
1.1.2 Expression and function of EGF-like ligands  
Mature EGF and TGFα are small peptides of 53 and 50 amino acids respectively with a molecular 
weight of ~6 kDa, encompassing only the EGF motif. EGF was initially identified in the mouse 
submaxillary gland as a peptide that induced incisor eruption and premature eyelid opening in 
newborn mice (20). In mammals EGF is generally found in saliva, urine, and in glands of the small 
intestine. EGF, but also TGFα and HB-EGF play a role in wound healing by enabling the promotion 
of angiogenesis in vivo and the migration of epithelial cells and keratinocytes in vitro (42, 53). In 
contrast to EGF, expression of TGFα has also been observed during embryogenesis. TGFα transcripts 
have been detected both in normal and a variety of tumour epithelial cells, as well as in macrophages 
and in brain. Recently it has been shown that TGFα is expressed rhythmically in the suprachiasmatic  
 
TABLE I 
Sequence alignment of the EGF domains of EGF-like growth factors 
 
       6        14    20           31 33       42 
hEGF        NSDSECPLS-HDGYCLHDGVCMYIEA---LDKYACNCVVGYIGERCQYRDLKWWELR 
mEGF      NSYPGCPSS-YDGYCLNGGVCMHIES---LDSYTCNCVIGYSGDRCQTRDLRWWELR 
hTGFα   VVSHFNDCPDS-HTQFCFH-GTCRFLVQ---EDKPACVCHSGYVGARCEHADLLA 
hAR         KKKNPCNAE-FQNFCIH-GECKYIEH---LEAVTCKCQQEYFGERCGEKSMKTHSM 
hHB-EGF   KKRDPCLRK-YKDFCIH-GECKYVKE---LRAPSCICHPGYHGERCHGLSLPVE 
hBTC       GHFSRCPFKQYKHYCIK-GRCRFVVA---EQTPSCICEKGYFGARCERVDLFYLRGD 
hEPR       VSITKCSS-DMNGYCLH-GQCIYLVD---MSQNYCRCEVGYTGVRCEHFFLTVH 
mEPG     LKFSHCLED-HNSYCIN-GACAFHHE---LKQAICRCFTGYTGQRCEHLTLTSYA 
hNRG-1α   SHLVKCAEK-EKTFCVNGGECFMVKDLSNPSRYLCKCQPGFTGARCTENYPM 
hNRG-1β   SHLVKCAEK-EKTFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVMAS 
mNRG-2α   GHARKCNET-AKSYCVNGGVCYYIEG---INQLSCKCPNGFFGDRCLEKLPLRLYMPDPKQS 
mNRG-2β   GHARKCNET-AKSYCVNGGVCYYIEG---INQLSCKCPVGYTGDRCQQFAMVNFSKHLGFEL 
mNRG-3   EHFKPCRDK-DLAYCLNDGECFVIETL-TGSHKHCRCKEGYQGVRCDQFLPKTDSILSDPTD 
mNRG-4   DHEQPCGPR-HRSFCLNGGICYVIPT---IPSPFCRCIENYTGARCEEVFLPSSSIPSESN 
VGF       DIPAIRLCGPA-GDGYCLH-GDCIHARD---IDGMYCRCSHGYTGIRCQHVVLVDY 
SFGF     IVKHVKVC-NHDYENYCLNNGTCFTIALDNVSITPFCVCRINYEGSRCQFINLVTY 
MGF      IIKRIKLC-NDDYKNYCLNNGTCFTVALNNVSLNPFCACHINYVGSRCQFINLITI 
 
 
Argos    RYLFAC-SPLTRLRCQRKQPCKLFTVRKRQEFLDEVNINSLCQCPK---GHRCPSHHTQ 
Spitz    FTPYKCPETFDAWYCLNDAHCFAVKIADLP--------VYSCECAIGFMGQRCEYKEID 
Keren   FPIFACPPTYVAWYCLNDGTCFTVKIHNEI--------LYNCECALGFMGPRCEYKEID 
Gurken     QMLPCSEAYNTSFCINGGHCFQHPMVNNTV-------FHSCLCVNDYDGFRCAYKSWN 
Vein    ASGIPC----NFDYCFHNGTCRMIPDIN----------EVYCRCPTEYFGNRCENKWPD 
Lin-3     LKEAKC-----KDYCHHNATCHVEVIFREDDRVSAV--VPSCHCPQGWEGTRCDRHYVQAF 
Conserved cysteine residues are indicated in bold face, numbering according to human EGF. Mammalian growth factors: 




nucleus, where it reversibly inhibits locomotor activity and sleep (54). Mature EPR comprises 46 
amino acids and was initially purified from conditioned media of a transformed NIH 3T3 derivative 
(24). EPR expression is observed in foetal tissues up to day seven in mouse embryos. EPR has 
bifunctional properties, such that it may either stimulate or inhibit the growth of epithelial cells in a 
concentration-dependent way. In keratinocytes it acts as an autocrine growth factor, and by 
upregulating the expression of TGFα, HB-EGF, and AR, it is part of an auto- and cross-induction 
mechanisms in the skin (55).  
All other members of the EGF-like family have extended N-terminal and C-terminal sequences 
flanking the respective EGF domains. HB-EGF, AR and BTC contain a highly hydrophilic Arg-Lys-
rich region N-terminal of their EGF-domain, through which they can tether heparan-sulfate groups 
present in the extracellular matrix on cell surfaces (23, 56). The closely related HB-EGF and AR also 
comprise two nuclear targeting signals within the heparin-binding sequence, suggesting a potential 
role in the nucleus (57). The 78-84 amino acid mature forms of HB-EGF, AR and BTC are 
glycosylated proteins, ranging from 19-32 kDa depending on the degree of glycosylation. HB-EGF 
was initially identified as a growth factor secreted by macrophages, and typically stimulates cell 
migration, chemotaxis and proliferation (25). Expression has been observed in epithelial, 
fibromuscular and other cell types in the lung, brain, heart and skeletal muscle (42). AR, or 
schwannoma-derived growth factor, can either inhibit or stimulate cell proliferation, depending on its 
concentration and the presence of other growth factors (57, 58). Besides its high expression in several 
breast and ovarian tumour cell lines, AR expression is strongly increased in breast tissue during 
puberty and pregnancy and has been shown crucial for ductal outgrowth (59, 60). Several isoforms of 
mature BTC have been detected: BTC-1α comprises 80 amino acids, BTC-1β has a 12 amino acids 
delection N-terminal of the EGF-module, and the 50 amino acids BTC-2 isoform corresponds to only 
the EGF domain (23, 56, 61). In man BTC is predominantly expressed in the pancreatic β-cells and 
small intestine, where it was found to mediate the differentiation of β-cells into insulin-secreting cells 
(23, 62). Soluble BTC is present in milk, suggesting a possible role in the growth and development of 
the neonatal gastrointestinal tract. Moreover, BTC promotes mitogenic activity in several other cells, 
including pigment epithelial cells and vascular smooth muscle cells (61). The 152 amino acid protein 
EPG was only recently identified from mouse keratinocytes as the newest member of the EGF-like 
family, and its expression appears restricted to adult testis, heart and liver (26). 
The NRG subfamily of EGF-like growth factors currently comprises four different genes. For NRG-1 
and NRG-2 many different isoforms arise as a result of extensive alternative splicing, while for NRG-
3 and NRG-4 no isoforms have been detected. Alternative names for NRG-1 are human heregulin 
(27), rat neu differentiation factor (NDF)(63, 64), glial growth factor (65), acetylcholine receptor-
inducing activity (ARIA)(66), and sensory- and motor neuron-derived factor, depending on the 
biological activity and tissue where the ligand was first recognised. NRG-2 is also known as divergent 
of NRG (Don-1) and neural- and thymus-derived activator for the ErbB kinase (NTAK)(28, 29, 67, 
68). NRGs are mosaic proteins containing an N-terminal a kringle-like domain, an immunoglobulin-
like (Ig) domain, a spacer region with glycosylation sites, an EGF-domain, and a juxtamembrane 
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region, while the precursor form contains in addition a transmembrane and a cytoplasmic region (27, 
63). Alternative splicing of at least 15 exons generates a minimum of 14 NRG-1 isoforms, in which 
the Ig-domain, kringle domain and a cytoplasmic tail may be either present or absent. Some of the 
NRG isoforms, such as NRG-1γ, are produced as secreted proteins instead of transmembrane 
precursors (69). The Ig-domain plays a role in binding to heparin-sulphate proteoglycans, which 
functions in the maintenance of sufficiently high ligand concentrations at local sites (70). In addition, 
alternative splicing results in sequence variance within the EGF-domain, juxtamembrane region, and 
cytoplasmic tail. Within the EGF-domain, the C-loop between the fifth and sixth cysteine and C-
terminal residues define the major α and β isoforms for NRG-1 and NRG-2 with only a low degree of 
sequence identity (27-29, 63).  
The 44 kDa NRG-1 was originally detected in the conditioned medium of the human breast cancer 
cell line MDA-MB-231 as agonist for ErbB-2 phosphorylation, which turned out later to result from 
heterodimerisation with ErbB-3 and ErbB-4 (27, 63). Cells that express NRG-1 include neurons and 
astrocytes, fibroblasts, keratinocytes and several mammary tumour cells. NRG-1 expression is further 
detected in skeletal muscle at the neuro-muscular junction, in breast, liver and lung. The NRG-1α 
isoforms are associated with connective tissue, while NRG-1β isoforms are associated with nervous 
tissue cells. In keratinocytes NRG-1α act as maintenance factors by eliciting epithelial morphogenesis 
and epidermal differentiation, while NRG-1β can induce strong mitogenic responses in these cells 
(71, 72). NRG-1 transcripts have specific functions in heart development, where it is expressed in the 
endocardium lining. In neuronal development NRG-1 mediates the proliferation and cell-fate of 
migrating cranial neural crest cells, maturation of astroglia, Schwann cell proliferation and survival 
and oligodendrocyte differentiation (73-75). Lately NRG-1 has been implicated as candidate gene for 
schizophrenia, possibly due to its role in the expression of transmitter receptors, including glutamate 
receptors, in the central nervous system (76). Expression of NRG-2α and 2β transcripts has been 
observed in restricted parts in the adult brain, in particular the granule and Purkinje cells in the 
cerebellum, and the dentate gyrus of the hippocampus (67). In addition, NRG-2 transcripts have been 
demonstrated in the endothelial lining of the embryonic heart, in particular the atrium (28, 29). NRG-
3, which is devoid of the Ig and kringle domains, has a highly restricted expression pattern in the 
nervous system both during development and adulthood (30). Moreover, NRG-3 expression is found 
in breast cancer cell lines (77). The most recently identified member of the NRG subfamily NRG-4 
shares little sequence homology with the other known NRGs apart from the EGF-domain (31). 
Expression of NRG-4 is limited to the adult pancreas and muscle, and unlike the other NRGs this 
particular NRG member does not appear to function in the nervous system.  
 
 
1.1.3 The EGF domain  
The structurally conserved EGF-like domain of approximately 50 amino acids is characterised by 
three disulphide-linked loops, the A-loop (C6-C20), B-loop (C14-C31) and C-loop (C33-C42), 
respectively, and flexible linear tails (numbering according to human EGF). This EGF domain is both 
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essential and sufficient to confer binding to ErbB receptors, although additional regions may further 
contribute to the receptor affinity (36, 78). The single amino acid between the fourth and fifth 
conserved cysteine located between the B- and C-loop is known as the so-called hinge residue, 
because it is believed to act as a hinge region along which the two parts of the proteins can move. In 
addition, all ligands share two conserved glycines and one arginine (Gly19, Gly40 and Arg41 in EGF) 
that are critical for tertiary structure maintenance and receptor binding (79). The linear endings of 
EGF-like ligands require a minimal length of five residues, as the C-terminal tail in EGF can be 
truncated up to residue 48 without loss of function (80). The EGF-like fold is not exclusively found in 
growth factors, but it is a common motif in multiple other proteins that lack growth factor function 
(81). For instance, the extracellular matrix protein laminin and blood coagulation factor IX and X 
contain multiple EGF-like repeats, which may have a role in mediating cell-cell contact. The EGF 
repeats found in these proteins are encoded by a single exon at the genome level, while in growth 
factors the EGF-domain is generally encoded by two exons (81).  
The three-dimensional solution structures of several EGF-like growth factors have been determined 
by nuclear magnetic resonance (NMR), including human and murine EGF (82-84), human TGFα 
(85), and the EGF-domains of human BTC (86) and NRG-1α (87, 88). Moreover, the structures of 
HB-EGF in complex with diphtheria toxin (89) and human EGF alone (90) or in complex with the 
ErbB-1 extracellular domain (91) have been determined by X-ray crystallography. The structure of 
TGFα has also recently been determined in a co-crystal with a truncated ErbB-1 receptor (92). As 
shown in figure 1, EGF-like ligands commonly comprise two anti-parallel β-sheets, a major β-sheet 
(residues 19-23 and 28-32 in EGF) in the B-loop region and a small β-sheet (residues 37-38 and 44-
45 in EGF) in the C-loop. Within the A-loop a β-turn is found which is in close proximity to the C-
loop. Maintenance of this conformation, which is stabilised by contacts between the conserved Tyr 
13, Leu15 and Arg41 residues, has been suggested as structural requirement for growth factor 
function (79). In the NRG-1α and BTC EGF-domains a short helical turn in the A-loop is observed, 
Figure 1: Ribbon presentation of the multi-dimensional NMR structures of human EGF (84), human TGFα (85), 
human BTC (86), and the EGF-domain of NRG-1α (88). PDB accession codes used were 1YUG, 1IOX and 1HAE, 
while for EGF coordinates were obtained via http://nmra.ocms.ox.ac.uk. The N-and C-terminal linear endings are 




where the other ligands lack a clear secondary structure. The most eminent differences between the 
EGF domains of the different ligands are found in the linear N-terminal region. While this region is 
completely flexible in human EGF, in both the NMR and crystal structures, it forms the third strand of 
the major β-sheet in NRG-1α and BTC. The N-terminus of TGFα is also disordered, although it has 
more structure than in the corresponding region in EGF. Truncation of the N-terminal seven residues 
of TGFα resulted in severe unfolding of the TGFα structure, indicating that the N-terminus is 
required for a proper conformation (93). The overall structure of TGFα is more pH dependent than 
that of EGF (85). In addition, the B-loop region in NRG-1 isoforms is extended by three amino acids 
in comparison with EGF, and the five residues connecting the strands of the β-sheet here form a 
irregularly structured Ω–loop (87, 88). Interestingly, the Droshophila EGF-like antagonist Argos has 
an elongated B-loop region of 20 amino acids, compared to the ten amino acid B-loop found in EGF. 
While this extended B-loop is required for Argos function, this region alone is insufficient to confer 
antagonistic activity, as indicated by insertion of Argos sequences into the B-loop region in EGF (80). 
Indeed, also sequences flanking the Argos EGF-domain at the linear C-terminal ending have been 
shown to contribute to Argos function (94). 
 
 
1.2  ErbB receptors 
 
1.2.1  ErbB family of growth factor receptors 
ErbB-1, classically known as the EGF receptor or HER-1 (for human EGF receptor), has been among 
the first recognised members of the receptor tyrosine kinase (RTK) family. These transmembrane 
receptors are characterised by the presence of a conserved tyrosine kinase domain in their intracellular 
part, which is either a single or a split kinase domain. The RTK family includes many growth factor 
receptors, whose extracellular domains are composed of diverse protein modules, including 
fibronectin-like, immunoglobulin (Ig)–like domains, leucine-rich and cysteine-rich domains (95). All 
RTKs appear to be activated through a generic oligomerisation mechanism, by which dimeric or 
tetrameric receptor complexes are formed in response to ligand binding. Oligomerisation allows the 
intrinsic kinase domain of a receptor to transphosphorylate the other receptor in the complex on 
specific tyrosine residues.  
The type I family of RTKs currently comprises four members, which includes besides ErbB-1 also 
ErbB-2 (or Neu), ErbB-3 and ErbB-4 (18, 19, 96, 97). While EGF is the prototype ligand for ErbB-1, 
ErbB-3 and ErbB-4 are commonly referred to as NRG receptors after their prototype ligand NRG. 
ErbB-2 binds none of the known ligands with high affinity, and is therefore considered as orphan, 
ligand-less receptor. ErbB receptors are highly N-glycosylated transmembrane proteins with a size 
between 160-180 kDa, with the sugar component comprising up to 30% of the molecular weight. 
ErbB proteins consist of an extracellular ligand-binding domain, a hydrophobic transmembrane region 
and an intracellular tyrosine kinase domain flanked by regulatory sequences (98). The extracellular 
domain is organised into subdomains I, II, III and IV, also referred to as L1, CR1, L2 and CR2. 
Domains I and III are structurally conserved L-type domains of approximately 190 amino acids that 
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are implicated in ligand recognition. Domains II and IV are cysteine-rich domains of ~120 amino 
acids, containing 20-22 cysteines organised in repeats of C1 and C2 modules (99). The extracellular 
domain (or ectodomain) of ErbB receptors resembles most closely (with 25% sequence identity) the 
extracellular domain of the IGF-1R, which comprises two cysteine-rich domains and one L-type 
domain (100). Notably, the ErbB receptor orthologues in Drosophila and C. elegans have an 
additional cysteine-rich subdomain V. Evolutionary analysis revealed that the different vertebrate 
ErbBs evolved from two ancestral proteins due to a gene duplication event, an ErbB-3/ErbB-4 
precursor and an ErbB-1/ErbB-2 precursor. Subsequent gene duplications generated the four ErbB 
members present in mammals (101). While C. elegans and Drosophila encode a single ErbB receptor, 
no intermediate species between evertebrates and mammals are known that express two distinct ErbB 
receptors. The sequence homology between the different ErbB members is particularly high for the 
tyrosine kinase domain (Figure 2). The extracellular domains of the ErbB proteins share less 
pronounced homology, which may be indicative for their differences in ligand specificity (101). 
ErbB-3 is exceptional in that it contains a defective kinase domain and the longest C-terminal tail 
(102). The catalytic activity of the ErbB-3 kinase is reduced by two orders of magnitude relative to 
that of ErbB-1 due to the alteration of three conserved residues in the active site of RTK (103).  
 
 
1.2.2 Structure of ErbB receptors 
The last year the three-dimensional structures of the extracellular domain of several ErbB receptors 
have been elucidated, after many earlier attempts had failed due to the high glycosylation content of 
the proteins. The 2.8 Å and 2.6 Å crystal structures of the deglycosylated soluble ectodomains of 
ErbB-1 and ErbB-3 revealed strong structural homology for the individual domains I, II and III with 
the corresponding domains of the IGF-1R α-chain (100, 104, 105). Moreover, the backbone structures 
of the individual domains are consistent with those of the corresponding domains of the ErbB-1 
 
Figure 2: Schematic representation of the four ErbB receptor tyrosine kinases. Within the extracellular region
the subdomains I, and III (also referred to as L1 and L2) and the cysteine-rich subdomains II and VI (CR1 and 
CR2) are indicated. The percentages refer to the amount of sequence homology with the corresponding




ectodomain crystallised in the ligand-occupied state at 2.6 Å (TGFα•ErbB-11-501) and 3.3 Å 
(EGF•ErbB-1) resolution, respectively (91, 92). In here, the L-type domains I and III fold into single-
stranded right-handed β-helical barrels, capped at each end by a α-helix and disulphide bond. Both 
domains comprise one large β-sheet plane flanked by two small β-sheets, with in each domain three 
loops pointing out of the barrels, which in ErbB-1 are involved in ligand binding. A comparison of the 
IGF-1R, the ligand-bound ErbB-1 and unliganded ErbB-3 structures shows differences in the relative 
orientation of domains I and III, indicating that interdomain flexibility may occur with residues 310-
314 in domain II and III figuring as hinge region (Figure 3). The cysteine-rich domains II and IV in 
ErbB receptors form β-finger modules organised into a rod-like structure similar to the laminin-γ1 
chain (99). In domain II a long β-hairpin loop is detected that extends nearly 20 Å out of the core of 
domain II, and which is specific for ErbB receptors. Within the structures of unoccupied ErbB-1 and 
ErbB-3 this loop is part of an intramolecular receptor contact with residues in the C-terminal region in 
domain IV, comprising a buried area of 810-1240 Å2 (104, 105). This domain II-IV contact 
constraints the relative orientations of the ligand-binding domains in the soluble extracellular domain, 
and thereby maintains an autoinhibitory conformation of ErbB-1 and ErbB-3 in absence of ligand. 
Note that the same extended loop within domain II serves as major dimerisation site for the inter-
receptor interactions within the liganded-ErbB-1 homodimer (91, 92). This remarkable difference in 
relative orientation of the individual subdomains suggests that the extracellular domain of ErbB-1 
undergoes a large conformational change upon ligand binding. 
Recently also the crystal structure of the ErbB-1 kinase domain has been determined at 2.6 Å 
resolution either alone or in conjunction with a specific inhibitor, a4-anilinoquinazoline (106). The 
ErbB-1 kinase domain adopts the typical bilobate fold that appears characteristic for other protein 
kinase domains (107). In the ErbB-1 kinase domain the N-terminal lobe is formed from mostly β-
Figure 3: Structures of the extracellular domains of IGF-1R, monomeric ErbB-1
1-501
, and monomeric ErbB-3 as 
determined by X-ray crystallography (92, 100, 104). The TGFα molecule present in the structure of the ErbB-1 
homodimer is not depicted. Note the differences in relative orientation of the subdomains I and III between the
structures. The arrow indicates the loop (in black) extending out of domain II that is involved in ErbB-1 
homodimerisation. The asterix points to the contacts between domain II and III that may serve as a hinge region
for rotational flexibility. Note that ErbB-3 is kept in an auto-inhibited conformation mediated by an intramolecular 
contact between loops in domains II and IV. 
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strands and a single α-helix, while the C-terminal lobe contains mainly α-helices, and the lobes are 
separated by a cleft in which ATP can bind. The current paradigm for activation of RTKs and non-
receptor tyrosine kinases is the requirement for initial phosphorylation of a tyrosine in the activation 
loop in the kinase domain. Structural comparison of unphosphorylated and phosphorylated versions of 
Src showed that the activation loop undergoes a large structural rearrangement upon phosphorylation 
of the critical tyrosine residue. In contrast to other RTKs, however, the tyrosine kinase domains of the 
ErbB receptors do not seem to depend on phosphorylation of the active-site tyrosine for full catalytic 
activity, which is reflected in the structure of the ErbB-1 kinase domain (106). The activation loop of 
ErbB-1 is found in the active conformation due to the presence of an acidic Glu848, mimicking the 
phosphorylation on the critical tyrosine in the other RTKs. The strongly conserved Asn residue, which 
is substituted for Asp834 in the kinase-defective ErbB-3 receptor, is located in the active site (103).  
 
 
1.2.3 ErbB heterodimerisation  
Activation of ErbB receptors is initiated by ligand binding, leading to the formation of both homo- 
and heterodimeric ErbB receptor complexes. Although none of the known EGF-like ligands binds 
ErbB-2 with high affinity, this receptor nevertheless has a pivotal role in ErbB signalling by serving 
as dimerisation partner to all other ErbB members, and heterodimerisation with ErbB-2 is prevalent in 
cells where multiple ErbB proteins are coexpressed (108-110). Initial evidence for the occurrence of 
heteromeric receptor interactions came from studies using dominant-negative forms of ErbB 
receptors. Coexpression of kinase-deficient mutants of ErbB-1 or ErbB-2 impaired the normal ErbB-1 
phosphorylation and signalling through the formation of inactive heteromeric complexes (111-113). 
However, a kinase-negative form of ErbB-1 was able to transphosphorylate ErbB-2 in response to 
EGF, suggesting that higher order complexes comprising more than one ErbB-2 receptor may be 
formed (114). The importance of ErbB-2 heterodimerisation in ErbB signalling was further 
emphasised by ErbB-2 retention in human breast cancer cells through endoplasmic reticulum trapping 
by single-chain antibodies. ErbB-2 retention resulted in a significant reduction of the ligand-induced 
receptor signalling, mitogenicity and cellular transformation (115-118). Downregulation of ErbB-2 in 
human breast carcinomas by anti-sense targeting resulted in diminished cell growth and stimulated 
apoptosis, while in lung adenocarcinoma cells the tumourigenity was lost (119, 120). ErbB-2 thus 
appears to augment ErbB signalling.  
In addition, biochemical evidence for functional heterodimeric interactions between ErbB proteins has 
been derived from studies using cells devoid of endogenous ErbB proteins that express defined 
combinations of ErbB receptors, by means of crosslinking, co-immunoprecipitation and 
transphosporylation analyses (31, 77, 117, 121-129). Heterodimerisation with ErbB-2 is particularly 
important for the kinase-deficient ErbB-3, since ErbB-3 homodimers are catalytically inactive. In cells 
expressing ErbB-3, NRG-induced phosphorylation is dependent on the coexpression of either ErbB-1 
or ErbB-2, where ErbB-3 serves as substrate for cross-phosphorylation by the kinase of the 
dimerisation partner (130). The ErbB-2/ErbB-3 heterodimer is the most prominent receptor complex 
activated in response to NRG-1, resulting in the phosphorylation of both receptors, and it is one of the 
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most potent ErbB signalling complexes in terms of proliferation and in vitro transformation (123, 131-
134). Heteromeric inter-receptor interactions between ErbB-1, ErbB-3 and ErbB-4 may also occur in 
absence of ErbB-2. There is controversy in the literature whether the ErbB-1 and ErbB-3 may form 
functional heterodimers under physiological conditions, where EGF can also induce ErbB-1 
homodimers. While transphosphorylation of ErbB-3 has been observed in response to either EGF, 
NRG-1β or NRG-2β in breast cancer cells that overexpress ErbB-1 and ErbB-3, no ErbB-1 
phosphorylation was observed in response to NRG-1β (135-137). Since some of these cells also have 
low endogeneous ErbB-2 levels, the ErbB-3 transphoshorylation might be attributed to the formation 
of ErbB-2/ErbB-3 complexes. In transfected cell systems devoid of endogeneous ErbB receptors no 
transphosphorylation of ErbB-3 in response to EGF could be demonstrated, while NRG-1β induced 
only a very weak ErbB-1 phosphorylation signal (117, 124). Importantly, in these cells no EGF-
induced ErbB-1/ErbB-3 complexes could be observed after chemical cross-linking, confirming the 
weak stability of this dimeric complex (138). Last but not least, unlike EGF, NRG-1β was unable to 
induce cellular transformation in cells coexpressing of ErbB-1 and ErbB-3 (134, 137). On the 
contrary, functional ErbB-1/ErbB-4 complexes seem to be apparent, since NRG-1β, NRG-2β and 
EGF can all strongly induce phosphorylation of both ErbB-1 and ErbB-4 receptors in transfected 
Ba/F3 and NIH3T3 cells (117, 134, 139). NRG-1 can induce cellular transformation in ErbB-1/ErbB-
4 coexpressing NIH3T3 cells, but not in cells transfected with ErbB-4 alone, thereby emphasising the 
synergy of ErbB-1/ErbB-4 heterodimers (134). However, heterodimers of a kinase-impaired ErbB-1 
mutant and ErbB-4 prove inactive in response to EGF, suggesting that the level of ErbB-1/ErbB-4 
heterodimerisation is only low and that ErbB-1 homodimers are favoured by EGF (129). Ligand-
induced dimerisation of ErbB-3 with ErbB-4 has not been convincingly demonstrated. NRG-1 could 
stimulate the phosphorylation of both ErbB-3 and ErbB-4 only in BaF3 cells, but NRG-1 activated 
ErbB-4 was unable to phosphorylate ErbB-3, nor induce in vitro transformation, in NIH 3T3 cells 
(117, 140).  
 
 
1.2.4 ErbB specificity of EGF-like growth factors 
Based on their receptor specificities, mammalian EGF-like ligands can be divided into three groups, 
as shown in Figure 4 (reviewed in 18, 19). Ligands that bind only ErbB-1 with high affinity include 
EGF, TGFα, AR and EPR. Some growth factors can interact with both ErbB-1 and ErbB-4, and this 
dual receptor specificity was recognised for BTC, HB-EGF and EPR (61, 122, 127, 128, 141-143). 
The distinct isoforms of NRG-1 and NRG-2 bind to ErbB-3 and ErbB-4 (27-29), whereas NRG-3 and 
NRG-4 are specific ErbB-4 agonists (30, 31). Although none of the known EGF-like ligands binds 
ErbB-2, ErbB-2 acts as preferred coreceptor and generally enhances the binding affinity of ligands 
relative to the homodimeric counterparts (131, 144, 145).  
The affinity enhancement by ErbB-2 is illustrated by HB-EGF and EPR, which can effectively bind 
and transphosphorylate heterodimers of ErbB-4 and ErbB-2, while binding to ErbB-4 ectodomains 
and 32D-expressed ErbB-4 homodimers was below detection level (127, 141, 145). However, HB-
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EGF readily induces chemotaxis but not cell growth through ErbB-4 activation in cells lacking other 
ErbB proteins, indicating that growth factor sequestering through the heparin-binding moiety may 
compensate for the low affinity interaction (143). While also preferential induction of ErbB-1/ErbB-2 
heterodimers has been observed, the affinity enhancement by ErbB-2 was less obvious for ligands 
binding to ErbB-1 than for those interacting with ErbB-3 and ErbB-4 (123, 145). AR and the viral 
growth factor VGF appear exceptional in having narrow specificity for ErbB-1, and fail to 
transactivate ErbB-2 in cells that coexpress ErbB-1 and ErbB-2 (40, 146). The affinity enhancement 
by ErbB-2 results from a decrease in the ligand dissociation rate, although the underlying mechanism 
is still unclear (147). 
EGF-like ligands seem to be able to interact with more than one receptor, albeit with large differences 
in binding affinities. For instance, EGF and BTC can activate cells expressing ErbB-2 and ErbB-3 in 
the absence of ErbB-1, although only at supraphysiological concentrations (125, 126). Likewise, EGF 
and TGFα have low proliferative activity on cells that coexpress ErbB-2 and ErbB-4 (127). Of 
particular importance is the notion that NRG isoforms differ both qualitatively and quantitatively in 
their abilities to bind and activate distinct ErbB combinations, whereby the β isoforms generally 
signal through a broader spectrum of ErbB dimers than the α isoforms. NRG-1β displays at least one 
order of magnitude higher binding affinity for ErbB-3, ErbB-4, ErbB-2/ErbB-3 and ErbB-2/ErbB-4 
complexes relative to NRG-1α, and unlike the latter, was able to transphosphorylate ErbB-3 via 
heterodimerisation with ErbB-1 (124, 139, 145). The increased affinity of NRG-1β compared to 
NRG-1α is accompanied by an increased mitogenic potency in tumourigenic cell lines of various 
origins. This difference in activity has been dedicated to the seven C-terminal residues in the EGF 


















Figure 4: The differential abilities of EGF-like growth factors to interact with distinct ErbB 
receptor combinations. The greyscale is indicative for the relative binding affinity and activity
mediated by ligands, with black representing high affinity ligands (IC50 ≤1 nM) and white low 
affinity ligands (>> 1 µM). ND, not determined. In case of the ErbB-3 homodimer only the 
binding abilities are depicted, as this dimer is defective in signal transduction (references used:




domain (148). Furthermore, both NRG-2 isoforms can bind and activate heterodimers of ErbB-2 and 
ErbB-4, but only NRG-2β induces ErbB-4 tyrosine phosphorylation and biological responses in cells 
that express only ErbB-4 (139). Although NRG-2β binds only weakly to ErbB-3, it stimulates ErbB-3 
tyrosine phosphorylation through heterodimerisation with either ErbB-2 or ErbB-1 in MDA-MB-468 
breast cancer cells (28, 137, 139, 145, 149). The receptor specificity of the other NRG ligands appears 
restricted to ErbB-4. One group reported that also NRG-3 would be able to activate ErbB- 2/ErbB-3 
heterodimers, although others did not observe NRG-3- induced signalling through other receptors 
than ErbB-4 (77, 139).  
Ligands execute their biological functions by the formation of distinct receptor combinations. The 
differential ability of ligands to form distinct ErbB receptor combinations underlies the complexity in 
signalling potential. A single growth factor can mediate diverse biological responses depending on the 
cell type and the relative expression levels of different ErbB receptors. For instance, NRG induces cell 
growth in breast cancer cells expressing normal levels of ErbB-2 (such as T47D and MCF-7), and 




1.2.5 ErbB function in development and tumour formation  
The ErbB-1 receptor is expressed in many tissues, but particularly epithelial cells strongly depend on 
this receptor for proliferation control. Knockout mice studies revealed that ErbB-1 is essential for 
epithelial development in the skin, lung, and gastro-intestinal tract (Table II)(153-155). Mice lacking 
only TGFα of the multiple ErbB-1 ligands have a rather mild phenotype, displaying skin, hair follicle 
and eye abnormalities (156, 157). In line with its function, ErbB-1 is implicated in epithelial tumour 
formation, including breast cancer and non-small cell lung carcinoma, and is associated with high 
metastatic rate, poor prognosis and short patient survival time. The correlation between ErbB-1 levels 
and neoplastic transformation in vivo is however controversial (158). While more than 40% of 
primary breast cancers express normal ErbB-1 levels, only a small fraction of those tumours with poor 
prognosis has elevated levels of ErbB-1, suggesting that additional events (such as ErbB-2 
heterodimerisation or alterations in ligand expression) may be involved in transformation (159). 
Indeed, the majority of breast carcinomas that overexpress TGFα also have increased ErbB-1 
expression, implicating a functional autocrine loop to escape hormone dependence (4). Consistent 
with the clinical studies, overexpression of ErbB-1 in presence of one of its ligands appears sufficient 
for cellular transformation of NIH 3T3 cells in vitro in soft agar growth assays (134).  
The avian erythroblastosis virus has converted the ErbB-1 receptor into one of its transforming 
oncogenes, v-ErbB, by chopping off most of the extracellular region and part of the C-terminal tail. 
Similarly, a constitutively active mutant form of ErbB-1 confers enhanced tumourigenicity to tumour 
cells through elevated proliferation and reduced apoptosis of the cells in vivo. This ErbB-1 variant, 
deltaEGFR or EGFRvIII, was found to be amplified and overexpressed in a series of human 
glioblastoma cell lines (160, 161). EGFRvIII lacks most of domains I and II in the extracellular 
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domain due to genomic deletions that eliminate exons 2-7. While this truncated receptor lacks EGF 
binding activity, its kinase is constitutively active due to homodimerisation (162). Moreover, another  
ErbB-1 mutant that contained an in-frame deletion of 83 amino acids in domain IV as a result of gene-
rearrangements, bound EGF and TGFα with high affinity and exerted enhanced kinase activity (163).. 
The ErbB-3 and ErbB-4 receptors are not only expressed in epithelial cells but also in neuronal and 
muscle cells where they exert distinct non-redundant functions. ErbB-3 is expressed primarily in 
epithelial layers of various organs, in the peripheral nervous system, and in adult brain (184, 185), 
while ErbB-4 is found at specialised locations of the adult brain (186). Both NRG receptors are 
crucial for for the development of cardiac muscle and the central nervous system, as transgenic mice 
lacking either ErbB-2, ErbB-3, ErbB-4 or NRG-1 die during midgestation as a result of heart failure 
(Table II) (166, 167, 174, 181, 182). These genetic studies further emphasise the importance of ErbB 
heterodimerisation for normal biological function, showing clear overlap in phenotypes. In myocytes 
ErbB-2 and ErbB-4 are required for the initiation of cardiac ventricular trabeculae formation in the 
developing heart and regulated by paracrine NRG stimulation (166, 174, 182). Recent work suggests 
that also HB-EGF as ligand for ErbB-2/ErbB-4 heterodimers may be involved in cardiac development 
(164, 165). The development of the cardiac cushion and valves is regulated by ErbB-3 expressed in  
the endocardial mesenchyme and the paracrine stimulation by NRG-1 present in the endothelial lining 
(167, 181). Both ErbB-3 and ErbB-4 receptors appear to play a major role in the morphogenic cell 
migration of neural crest derived cells (168, 183). In addition, NRG-1-stimulated ErbB-2/ErbB-3  




Loss-of-function mouse models for ErbB and EGF family members 
Gene Phenotype Refs 
TGFα viable growth retardation, 'waved' hair, curley whiskers, impaired eyelid opening (156, 157)
EGF viable no abnormalities (60) 
AR  viable ductal outgrowth defects in mammary gland  (60) 
TGFα/EGF/AR viable stunted mammary ductal outgrowth, impaired alveolar differentiation and lactation (60) 
HB-EGF >50% lethal 
after birth 
cardiac defects; enlarged ventricles, enlarged and malformed semilunar valves, 
hypoplastms, poorly differentiated lungs, reduced lifespan 
(164, 165)
BTC viable fertile, no overt defects (165) 
NRG-1 lethal 
E10.5 
cardiac ventricular myocyte malformation, cranial sensory ganglia defects, Schwann cell 




growth retardation, neural and epithelial defects (including skin, hair-follicle, lung and 





viable affected 'waved' hair, impaired eyelid opening, impaired lubulo-alveolar development, 




cardiac ventricular trabeculae malformation, cranial ganglia defects (both sensory and 
motor), impaired hindbrain innervation, Schwann cell defects, impaired migration of 







cardiac ventricular trabeculae malformation, cranial ganglia defects (sensory and 




viable muscle-specific: progressive defects in proprioception due to loss of muscle spindles 




cardiac cushion abnormalities, defective valve formation, generalised neural crest 
defect, lack of Schwann cell precursor, impaired migration of sympathetic cells from 







cardiac venticle trabeculae malformation, axon guidance defects (hindbrain)   (182, 183)
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sympathic nervous system (167, 168, 175). ErbB-2 and ErbB-3 are further coexpressed in skeletal 
muscle cells at the motor end plate, where neuron-derived NRG-1 controls the number of 
achetylcholine receptors at the neuro-muscular junction (176, 187-189).  
In many epithelium-derived human cancers ErbB-2 is overexpressed, and this event is associated with 
tumourigenesis as well as tumour progression. The ErbB-2 gene is amplified in 15-30% of the cases 
in early stages of breast cancer (hyperplasia and ductal carcinoma), and overexpression correlates with 
tumour size, chemoresistance and poor prognosis in lymph-node positive tumours (1, 2, 190). In 
breast cancer the overexpression of ErbB-2 but also of ErbB-1 is negatively correlated with 
expression of the estrogen receptor, and to a lesser extent also with progesteron receptor expression in 
lymph-node positive tumours (2). Herceptin, a monoclonal antibody against ErbB-2, is currently in 
use as an effective treatment for a subset of patients with advanced breast cancer, although 
cardiomyopathy was observed as an adverse side effect (6). ErbB-3 and ErbB-4 are also frequently 
expressed in human tumours, but their specific role in tumourigenesis is presently unclear (2, 191). 
Analysis of primary human breast cancers indicated that ErbB-3 expression correlates with ErbB-2 
expression (192). The lack of overexpression of NRG receptors in human cancer is in line with in 
vitro studies finding that expression of ErbB-3 or ErbB-4 alone was insufficient for NRG-1-dependent 
cell transformation of NIH3T3 cells, which was only observed when ErbB-2 was additionally present 
(132-134, 140). Overexpression of ErbB-2 induces only small colony growth of NIH3T3 cells in soft 
agar, indicating that the transforming potential of ErbB-2 relies on the formation of heterodimers with 
other ErbB members. Only very high ErbB-2 expression levels could drive cellular transformation, 
suggesting that ErbB-2 homodimer formation, if occurring at all, is density dependent (134, 193-195).  
In human primary breast tumours and normal tissue a low expression level of an alternative splice 
transcript of ErbB-2 possessing transforming activity has been observed (196). This rare ErbB-2 
mutant lacks 16 amino acids in the juxtamembrane region preceding the transmembrane domain, 
leading to ligand-independent ErbB-2 activation through heterodimer formation. Similar sporadic 
deletions in this region have been observed in Neu transgenic mice, where the mutant protein formed 
disulphide-bonded dimers that were constitutive catalytically active (197). The human and murine 
ErbB-2 splice variants differ in that the former lacks two cysteine residues, while the latter lacks one 
cysteine leaving a single unpaired cysteine to induce the dimer. 
 
 
2 ErbB signalling network 
 
2.1.1 ErbB activation and signal transduction  
The activation of ErbB receptors in response to growth factor binding involves receptor 
oligomerisation, thereby bringing the intracellular kinase domains in close proximity. This results in 
transphosphorylation of the receptors on specific tyrosine residues in the intracellular tail. While the 
ErbB kinase domains are not dependent on phosphorylation of a critical tyrosine in the activation loop 
for full kinase activity, as is the case in other RTKs, additional Src-dependent phosphorylation of 
Tyr845 in ErbB-1 has frequently been observed in breast cancer cells. This suggests that additional 
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modification may further enhance receptor function by removal of auto-inhibitory constraints (198). 
Furthermore, ligand-induced phosphorylation of tyrosines 992, 1068, and 1086 in ErbB-1 was found 
to alter the conformation of the cytoplasmic tail, suggesting that a ligand-induced conformational 
switch enables the phosphorylation of additional tyrosine residues (199). The kinetics of 
phosphorylation of ErbB proteins and second messengers are very fast, with a peak in ErbB 
phosphorylation after 15 seconds following ligand administration (200).  
Phosphorylated tyrosine residues can serve as docking sites for signalling proteins possessing 
phosphotyrosine-binding (PTB) domains or Src-homology-2 (SH2) domains, which can be either 
substrate molecules with enzymatic activity or adapter molecules (reviewed in 201).  In the case of 
ErbB receptors, signalling proteins with catalytic activity include phospholipase C γ (PLCγ), 
phosphatidylinositol 3-OH kinase (PI3-K), p21-activated kinase (Pak), the non-receptor tyrosine 
kinases Src, Chk, and focal adhesion kinase (FAK), the ubiquitin ligase Cbl, the protein tyrosine 
phosphatases Shp1 and Shp2, and the signal transducers and activators of transcription (STAT) 
proteins. Adapter molecules include growth factor receptor-binding protein 2 (Grb2) and Grb7, Shc, 
Grb2 activating proteins (Gab)-1 and 2, Nck, and Crk. Each ErbB displays a specific pattern of 
autophosphorylation sites in its C-terminal domain, and has thereby the ability to associate with a 
distinct set of intracellular signalling molecules. Besides the common ErbB signalling proteins Shc 
and Grb2, each ErbB member also has unique substrates (Figure 5). For instance, ErbB-1 contains 
specific docking sites for Cbl and PLCγ, ErbB-2 contains a recognition site for Chk and specifically 
recruits Shp2, while ErbB-3 and ErbB-4 contain Grb7 binding sites (202 and references therein, 189, 
203). Moreover, ErbB-3 contains six recognition motifs for association with the p85 subunit of PI3-K, 
and thus couples strongly to the PI3-K pathway, while ErbB-4 contains only a single p85-binding site 
(204-206). 
Figure 6 gives an overview of the different major pathways activated by two ErbB combinations, the 
ErbB-1 homodimer and the ErbB-2/ErbB-3 heterodimer. One of the most important downstream 





Figure 5: Schematic representation 
of specific tyrosine residues within 
the intracellular C-terminal region of 
ErbB receptors that are subject to 
autophosphorylation, and that  bind 
SH2-containing signalling proteins. 
Some of the tyrosines in ErbB-1 are 
phosphorylated by Src kinases 
(white boxes). The phosphorylation 
site marked with an asterix was 
found to increase the ErbB-1 kinase 




(MAPK) pathway, of which the extracellular signal-regulated kinase (Erk)-1 and -2 MAPK route is 
commonly used by all ErbBs for the regulation of cell proliferation and differentiation. The p38 
MAPK activation is elicited via NRG receptors, leading to an apoptotic response or to increased 
motility (123, 207-209). The Jun N-terminal kinase (Jnk) MAPK pathway is also coupled to NRG 
receptor activation, and involves NRG-induced growth inhibition and apoptosis in cells 
overexpressing ErbB-2 (152, 209). Transforming ErbB complexes, including EGFRvIII, appear to 
induce threshold levels of constitute tyrosine phosphorylation, and sustained, unattenuated activation 
of Erk and Jnk MAPK activities that may contribute to increased transformation and resistance to 
apoptosis (210-212). ErbB-mediated Erk-1 and Erk-2 activation occurs through several pathways, 
involving the Ras-Raf-Mek-Erk pathway, or the PLCγ-PKC-Raf pathway. The former starts with 
binding of the adaptor Shc to the activated receptor, leading to formation of the Shc-Grb2 complex 
with the nucleotide exchange factor son-of-sevenless, which subsequently activates the small GTPase 
Ras. Ras-dependent Erk activation results in the regulation of expression of the early response genes 
c-fos and c-jun. The alternative route for Erk-activation is mediated by PLCγ, and is restricted to 
ErbB-1 and ErbB-2. Active PLCγ results in an increase of the intracellular calcium levels and the 
activation of the cytosolic Ser/Thr kinase protein kinase C (PKC). PKC subsequently couples to Raf 
and Erk in a Ras-independent manner.  
Another important cellular signalling route targeted by ErbB proteins is the PI3-K pathway, which is 
involved in the activation of cell-survival pathways, cell-cycle entry, cell migration and cytoskeleton 
rearrangement (143, 204). This pathway involves the activation of protein kinase B/Akt, the 
downstream ribosomal p70S6 kinase, the small GTPase Rac, and the inactivation of BAD protein. 
Docking of the p85 regulatory subunit of PI3-K to the receptor is necessary for recruitment and 
activation of the p110 catalytic subunit, which stimulates the accumulation of phospho-lipid products. 
These lipid products then engage Akt and translocate it to the plasma membrane. While ErbB-3 and 
ErbB-4 can directly associate with the p85 subunit, ErbB-1 couples only indirectly to the PI3-K 
pathway through the adapter proteins Grb2 and Cbl (213, 214). Upon EGF stimulation, Grb2 recruits 
the adapter Gab1/Gab2, which provides a platform for Shp2 and p85 association in a multi-protein 
complex (214-219). EGF-stimulated Erk controls the activity of Shp2, which negatively regulates 
PI3-K activation by dephosphorylating the p85 binding sites on Gab1, thereby terminating the Gab1-
PI3-K positive feedback loop. This Shp2-mediated control of the kinetics and magnitude of PI3-K 
signalling appears specific for ErbB-1 (220, 221).  
 
 
2.1.2 Inactivation of ErbB signalling  
ErbB signalling requires regulated spatio-temporal activation as well as downregulation of ErbB 
receptors and down-stream signalling events. Inactivation of ErbB signalling is basically achieved 
through three mechanisms: i) regulation of ErbB receptor activity through threonine phosphorylation, 
ii) receptor internalisation and degradation through the lysosomal and proteasomal pathways, and iii) 
dephoshorylation by specific protein-tyrosine phospatase (PTP) activity. In the first place, 
juxtamembrane phosphorylation of receptor protein kinases has been implicated in the regulation of 
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kinase activity. Reduced ErbB-1 and ErbB-2 tyrosine kinase activity is induced by threonine and 
serine phosphorylation in the juxtamembrane region (Thr654 and Ser1046/7 of ErbB-1) in both a 
PKC-dependent and independent manner (222-225). Activation of the PLCγ-PKC route by ErbB-1 
and ErbB-2 may thus result in subsequent receptor inactivation through a negative feedback loop. 
Threonine phosphorylation can rescue internalised ErbB-1 receptors from degradation and diverts 
them to the recycling pathway (226). Moreover, PKC was found to regulate NRG signalling through 
the ErbB-4 receptor in a negative manner by the activation of a selective proteolytic mechanism, 
involving the release of the ectodomain by cleavage of the juxtamembrane region. This ectodomain 
cleavage has been observed only for ErbB-4 receptors, although juxtamembrane-isoforms of ErbB-4 
have been isolated that are insensitive to proteolytic processing (227, 228). In addition, disruption of a 
dileucine motif in the juxtamembrane region of ErbB-1 causes internalised receptors to enter the 
recycling pathway, suggesting that this motif is a recognition sequence for components involved in 
selective sorting to early endosomal compartments (229, 230). 
In the second place, ErbB-1 receptors are rapidly concentrated as clusters in clathrin-coated pits upon 
EGF binding, followed by internalisation into early endosomes and subsequent recycling or 
degradation of the receptor complexes. The receptor-loaded early endosomes mature into late 
endosomes, multivesicular body, and lysosomal compartments. It has been proposed that during this 
internalisation process ErbB-1 signalling is prolonged in the endosomes until the ligand dissociates 
due to progressive acidification of the endocytotic vesicles (231, 232). All ErbB proteins other than 
ErbB-1 have been shown to be internalisation impaired (233, 234). The internalisation process is 
controlled by prior ubiquitination of the receptors, and in case of ErbB-1, interaction with Cbl at the 
plasma membrane is essential (235-237). Cbl is a multi-domain adapter protein containing a RING-
finger domain with E3 ubiquitin ligase activity, which upon activation promotes the recruitment of the 
E2 enzyme UbcH7 and transfers ubiquitin molecules to the substrate receptor (235). The recognition 
site for Cbl association appears unique for ErbB-1 and involves phosphorylation on Tyr1045, 
although Cbl may also be recruited via interaction with the Grb2 adapter (238, 239). It has recently 
been shown that Tyr1112 of ErbB-2 could also act as a poor Cbl docking site, thereby mediating the 
lysosomal degradation of ErbB-2 complexes in response to Herceptin (239). This suggests that Cbl is 
able to bind ErbB-2 under some circumstances. In addition, the protein Chip, which interacts with the 
ErbB-2 chaperones Hsp70 and Hsp90, displays E3 ubiquitin ligase activity through its U-box domain. 
It has been reported that Chip can induce the ubiquitination of ErbB-2 in vitro and mediate ErbB-2 
downregulation most likely through proteasomal degradation (240). Furthermore, a recenty identified 
protein involved in the localisation and sorting of ErbB-3 and ErbB-4 has been implicated in the 
downregulation of the NRG receptors. This so-called NRG receptor degradation protein-1 (Nrdp) is a 
tripartite protein comprising an atypical RING finger, B-box and coiled-coil domain (241). Similar to 
Cbl, its RING-finger domain has E3 ubiquitin ligase activity. Indeed, Nrdp1 has been shown to 
mediate the ubiquitination of ErbB-3 (and possibly also ErbB-4) in the presence of UbcH5 and the 
subsequent delivery to intracellular compartments for proteosomal degradation (242). The differential 
targeting to proteasomes and lysosomes could possibly explain the relatively low rate of 
internalisation and degradation of these receptors.  
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Finally, the phosphotyrosine levels of ErbB receptors and signalling components are regulated by the 
antagonistic activity of protein tyrosine phosphatases. The phosphatases Shp1 (PTP-1C) and Shp2 
(PTP-1D, SHPTP2, SHPTP3, Syp) contain two SH2 domains in tandem through which they can 
associate both directly and indirectly with ErbB receptors and regulate down-stream signalling (243, 
244). Particularly Shp2 can regulate the kinetics and magnitude of ErbB signalling in a receptor-
specific manner, by integrating the Ras-Erk and PI3K signalling pathways (220, 221, 245). Shp2 
associates with the transmembrane protein Sirpα, which can negatively modulate the ErbB-1-
mediated PI3K pathway (151, 246). ErbB-1 also interacts with the dual-specificity protein 
phosphatase Cdc25A, which plays a critical role in cell cycle progression using cyclin-dependent 
kinases as substrates, with the receptor RPTPσ, and with a TC-PTP splice variant (247-249). ErbB-1 
itself is targeted for dephosphorylation by the cytosolic PTP-1B, which lacks SH2 or PTB domains. 
Recently it has been established that PTP-1B resides on the cytoplasmic surface of the endoplasmatic 
reticulum, where it dephosphorylates the internalised ErbB-1 prior to degradation in the lysosomal 
compartment (250). The interaction of PTP-1C with ErbB-1 occurs similarly at perinuclear structures, 
and is mediated through phosphorylation of Tyr1147 (251, 252). It thus appears that ErbB activation 
and inactivation are spatially and temporally partitioned within the cell.  
 
 
2.2 Signalling diversity by the ErbB network 
 
EGF-like growth factors elicit pleiotropic effects in cultured cells, varying from cell proliferation to 
survival, growth-inhibition, differentiation, cell motility and chemotaxis. This large variety of 
biological signals is generated through a combinatorial network of signal transduction, in which 
different growth factors are capable of stabilising distinct homo- and heterodimeric ErbB receptors, 
each coupled to a specific set of cytoplasmic signalling proteins (Figure 6). Because each receptor is 
unique in terms of catalytic activity, cellular routing and transmodulation, the resulting network 
allows not only an enormous potential for signal diversification, but also for fine-tuning and stringent 
control of cellular functions. Several levels of regulation for achieving diversity in ErbB signalling 
can be distinghuished. 
At first, the ligand preferences determine which receptor combination may become activated in cells 
coexpressing different ErbB proteins (see section 1.24). The interaction of a ligand with different 
ErbB homo- and heterodimers offers the possibility of a broader signalling diversity, as 
heterodimerisation leads to an increase in the repertoire of signalling proteins recruited by the receptor 
complex (110, 253). Moreover, the dimerisation partner receptor directly influences the tyrosine 
phosphorylation site usage within an ErbB receptor (254). Ligands thus specify the cellular response 
by selectively dictating which pair of receptors becomes activated in cell types with multiple ErbB 
members coexpressed (19). In MDA-MB-361 human breast cancer cells EGF acts through ErbB-
1/ErbB-2 heterodimers, while NRG-1β specifically activates ErbB-2/ErbB-3 dimers, thereby 
generating partly overlapping and differential gene expression patterns (255). Differential signalling 
patterns between ErbB-1 homodimers and heteromeric ErbB-1/ErbB-2 complexes were observed after 
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controlled dimerisation by the use of bivalent synthetic ligands (253). As an exemple, homodimers of 
ErbB-1 but not heterodimers with ErbB-2 couple to the STAT pathway (129). Thus, inter-receptor 
interactions can diversify, modify or amplify signalling pathways. Rather than recruiting new 
signalling components, ErbB-2 may serve such an signal diversification function.   
In the second place, signal transduction by a given ErbB dimer does not appear to be generic, since 
individual receptors seem to be able to distinguish between different ligands, a feature referred to as 
ligand discrimination. In case of ErbB-4 homodimers this gives rise to differential use of 
phosphorylation sites, and coupling to different signalling cascades and gene expression patterns (255, 
256). Similarly, in mammary carcinomas differences in ErbB-2 and ErbB-4 phosphorylation patterns 
have been observed, depending on association with steroid receptors (257). The ligand-dependent 
differential use of signalling pathways through ErbB-2 and ErbB-3 receptors was also observed in 
MDA-MB-453 human breast cancer cells, where NRG-1β but not NRG-2β induced differentiation. In 
this cell line NRG-1β and NRG-2β induced similar extents of ErbB-2 and ErbB-3 phosphorylation, 
regulated partially overlapping but distinct sets of genes, but in contrast to NRG-2β, NRG-1β 
stimulated prolonged signalling of all pathways (137, 255). It has been proposed that a different 
 
Figure 6: Schematic representation of the ErbB signalling network. For simplicity only the signal transduction routes
mediated by the ErbB-1 homodimer and the ErbB-2/ErbB-3 heterodimer are depicted. The ErbB specificity of the 
ligands is indicated between brackets, where 1 stands for ErbB-1, 2 for ErbB-2, etc. In here the ErbB network 
comprises an input-layer (A, ligand-receptor interactions), a signal-processing layer (B, signalling and transcription 
initiation), and an output layer (C, ultimate biological response)(Figure adapted from ref.8).  
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conformation of the receptor dimer may underlie the ligand-dependent qualitative differences in 
receptor phosphorylation. 
In the third place, differences in the kinetics of ligand-receptor binding were found to play an 
important role in the induction of signalling and mitogenesis. Several chimeras between EGF and 
TGFα with superagonistic activity on ErbB-1 expressing cells show increased dynamic association 
and dissociation rate constants, correlating with an increased potency in inducing Erk phosphorylation 
(258). The ligand capture and release may thus be an important specific parameter for determining the 
mitogenic activity of ligands (259, 260). Similarly, low affinity ligands have been identified which 
nevertheless induce strong activation of signalling pathways and biological responses, showing 
uncoupling of binding and mitogenic parameters. The synthetic EGF domain of the poxvirus-encoded 
SFGF induced sustained Erk and Jnk activation and strong proliferative activity, despite its moderate 
to low affinity for cells expressing ErbB-2 and ErbB-3 (40).  
Furthermore, ligands were found to differently influence the routing of the receptor after ligand-
induced internalisation, inducing either recycling or degradation of the ErbB proteins and thereby 
affecting the signalling strength and duration (138, 261). During the internalisation process the 
signalling is prolonged until the ligand dissociates and the kinase of the receptor becomes inactivated. 
In case of ErbB-1, the pH stability of the ligand-receptor complex in the acidic early endosomes 
determines whether the internalised receptor is directed into the degradation pathway, as is seen with 
EGF, or is recycled back to the cell membrane through a default pathway, as in case of TGFα (138, 
233). The differential pH sensitivity of these two ligands thus accounts for the different signal 
strength induced. The rate of receptor internalisation also controls ligand depletion and thereby the 
strength of the mitogenic response (van de Poll, unpublished observations). In addition, 
heterodimerisation of ErbB-1 with ErbB-2 or ErbB-3 affects the time frame of signalling due to 
altered receptor downregulation. ErbB-2 heterodimerisation antagonises the association with Cbl to 
ErbB-1 and increases the amount of ErbB-1 recycling, and thereby rescues ErbB-1 from lysosomal 
degradation (138, 262, 263).  
Finally, the selective ectodomain shedding of ErbB members appears to add another function to ErbB 
signalling. After binding its ligand or activation of PKC by the phorbol ester TPA, the ErbB-4-
ectodomain is cleaved off by a metalloprotease (227). Subsequent cleavage by γ-secretase releases the 
ErbB-4 intracellular domain from the membrane and facilitates its translocation to the nucleus, which 
may be involved in the growth inhibitory action by NRG-1. Similarly, a nuclear localisation of ErbB-
1 and ErbB-3 fragments has been reported in mammary epithelial cells (264, 265). Moreover, several 
alternative splice variants of ErbB receptors proximal to the transmembrane region give rise to 
secreted forms, which can act as dominant-negative receptor. Herstatin, a soluble ErbB-2 fragment 
comprising residues 1-340 in combination with a newly encoded tail of 81 residues, has an inhibitory 
activity by dimerisation with ErbB-1 or full-length ErbB-2 (266). The herstatin mRNA was expressed 
in normal human fetal kidney and liver, but was present at reduced levels relative to full-length ErbB-
2 in carcinoma cells that contained genomic ErbB-2 amplifications. Herstatin interferes with ErbB-2 
function by disruption of heterodimer formation with ErbB-1 and ErbB-3, reduces ErbB-2 tyrosine 
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2.3 ErbB localisation  
 
Recent studies have emphasised the importance of the localisation of ErbB receptors to specific lipid 
microdomains in the plasma membrane during endocytosis and cell signalling (reviewed in 268). 
Lipid rafts are small membrane domains enriched in cholesterol and sphingolipids that have a low 
buoyant density and decreased fluidity compared to the rest of the membrane environment. Caveolae 
are a subset of lipid rafts, which show v-shaped invaginations of the membrane that are coated with 
the protein caveolin. The general idea is that the lipid environment in rafts organises higher order 
associations between membrane proteins. In case of ErbB-1, localisation to caveolar and non-caveolar 
lipid rafts appears to be related to the receptor density. In quiescent cells with low ErbB-1 expression 
levels, around 40% of the total ErbB-1 membrane fraction is present within lipid rafts, with only 5-7% 
colocalising with caveolin-1, as determined by electron density microscopy and detergent-free 
fractionation combined with co-immunoprecipitation studies (269, 270). In nonstimulated A431 cells, 
that have very high ErbB-1 expression levels, the majority of ErbB-1 was randomly distributed over 
the plasma membrane in low buoyant density domains (271). In both cell types ErbB-1 receptors 
migrate out of the lipid compartment into clathrin-coated areas upon EGF stimulation, indicating that 
lipid rafts may serve as reservoir for receptors while preventing autoactivation (269-272). The 
importance of relocation to non-caveolar regions for signalling was reinforced by the observation that 
cholesterol depletion of membranes increased the amount of EGF binding, the number of available 
ErbB-1 receptors, ErbB-1 dimerisation and phosphorylation, while ErbB-1 internalisation was 
impaired (270, 273, 274). Thus, localisation to non-caveolar lipid rafts partially suppresses the 
binding and kinase functions of ErbB-1 by sequestering a fraction of the receptors in a state 
inaccessible for ligand binding. Interestingly, in caveolin-negative LNCaP prostate cancer cells, 
cholesterol-rich lipid rafts mediate both EGF-induced and constitutive ErbB-1 signalling, suggesting 
that these microdomains do not inhibit ErbB activation but instead form specialised signal transducing 
platforms. In line with such a function, cholesterol depletion in these cells abolished ErbB signalling 
and Akt-mediated cell survival (275). 
In case of ErbB-2, localisation to lipid rafts strongly determines its ability to form heterodimers, as 
revealed by quantitative fluorescent microscopy studies. In MDA-MB-453 and SKBR-3 breast cancer 
cells around 75% of the membrane ErbB-2 receptors are clustered in non-caveolar lipid rafts, and this 
lipid environment may prevent ErbB-2 autoactivation in aggregates (276, 277). Disruption of lipid 
rafts by crosslinking with cholera toxin interfered with the formation of ErbB-2/ErbB-3 heterodimers, 
and ErbB-2 aggregates were not observed outside rafts at sites of local ErbB-3 density. Remarkably, 
the formation of heterodimers between ErbB-2 and ErbB-1 were not dependent on intact lipid rafts in 
these cells (277).  
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The proper localisation of ErbB receptors to specific lipid microdomains is an important factor in the 
efficiency and specificity of signalling (reviewed in 278). The C-terminal region of ErbB receptors 
can interact with certain PDZ domain-containing proteins that are involved in the localisation, 
trafficking and anchoring to specific membrane subdomains, for instance the neuromuscular junction. 
In here, ErbB-4 associates with Psd-95-family members, including Psd-95, Sap-97, and Sap-102, 
whereas ErbB-2 interacts with Erbin and Pick-1 (279). Erbin mediates the initial localisation of ErbB-
2 to the basolateral membrane, and is phosphorylated and released upon ErbB-2 activation (280, 281). 
Psd-95 may facilitate the dimerisation of ErbB-4 and serves as a scaffold for several ion channels and 
signalling molecules at the post-synaptic density of neurons (279, 282). Most likely also other PDZ-
domain containing proteins will be involved in the localisation of ErbB-1 and ErbB-3, although the 
latter receptor lacks a clear PDZ-recognition sequence. In addition, PDZ-domain containing proteins 
may also target growth factor precursors, since the cytoplasmic portion of the TGFα transmembrane 
precursor also encodes recognition sequences for PDZ-modules (283). Furthermore, the cytoplasmic 
tail of membrane-bound HB-EGF has been shown to interact with the co-chaperone protein Bag-1 
through its ubiquitin homology domain (264). The multifunctional Bag-1 also associates with the anti-
apoptotic protein Bcl-2 and has a known function as prosurvival factor. The TGFα and HB-EGF 
transmembrane precursors were found to associate with Drap-27, a tetraspan membrane protein 
involved in cell adhesion and migration homologous to CD9. These molecules colocalise with ErbB-1 
and integrin α3β1 at cell-cell contact sites near adherence junctions. In case of TGFα, the interaction 
with CD9 was mediated through its extracellular domain, and protected the precursor from proteolytic 
processing to release the mature growth factor (284). Furthermore, HB-EGF interacts with the 
metalloendopeptidase ‘N-arginine dibasic convertase’ (Nrdc), which was found to enhance the HB-
EGF-induced cell migration via ErbB-1 (285). Interestingly, NRG precursors localised to lipid rafts 
may play a role in neuregulin signaling within the nervous system. In rat brain synaptosomes around 
45% of the membrane-anchored NRG-1 isoforms have been localised to lipid raft fractions enriched 
in Psd-95 proteins (286). 
Some of the colocalising proteins are able to modulate the signalling potential by either potentiating 
or suppressing the response of ErbB receptors to growth factors. Several cell surface glycoproteins 
have been found to interact directly with the extracellular domains of ErbB receptors, such as the 
small leucine-rich repeat proteoglycan decorin. Decorin was found to directly interact with ErbB-1 
and ErbB-4, and suppressed ErbB-1-mediated proliferation by inducing sustained ErbB-1 
downregulation (287, 288). Decorin can compete with EGF for binding to domain III of ErbB-1 
(289). Similarly, in Drosophila the leucine-rich-repeat protein kekkon-1 was also found to negatively 
regulate DER activity (290). The murine kekkon homologue, Lig-1, was predominantly found in brain 
and skin and contains 15 leucine-rich-repeats and three Ig domains. A role for LIG-1 as negative 
regulator in ErbB-1-mediated proliferation was suggested by the results of the LIG-1 null mice, which 
display severe skin hyperplastic lesions (291). Furthermore, the tetraspan membrane protein CD82, 
originally identified as a metastasis suppressor, was shown to interact with ErbB-1 and to accelerate 
its internalisation rate (292). In Schwann cells the adhesion molecule CD44 was found to enhance 
ErbB-2/ErbB-3 signalling by facilitating receptor heterodimerisation (293). In the rat mammary gland 
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ErbB-2 activity was potentiated by constitutive association with the transmembrane glycoprotein 
Asgp2, a subunit of a sialomucin located at apical membranes. Coexpression studies revealed that the 
interaction with ErbB-2 is mediated by one of the two EGF-like domains in Asgp2. Similarly as 
observed for CD44, Asgp2 appears to facilitate the heterodimerisation of ErbB-2 and ErbB-3 (294). 
Furthermore, the ubiquituously expressed Ebp1 protein binds the ErbB-3 receptor in a PKC-
dependent manner, inhibits proliferation and induces differentiation of ErbB-2/ErbB-3-expressing 
human breast carcinoma cell lines (295, 296). Upon NRG-1 treatment Ebp-1 dissociates from ErbB-3 




2.4 Receptor cross-talk  
 
Besides activation by EGF-like growth factors, emerging evidence has been obtained that various 
other extracellular stimuli can activate ErbB-1 receptors, thereby adding another level of complexity 
to ErbB signalling. These stimuli are diverse and include agonists for G protein-coupled receptors 
(including bradykinin, bombesin, thrombin, lysophosphatidic acid, endothelin and angiotensin II), for 
cytokine receptors (prolactin, growth hormone, IL-8, tumour necrosis factor), for other RTK (PDGF, 
IGF-1 and hepatocyte growth factor), for adhesion receptors (integrins), membrane-depolarising 
agents (KCl) and environmental stress factors such as UV and gamma irradiation, oxidative agents, 
heat-shock, osmotic shock, and heavy metal ions (reviewed in 298-300). This communication 
between unrelated transmembrane receptors has been termed receptor cross-talk or transactivation. 
The widely expressed ErbB-1 thus appears a critical integrator of multiple cytokine and growth factor 
receptor pathways. Transactivation of PDGF receptors has also frequently been reported, indicating 
that this feature is not unique for ErbB-1. Moreover, also other ErbB members may play a role in 
receptor cross-talk, since the cytokines tumour necrosis factor α and IL-6 have also been shown to 
induce the tyrosine phosphorylation of ErbB-2 and ErbB-3 receptors and activation of PI3K in 
prostate cells with a concomitant reduction in insulin signaling (301, 302).  
The precise mechanism underlying receptor-crosstalk may differ between cell types. Upon G protein-
coupled receptor (GPCR) activation an intracellular response is induced involving PLCγ, Ca2+, the 
intracellular Src kinase and Pyk2-related adhesion focal kinase (303-306). This signalling was 
initially suggested to affect the activity of the ErbB-1 kinase domain directly, but recent work 
indicated that it may be involved in the activation of specific metalloproteinases of the ADAM family, 
following an “outside-inside-outside” mechanism. In this case, activation of GPCR stimulates a 
protease activity that mediates the release of diffusable HB-EGF from its precursor, resulting in 
ligand-induced ErbB-1 activation (298, 307). In this respect GPCR activation was found to enhance 
the association of ADAM-10 and HB-EGF with tetraspanin CD9 prior to HB-EGF ectodomain 
shedding (51). Besides shedding of HB-EGF from its transmembrane precursor, also TGFα and AR 
may be targeted for proteolytic release as a result of ionising radiation receptor crosstalk (308). 
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Oxidative stress induced sustained transactivation of ErbB-1 receptors because these receptors fail to 
undergo Cbl-mediated down-regulation (309).   
 
 
3 Receptor-ligand interaction 
 
3.1 Ligand binding to ErbB receptors  
 
Kinetic and calorimetric analyses of the interaction of EGF with the soluble extracellular domain of 
ErbB-1 cannot adequately be described by a simple 1:1 Langmuirian interaction, but show two 
distinct binding phases (310-312). Moreover, Scatchard analysis on EGF binding to whole cells and 
membrane preparations have indicated the presence of a small number of high affinity ErbB-1 
receptors (10-15%, Kd 10-20 pM) and a large number of low affinity receptors (Kd 1-10 nM) (312, 
313). Importantly, the high affinity class of receptors has been implicated in EGF-induced signal 
transduction and mitogenesis in vitro and in vivo (314, 315). Non-linear Scatchard plots are indicative 
of ligand binding to more than one class of receptor binding sites, including multiple binding sites on 
a single receptor, multiple receptor populations or cooperative ligand binding. It has been proposed 
that ErbB receptors exist in a reversible equilibrium between monomeric and dimeric forms, and that 
ligand binding shifts the equilibrium from the monomeric to dimeric species, which represents the 
active form of the receptor (311, 313, 316, 317). Indeed, upon addition of EGF to monomeric ErbB-1, 
this receptor dimerises and activates in a reaction that has all the characteristics of a rapidly 
equilibrating system (318). Evidence for this model is further provided by chemical or disulphide 
cross-linking of ErbB-1, showing that EGF binding enforces dimers with higher affinity in 
comparison to the monomeric receptors due to a reduced ligand dissociation rate (310, 316). 
Alternatively, multiple ErbB-1 receptor classes may be the result of conformational heterogeneity of 
the ErbB-1 receptor. Indeed, Greenfield and coworkers used circular dichroism and spectroscopic 
analysis to show the occurrence of conformation changes in the ErbB-1 receptor ectodomain upon 
EGF binding (319). The crystal structure of the ligand-occupied ErbB-1 extracellular domain is in 
good agreement with both models. This complex reveals a receptor-mediated ErbB-1 homodimer, in 
which the relative orientation of the subdomains deviates consistently from those in the monomeric 
ErbB-3 and the homologous IGF-1R ectodomain (91, 92, 100, 104)(Figure 7A). Moreover, the high 
versus low affinity ligand binding sites of ErbB-1 receptors are also affected by cellular factors, 
presumably by influencing the availability of the receptors for dimerisation (see section 2.3). For 
instance, the high-affinity class of ErbB-1 receptors was implicated with cytoskeleton association in 
A431 cells (320, 321). While ErbB-1 was found to directly bind actin, disruption of actin binding did 
not affect the affinity of interaction, suggesting that other cell specific proteins may be involved 
(322).  
Cells expressing only ErbB-3 or ErbB-4 display a single class of NRG-1 binding sites with a Kd of 1-
10 nM (27, 123, 131, 132, 323). On the contrary, biphasic Scatchard plots were observed for NRG-1 
binding to cells coexpressing ErbB-3 and ErbB-2, with similar binding affinities as on heteromeric 
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ErbB2/3-IgG fusionproteins, which exist as sulphide-linked dimers (Kd 6.5 nM and 0.13 nM, 
respectively)(27, 131, 324). The affinity for ErbB-3 was not affected by ErbB-2 in case soluble 
monomeric ectodomains were used (325). Similarly, both low and high affinity binding of NRG-1β 
was observed for heterodimeric ErbB-2/4-IgG fusionproteins (4.3 nM and 0.025 nM, respectively) 
(324). NRG-1 binding to ErbB-2 expressed on cells or to homodimeric ErbB-2-IgG fusionproteins 
was not detected (131, 324). In cells that co-express ErbB-1 and ErbB-2, a class of high affinity 
binding sites have been revealed that was susceptible to anti-ErbB-2-mediated inhibition (144). While 
in other studies the affinity enhancement of ErbB-1 by ErbB-2 was less evident (123), real-time 
measurements on 32D cells expressing ErbB-1 with gradual increased ErbB-2 levels demonstrated a 
shift of receptors from the low towards the high affinity class, implying that ErbB-2 increases the total 
numbers of presumably dimeric high affinity binding sites (260). Thus, heteromeric complexes with 
ErbB-2 exert 200-700 fold higher apparent binding affinities in comparison to the corresponding 
homodimers. 
Compared to full length receptors, soluble ErbB receptor ectodomains displayed 20-50 fold lower 
binding affinities with Kd values of 100-500 nM (312, 326). However, the additional presence of the 
transmembrane region restores the affinity of soluble ErbB-1 to that of the full-length receptors (327). 
A truncated ErbB-1 form comprising residues 1-501 binds EGF with an increased affinity of 13-21 
nM, suggesting that the cysteine-rich domain IV might contain autoinhibitory sequences for ligand 
binding (328). In agreement with this observation, a naturally occuring ErbB-3 isoform lacking 
subdomain IV competes with cell-bound ErbB-2/ErbB-3 heterodimers for NRG-1β binding (329). 
These findings led Tanner and Kyte to propose that the unoccupied extracellular domain of native 
ErbB-1 may sterically inhibit its dimerisation, which is only relieved upon ligand binding (327). Such 
an apparent autoinhibitory role for domain IV in ligand binding has also been suggested by the crystal 
structure of the ErbB-3 ectodomain, in which an intra-molecular contact between the cysteine-rich 
domains II and IV was observed (104).  
 
 
3.2 Determinants of receptor-ligand interaction 
 
3.2.1 ErbB determinants  
Early studies using chimeras between the ErbB-1 receptors of chicken and human origin revealed the 
importance of domain III as major, and domain I as minor determinant for EGF and TGFα binding 
(330, 331). The importance of both domains in ErbB-1 binding was further established by the 
observation that Arg45 in an EGF derivative could be cross-linked to Lys465 within domain III, while 
the N-terminal aminogroup of EGF could be cross-linked to Tyr101 in domain I (332, 333). Another 
group detected radiolabelled mEGF and rTGFα cross-linked to residues Phe321 to Glu367 in a 
truncated ErbB-1 (334). Chimeras between human ErbB-1 and ErbB-4 receptors have indicated that 
ErbB-4 receptors containing the ErbB-1 domains I-III could bind EGF, but not if only domains I and 
II were substituted  (335). An ErbB-1 receptor in which domain I was substituted for ErbB-4 bound 
EGF albeit with reduced affinity, indicating that domain I of ErbB-4 does not contain large negative 
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constraints for EGF binding. Interestingly, NRG-1 could compete with EGF for binding to this 
chimeric receptor, and both ligands were equal inducers of receptor phosphorylation, indicating that 
domain I of ErbB-4 confers specificity to NRG binding. It also suggests that the individual domains I 
and III are capable to bind one ligand molecule by itself. Indeed, a proteolytically derived ErbB-1302-
503 fragment comprising domain III bound a single EGF or TGFα molecule with an affinity of 0.44-1 
µM (311, 336), while an ErbB-3 I-II fragment encompassing residues 20-329 could bind NRG-1 with a 
Kd value of 68 nM (337). NRG-1 binding to the ErbB-3 ectodomain prevented proteolytic cleavage at 
Tyr50 within domain I, suggesting this residue is located in proximity of the ligand binding interface. 
Together it appears that NRG binding involves predominantly sequences in domain I of ErbB-3 and 
ErbB-4 receptors. While the domains I and III are directly implicated in ligand interaction, the 
cysteine-rich domains influence ligand binding indirectly by dictating the conformation of the binding 
epitope. Mutations in ErbB-1 domain II were found to interfere with TGFα binding but not with EGF, 
implicating that these ligands bind their receptor through partly distinct epitopes (338). Mutation and 
deletion of residues in the first module of domain IV affected EGF binding, possibly by disruption of 
the structure of the constrained cysteine-rich domains (99, 339). The deletion mutants ErbB-1∆520-
603 retained high affinity for both EGF and TGFα (163), while the R497K substitution resulted in 
loss of the high affinity receptor class of ErbB-1 for TGFα (340).  
 
 
3.2.2 Structural analyses of ligand- receptor interaction  
Recently the three-dimensional structure of the ErbB-1 receptor ectodomain in complex with either 
EGF or TGFα has been derived from two crystal structures, both showing a 2:2 receptor-ligand dimer 
(91, 92). Both ligands bind ErbB-1 in a similar configuration, where one ligand molecule fits into the 
cleft between domain I and III of one receptor (Figure 7 A). Based on these two structural studies, the 
determinants for ErbB-1 binding can be divided into two clusters of contact residues within ErbB-1 
ligands. At first, the interaction with domain I involves side-chain contacts with residues in the B-loop 
region, in EGF Met21, Ile23, Leu26 and Lys28, in TGFα the equivalent Arg22, Leu24, and Lys29. 
The interface of TGFα is slightly different, since residues in the linear N-terminal region are not 
flexible but form the third strand of a β-sheet and participate in binding. While in EGF Ile23 and 
Leu26 undergo hydrophobic interaction with the sidechains of Leu14, Leu69 and Leu98 in domain I, 
in TGFα this contact is provided by Leu24 and by His4 and Phe5 in the N-terminus (Figure 7B). The 
tip of the B-loop of TGFα contacts more distant located residues as Tyr101 and Asn128, which are 
implicated in hydrophilic interaction with Gln26, and Arg125, which form a salt-bridge with Asp27. 
In the receptor, the V-shaped N-terminal residues 8-18 in domain I form a major part of the ligand-
interface, of which residues 15-18 form a short β-strand parallel to the major β-sheet in the ligand. 
Other receptor residues participating in ligand binding are mainly located at the ridge between the 
large and small β-sheet and include Leu14, Tyr45, Leu69, Glu90, Leu98.  
The ligand interface of EGF and TGFα on domain III of ErbB-1 appears more conserved, and 
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Figure 7: Representation of the crystal structure of the 2:2 TGFα•ErbB-1 ectodomain complex. (A) The ErbB-1 
homodimer with two TGFα molecules binding in the cleft between subdomains I (in red) and III (in blue). The
loops in domain II (in yellow and green) are predominantly involved in dimerisation. The lower panel shows the
contact residues within the receptor-ligand interface of TGFα site 1 to ErbB-1 subdomain I (B) and site 2 
interactions with subdomain III (C), respectively, in more detail.  
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In site 2, conserved residues in the A- and C-loop region of EGF and TGFα, that are in close contact 
with each other, contact the loop comprising residues 351-369. The anti-ErbB-1 monoclonal antibody 
LA22 that prevents ligand binding was found to recognise this loop (341). Central element in this 
binding site is the salt-bridge between Arg41 in EGF and Asp355 in ErbB-1. The strong conservation 
of these residues in both the mammalian ligands and ErbB members indicates that this interaction is of 
crucial importance for binding. The side chains of Tyr13 and Leu15 in EGF preserve the orientation 
of the Arg41 guanidium group, and thereby contribute to this interaction in an essential manner. 
These residues show hydrophobic interactions with Val350 and Phe357 in the receptor. Finally, 
residues in the C-terminal linear region of EGF and TGFα are sandwiched between domain I and III, 
and several residues, including Asp47 and Leu49 in TGFα, directly contact residues in both domains 
(92). The conserved Leu47 of EGF fits into a hydrophobic pocket centered over Ala415, and covers 
the largest contact area with the receptor. This hydrophobic pocket involves residues Leu382, Phe412, 
Val417, Ile438 and Gln408 in ErbB-1, most of which have conservative substitutions in the other 
ErbB members. Interestingly, the contact residues in TGFα extend over the large β-sheet plane and 
include contacts of His18 and His45 with complementary histidines in domain III, resulting in an 
elongated domain III interface compared to EGF. 
 
 
3.2.3 Mutational analysis of ligand-receptor interaction  
While these structural studies revealed the complete receptor-ligand interface, numerous site-directed 
mutagenesis on EGF and TGFα have elucidated the relative contribution of individual residues for 
receptor binding (reviewed in 79, 342). In particular mutation of residues Tyr13, Leu15, Arg41 and 
Leu47 resulted in a strong loss of ErbB-1 binding and function, indicating that the amount of 
sequence conservation is a good measure for functional importance (79, 343-345). Besides mutational 
analysis, which typically measures a loss-of-function, also homologue exchange mutagenesis proved 
useful to determine the structure-function relationship of EGF-like ligands. The minimal sequence 
requirements for ErbB-1 interaction were determined by sequential re-introduction of EGF residues 
into an EGF repeat from Drosophila Notch, thereby recognising Tyr13, Met21, Tyr22, Ala30 as 
important residues (346). Receptor specificity of EGF-like ligands is not only achieved by residues 
that contribute to interaction with an ErbB receptor, but also by negative elements that prevent 
interaction with other ErbB members. For instance, the presence of Arg45 in human EGF prevents its 
interaction with the chicken ErbB-1, while TGFα containing Ala at the equivalent position is fully 
able to activate this receptor (347-349). Consequently, the substitution of Gly441 in human ErbB-1 to 
lysine present in the chicken orthologue selectively reduces the affinity for EGF (328). The relative 
weight of single residues for receptor binding site was further derived from NMR spectra on TGFα 
alone and in conjunction with the soluble ErbB-1 ectodomain. In the receptor-complexed TGFα, 
mainly the residues binding to domain III of ErbB-1 were immobilised, while the linear N-terminal 
region and the β-turn at the tip of the B-loop maintained a high degree of mobility (350). In here, 
Leu15, His16 and Leu47 contributed for the most part to the immobilisation in the bound form of 
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TGFα (351). Together, it appears that ligand residues that interact with ErbB-1 domain III are most 
sensitive to mutation. 
The EGF domain sequences of the different NRG isoforms differ particularly in the linear N-terminal 
region and the Ω-loop from the ErbB-1 ligands, suggesting these regions may contain determinants 
for specificity towards ErbB-3 and ErbB-4 (352). As an approach to identify domains involved in 
specific ErbB interaction, several groups used homologue exchange mutagenesis of EGF-like ligands. 
The introduction of the linear N-terminal region of NRG-1 into EGF resulted in a chimera, named 
biregulin that bound both ErbB-1 and NRG receptors with high affinity (78). Apparently the NRG-1 
linear N-terminus contains residues that confer specificity for NRG receptors ErbB-3 and ErbB-4. 
While almost every inter-cysteine region in NRG could be substituted for EGF residues without loss 
of binding to NRG receptors, the inverse substitutions in EGF largely affected the ErbB-1 binding 
(78). In line with these observations, loss of NRG-1α binding was only observed when its N-terminus, 
the A-loop and the second strand of the β-sheet in the B-loop region were replaced for TGFα residues 
(353). Furthermore, truncation of the NRG-1 B-loop to ten residues, or replacement of the NRG-1 Ω-
loop by the equivalent EGF residues, did not affect NRG binding, implying that the elongated Ω-loop 
may serve primarily as a negative regulatory element to prevent interaction with ErbB-1 (353, 354). 
Exchange of the NRG residues in the C-terminal linear region for the corresponding TGFα residues 
resulted in NRG mutants with 10-fold increased receptor binding affinity, indicating that this 
sequence may also contribute to receptor binding (353).  
In contrast to the many site-directed mutagenesis studies on EGF and TGFα, much less is known 
about the effects of single amino acid mutations in NRGs. A notable exception is the alanine scanning 
mutagenesis of the NRG-1β EGF domain by Sliwkowski and colleagues (355). These authors showed 
that mutation of His178 or Leu179 in the linear N-terminal region, as well as of specific amino acids 
in the A-loop, C-loop or linear C-terminal region strongly impairs the ability of NRG-1β to bind 
ErbB-3. Binding to ErbB-4 is particularly impaired by mutations in the C-loop. In a parallel phage 
display study the complete amino acid sequence of NRG-1β has been randomly mutated in a segment-
wise approach (354). This study showed a high degree of conservation of the wild type residues 
Leu179, Val199, Gly215, Tyr224-Val225 and residues in the two β-turns (Val191-Glu195 and 
Arg220-Gln223) in NRG-1β variants optimised for high affinity ErbB-3 binding. Interestingly, by 
combining the sequence information for high affinity ErbB-3 binding of the individually mutated 
segments into one protein, a NRG-1β mutant has been generated with ~50-fold higher binding affinity 
for ErbB-3 than wild-type NRG-1β (354). Besides the six conserved cysteines, this super-binding 
mutant has identical residues as wild type NRG-1β in only 22 out of 44 positions. In the NMR 
structure of NRG-1α the N-terminal residues are embedded in a cluster of hydrophobic and positively 
charged residues in the major β-sheet, comprising His178, Leu179, Phe189, Val199, Arg208, Leu211 





4 Receptor oligomerisation 
 
4.1 Ligand-induced ErbB dimerisation 
 
Ligand-induced receptor oligomerisation is a universal phenomenon among RTKs and other hormone 
and cytokine receptors to bring multiple kinase domains in proximity as a requirement for 
transphoshorylation (95). Numerous studies using sucrose density gradient ultracentrifugion, chemical 
cross-linking and non-denaturing gel electrophoresis showed that ErbB-1 receptors isolated from 
A431 cell extracts are in part present as dimers in the absence of ligand, and that EGF binding 
strongly increased dimmer formation (313, 327, 356, 357). Furthermore, the ligand-dependent 
formation of homodimeric and heterodimeric ErbB complexes on whole cells has been demonstrated 
by co-immunoprecipitation in combination with cross-linking agents (162, 331, 358-362). Since 
internalised crosslinked ErbB-1 dimers could be detected in the endosomal compartment, the dimeric 
state appears to be preserved for some time after internalisation (231). Impairment of clathrin-
mediated endocytosis by expression of mutant dynamin disrupted the high affinity interaction of EGF 
with ErbB-1 in HeLa cells (269, 363). Moreover, direct visualisation of receptor dimerisation on 
living cells has been achieved by the use of β-complementation studies (364) and fluorescence 
resonance energy transfer (FRET) of ErbB-1 fusion proteins (365-367). 
It is currently unclear whether dimerisation is responsible for activation of the intracellular tyrosine 
kinase domain or just plays a role in the stabilisation of the ligand-induced active form. In line with 
the low level of preformed ErbB-1 dimers observed by biophysical techniques, FRET studies in fixed 
A431 cells or single-molecule fluorescence imaging of ErbB-1 on living cells have demonstrated the 
existence of 7-13% constitutive ErbB-1 homodimers on the cell surface in absence of externally 
added ligand (357, 365, 367, 368). Subsequent ligand administration resulted in a transient increase in 
microclustering of receptors, reaching up to 69% of ErbB-1 receptors in a dimeric state (365). The 
constitutive formation of ErbB-1 dimers could result from autocrine TGFα production in these highly 
overexpressing A431 cells, and thus not represent a normal physiological event. The ligand-
independent formation of inactive ErbB-1 dimers has also been demonstrated, however, in Ba/F3 cells 
engineered to express ErbB-1, a phenomenon for which the cytoplasmic domain proved essential 
(369). It has been proposed that preformed dimers become activated by a ligand-induced 
conformational change, involving a structural rearrangement of the intracellular kinase domains (357, 
368). Similarly, constitutive oligomers of ErbB-1 and ErbB-2 have been reported in HeLa cells, 
although these heterodimers were activated only after ligand treatment (363). Co-immonoprecipitation 
has indicated the ligand-independent dimer formation of ErbB-2 and ErbB-3, accompanied by a low 
basal level of phosphorylation of both ErbB-2 and ErbB-3 that can be enhanced upon ligand 
stimulation (133). It has been suggested that the relative expression levels of ErbB-2 and ErbB-3 
determine the amount of basal ErbB-3 phosphorylation (133). Finally, Bastiaanse et al. have 
presented a novel signalling mechanism consisting of ligand-independent lateral propagation of 




4.1.1 The role of the extracellular domain in dimerisation 
Since ligands bind to the extracellular domains of the ErbB receptors, these regions were thought to 
be essential and sufficient for receptor oligomerisation. In case of ErbB-1 and ErbB-4, the soluble 
extracellular regions indeed appear sufficient to mediate ligand-induced homodimerisation, as 
demonstrated by various biophysical methods (311, 312, 317, 326). In the case of EGF binding to the 
soluble extracellular domain of ErbB-1, the formation of a 2:2 receptor-ligand complex has been 
established by calorimetric analysis, small-angle X-ray scattering gel permeation chromatography and 
fluorescence anisotropy (311, 312, 317). In good agreement, in the crystal structure the ErbB-1 
homodimer is also complexed by two EGF or TGFα molecules (91, 92).  
In contrast to ErbB-1, the ErbB-4 ectodomain oligomers induced by NRG-1β appear to be larger than 
dimers, suggesting that in addition to dimers also tetrameric complexes can be formed (326). The 
soluble ectodomains of ErbB-3 did not readily form homodimers in response to NRG-1β, and it has 
been shown using different ErbB-3 mutants that membrane anchoring is a prerequisite for the 
formation of ErbB-3 dimers (325, 326, 361). Ligand-induced heterodimerisation of the soluble 
ectodomains of ErbB-1, ErbB-3 and ErbB-4 with ErbB-2 was only demonstrated for the ErbB-
2/ErbB-4 combination, and the composition of the NRG-induced complexes again had an apparent 
higher order than dimers (325, 326).  
In the ligand-occupied ErbB-1 homodimer the dimerisation is mainly mediated through inter-receptor 
contacts between residues in domain II comprising 1270 Å2 buried surface area (91, 92). Within 
domain II an antiparallel β-hairpin formed by residues 242-259 extends from the core of the domain 
globule. This loop has been referred to as dimerisation arm of ErbB-1, with the seven residues at the 
tip of the dimerisation loop serving as ‘hand’ that interacts with the globule of the other receptor. The 
receptor-receptor contact also involves an additional hydrogen bond contact with residues Arg85 and 
Asn86 in domain I. The inserted loop in domain II is conserved among ErbB members and has a 
similar β-hairpin structure in the unliganded ErbB-3 monomeric ectodomain, and in the ErbB-1 
monomer complexed with EGF at low pH (104, 105). In both monomeric structures the large 
dimerisation loop forms an intramolecular contact with residues in domain IV, thereby holding the 
receptor in an auto-inhibited conformation. In ErbB-3 the contact buries 810 Å2 surface area and is 
mediated by three side-chain interactions (Tyr246 with Lys583 and Asp562, Phe251 with Gly563, 
and Gln252 with His565)(104). These three residues in domain II and four in domain IV are 
conserved among ErbB-1 ErbB-3 and ErbB-4, while ErbB-2 has Gly-Gln, Pro-Gly and Phe-His 
substitutions. Hence, in case of ErbB-2 it seems unlikely that a similar intramolecular contact may 
possibly be formed to keep the receptor in an autoinhibited conformation. 
Interestingly, the dimerisation ability of extracellular domains may be influenced by their 
glycosylation content. One group reported self-association of ErbB-3 ectodomains produced in S2 
insect cells, which could be reversed by NRG-1 binding (352), while ErbB-3 ectodomains produced 
in CHO cells did not exert this propensity (337). On the other hand, mutation of potential N-
glycosylation sites indicated that the receptor-receptor association is highly dependent on a 
conformation induced by N-linked glycosylation (162). This observation was subscribed by the 
observation that the Asn420-linked sugar in ErbB-1 domain III suppressed ligand-independent 
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spontaneous oligomerisation. Glycosylation may thus serve a role in preventing uncontrolled 
oligomerisation events on the cell surface by putting orientational constraints to the extracellular 
domains of ErbB receptors (370). 
 
 
4.1.2 The role of the transmembrane domain in dimerisation 
Transmembrane domains play a more substantial role than only serving as structural elements for 
membrane anchoring, as certain point mutations in the transmembrane domains of RTKs are 
associated with constitutive receptor activation and oncogenic transformation. A well-known example 
is the Neu oncogene, an oncogenic rat ErbB-2 mutant containing a single point mutation,Val664 to 
Glu, which was first discovered in chemically induced rat neuroblastomas (371). Constitutive Neu 
activation is mediated by ligand-independent oligomerisation with the full-length ErbB receptor, 
causing an increase in the tyrosine kinase activity of the receptor and transformation potential (372, 
373). In humans this activating mutation has not been observed, however, although similar mutations 
introduced into the corresponding position of human ErbB-1, ErbB-2 and DER also gives rise to 
constitutive activation (374, 375). Numerous biophysical studies have addressed the mechanism by 
which interactions between the altered transmembrane domains affect the dimerisation properties. The 
positioning of the mutation appears critical; the transmembrane region is proposed to comprise a α-
helical structure for a coiled-coiled arrangement within the dimer. By step-wise introduction of 
cysteine residues at strategic positions about the putative alpha-helix axis in the juxtamembrane 
region, ligand-induced rotation of the transmembrane regions was achieved. This study showed that 
ligand binding to the flexible extracellular domains of the receptor dimer induce a rotation of the 
juxtamembrane regions, hence the transmembrane domains, indicating that there are clear restrictions 
in the relative orientation of the receptor for dimerisation and kinase activity (357). Moreover, 
analysis of transmembrane interactions in E. coli cell membranes revealed that the transmembrane 
domains of ErbB receptors self-associate strongly in the absence of their extracellular domains, with 
the rank order ErbB-4 > ErbB-1 = ErbB-2 > ErbB-3. Further mutational analysis suggests that the 
dimerisation of these transmembrane domains involves one or more GxxxG motifs (376). 
 
 
4.1.3 The role of the intracellular domain in dimerisation  
Although the extracellular domain is essential for receptor dimerisation, the cytoplasmic domains of 
ErbB proteins also contain sequence constraints for transactivation. Heterodimerisation with ErbB-2 
depends on the integrity of a Leu-Val-Ile (955-957) motif present at the C-terminal end of the kinase 
domain of ErbB-3 (377). This intracellular dimerisation motif was absolutely required for 
transactivation of ErbB-3, suggesting a physical interaction between the two cytoplasmic domains. 
This LVI motif is conserved within the ErbB family, with ErbB-2 harbouring a VVI (966-968) 
sequence, and was found to regulate the dimerisation of the intracellular domains of both ErbB-1 and 
ErbB-2 (378). However, this tripeptide segment does not appear to mediate direct interaction between 
two receptor molecules or other proteins, since in the crystal structure of the ErbB-1 kinase domain 
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the Leu955 within the LVI motif was in close contact with the C-lobe of the kinase domain (106). It is 
therefore possible that the segment mediates an allosteric effect in the cytoplasmic region following 
Leu955, which affects its availability for transphosphorylation. A C-terminally truncated ErbB-11-1000 
has a strong tendency to interact with ErbB-2 in response to EGF but not to AR, supporting the notion 
that the C-terminal tail prevents inappropriate ErbB-1/ErbB-2 interaction in absence of ligand (146). 
The strong evolutionary sequence conservation suggests that the kinase domain may have an 
additional function in mediating protein-protein interactions (101).  
 
 
4.2 Models for ligand-induced ErbB heterodimerisation 
 
Ligand-induced receptor oligomerisation appears a generic mechanism for the regulation of RTK 
activity, but there is substantial variation in the manner by which ligands form oligomeric complexes  
(379). While peptide hormones such as VEGF and PDGF are disulphide-linked dimeric ligands, 
which can directly induce two of their receptors to form a dimeric complex, ligands such as EGF, 
growth hormone (GH) and fibroblast growth factor (FGF) are essentially monomeric and induce 
oligomerisation of their receptors by a variety of distinct mechanisms. Monomeric human GH and 
erythropoietin (EPO) can simultaneously bind two receptor molecules through independent binding 
sites (380). These bivalent ligands combine a high affinity-binding site for one receptor molecule and 
a low affinity-binding site for another receptor molecule, yielding 2:1 complexes with a biphasic 
function of the concentration of the ligand (381). In case of EPO, it has been demonstrated that 
receptor dimers are preformed and become activated as a result of ligand-induced conformational 
changes (reviewed in 382). For both receptors effective antagonists have been designed which can 
bind only one of the two receptors through an affinity-optimised binding site. FGF has a bivalent 
interaction with two FGF receptors, where in addition heparin augments the interaction by linking the 
ligands to the receptors (383, 384). The preformed tetrameric IGF-1R and insulin receptors interact 
with their respective ligands in a 2:1 stoicheometry.  
At the preset of this thesis, two sorts of models were proposed for the mechanism of ligand- induced 
ErbB receptor oligomerisation, including ligand-mediated and receptor-mediated dimerisation models. 
In the ligand-induced dimerisation model, receptors are bridged in a dimeric complex by bivalent 
ligands with independent binding sites for both receptor molecules (311, 361, 385). Ligand bivalence 
is a particularly attractive model to explain how growth factors selectively induce different ErbB 
heterodimers, since ligands would simply contain a distinct binding site for interaction with different 
ErbB members. The ligand bivalence model as driving force for ErbB dimerisation has been 
subscribed by several reports (311, 361, 385). Based on calorimetric studies, Lemmon and coworkers 
proposed that the kinetic mechanism for EGF-ErbB-1 interaction involves dimerisation of two ligand-
bound receptor complexes due to ligand bivalence, with an intermediate 2:1 stoicheometry. Based on 
the dual specificity of the NRG-1/EGF chimera biregulin, Tzahar and coworkers postulated that 
NRG-1 is a bivalent molecule, combining a primary specific high affinity binding site for ErbB-3 
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attributed to the linear N-terminal region with a secondary, less specific, low affinity binding site for 
ErbB-2 residing in the C-terminal tail (361).  
In the receptor-mediated model, ligand binding induces a conformational change that exposes a 
previous cryptic dimerisation site on the extracellular domain of the receptor. This model was initially 
proposed after the observation of conformational changes occurring in ErbB-1 upon TGFα binding 
(319). The recently resolved two crystal structures of the liganded ErbB-1 ectodomains are consistent 
with such a conformation-driven dimerisation mechanism, and suggests that the formation of ErbB-1 
homodimers and possibly also other homodimers occurs through a receptor-mediated interaction (91, 
92). It is unclear, however, how the selective formation of heterodimeric ErbB complexes by different 
ligands could be achieved through such a mechanism.  
Recent studies have suggested that homo- and heterodimer formation occurs through fundamentally 
different mechanisms, and that transactivation of ErbB-2 may involve the formation of transient, 
tetrameric heterooligomers (326, 362). In this case ligands only induce homodimers, which 
subsequently recruit two ErbB-2 molecules or other unliganded ErbB molecules in the complex, 
allowing proxy activation of these receptors. Evidence for this mode of activation is derived from 
crosslinking experiments, which demonstrate the formation of higher order oligomeric complexes of 
cell-expressed ErbBs, and the biophysical association of soluble ErbB-4 ectodomains at ratio’s higher 
than two, which possibly contain a mixture of dimeric and tetrameric receptors (326, 386). 
Furthermore, results from homology modelling and intermolecular interaction calculations also 
suggested that the kinase domains of ErbB receptors undergo tetrameric oligomeric association, 
whereby heterodimerisation between ErbB-2 and ErbB-1 kinase domains is favoured over 
homodimers (387). Finally, Gamett and coworkers have proposed secondary (or lateral) dimerisation 
as mechanism for ErbB heterodimer formation. In this model ligand-induced dimerisation and ensuing 
receptor transphosphorylation results in the dissociation of the original receptor dimer. Each 
phosphorylated receptor monomer then interacts with a new receptor to form a secondary dimer, such 
that EGF stimulation also yields ErbB-2/ErbB-3 secondary dimers, and NRG-1 also induces the 
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Figure 8:  Distinct models for ligand-
induced heterodimerisation with ErbB-2. 
For simplicity only the extracellular 
domains of ErbB-3 (in white) and ErbB-2 
(in grey) are depicted. A Ligand-mediated 
heterodimerisation through bivalent 
ligands. B, C, D, Receptor-mediated 
heterodimerisation. C, Formation of 
tetrameric complexes with ErbB-2. D, 




5 Thesis outline 
 
Since growth factor binding to the ErbB receptor extracellular domain and the subsequent receptor 
dimerisation are the initial interactions in the response pathway, an elucidation of the molecular 
mechanism of this interaction is required for the rational design of receptor antagonists. In the context 
of the regulation and interactions of the ErbB network we posed the following questions:  
(i) Which are the determinants in EGF-like growth factors that confer ErbB specificity?  
(ii) What mechanism underlies preferential ErbB-2 heterodimerisation and what is the role of 
the ligand therein? 
We have investiged the role of ligands in selective ErbB heterodimerisation using the ErbB-2/ErbB-3 
heterodimer as model system. A strong advantage of the ErbB-2/ErbB-3 heterodimer is the mutual 
dependency of the receptors for signalling activity, since only the heterodimer forms a biologically 
active complex. The ErbB-2/ErbB-3 complex is the preferred signalling complex of the NRGs, and 
among the most potent ErbB combinations with respect to mitogenicity, which emphasises the 
physiological importance of this complex. In chapter 2 we used a chimeric approach to identify 
regions in EGF-like ligands that confer specificity to cells expressing ErbB-2 and ErbB-3 receptors. 
The chimera T1E can strongly bind and activate ErbB-2/ErbB-3 receptors in addition to ErbB-1, but 
binds only poorly to ErbB-3 alone. Chapter 3 further analysed the role of residues within the linear N-
terminal region of ligands for ErbB-2/ErbB-3 interaction by the application of the phage display 
technique. The optimal sequences within EGF for high affinity interaction with ErbB-2/ErbB-3 
receptors were identified. Since the selected EGF variants exerted increased binding affinity for cells 
that express ErbB-3 alone, the optimised N-terminal region appears to mediate primary binding to 
ErbB-3. Chapter 4 describes the effects of point mutations in T1E at critical positions for binding to 
ErbB-1, in an attempt to modify the ErbB-1 binding ability but not the ErbB-2/ErbB-3 interaction. 
The properties of these mutants suggest that the binding determinants in T1E for ErbB-1 and ErbB-3 
show considerable overlap. The hypothesis that EGF-like ligands are bivalent molecules has been 
tested in Chapter 5. The phage display approach was used to investigate the role of the linear C-
terminal region of ligands in the selective formation of homodimeric and heterodimeric ErbB-3 
species. The appendix (chapter 6) gives an extensive overview of the structure-function relationships 
of EGF-like growth factors and homology exchange mutagenesis studies. The implications of the 
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Epidermal growth factor (EGF) and transforming growth factor (TGF)-α are potent activators of the 
ErbB-1 receptor but, unlike TGFα, EGF is also a weak activator of ErbB-2/ErbB-3 heterodimers. To 
understand the specificity of EGF-like growth factors for binding to distinct ErbB members, we have 
used EGF/TGFα chimeras to examine the requirements for ErbB-2/ErbB-3 activation. Here we show 
that in contrast to these two wild-type ligands, distinct EGF/TGFα chimeras are potent activators of 
ErbB-2/ErbB-3 heterodimers. On the basis of differences in the potency of these various chimeras, 
specific residues in the linear N-terminal region and the so-called B-loop of these ligands were 
identified to be involved in interaction with ErbB-2/ErbB-3. A chimera consisting of human EGF 
sequences with the linear N-terminal region of human TGFα was found to be almost as potent as the 
natural ligand neuregulin (NRG)-1β in activating 32D cells expressing ErbB-2/ErbB-3 and human 
breast cancer cells. Binding studies revealed that this chimera, designated T1E, has high affinity for 
ErbB-2/ErbB-3 heterodimers, but not for ErbB-3 alone. Subsequent exchange studies revealed that 
introduction of both His2 and Phe3 into the linear N-terminal region was already sufficient to make 
EGF a potent activator of ErbB-2/ErbB-3 heterodimers, indicating that these two amino acids 
contribute positively to this receptor binding. Analysis of the B-loop revealed that Leu26 in EGF 
facilitates interaction with ErbB-2/ErbB-3 heterodimers, while the equivalent Glu residue in TGFα 
impairs binding. Since all EGF/TGFα chimeras tested have maintained high binding affinity for ErbB-
1, it is concluded that the diversity of the ErbB signalling network is determined by specific amino 
acids that facilitate binding to one receptor member, in addition to residues that impede binding to 





Members of the epidermal growth factor (EGF) family of peptide hormones exert their action by 
binding to the ErbB family of tyrosine kinase receptors (1, 2). This family comprises four members, 
designated ErbB-1, 2, 3 and 4, which have frequently been found to be overexpressed particularly in 
epithelial tumours such as breast cancer, corresponding with a poor patient prognosis (3, 4). EGF-like 
growth factors are also frequently expressed in these tumours, thus giving rise to the possibility of 
autocrine tumour cell proliferation (5).  
EGF and all other members of this growth factor family have a characteristic spacing of six conserved 
cysteine residues, arranged in three disulphide bridges. In combination with two conserved glycine 
residues this provides the three-dimensional scaffold that is required for proper ErbB receptor binding 
(6). On the basis of their cysteine spacing these molecules can be divided into three looped regions, 
designated the A-loop (Cys6-Cys20),
 
B-loop (Cys14-Cys31) and C-loop (Cys33-Cys42, numbering 
according to human EGF), in addition to a linear N-terminal region, a linear C-terminal region and a 
single amino acid hinge region between the fourth and the fifth cysteine. Structural studies using 




stranded β-sheet. Moreover, the N-terminal linear region and the B-loop are located on one side of the 
molecule, while the A-loop, C-loop and linear C-terminal region are directed to the other side (7).  
EGF itself is the best-characterised member of this growth factor family. In its mature form it consists 
of 53 amino acids, and it selectively binds with high affinity to ErbB-1, also known as the EGF 
receptor (8). Besides EGF, five other mammalian EGF-like growth factors have been identified as 
ligands for ErbB-1, namely transforming growth factor (TGF)-α, amphiregulin, heparin-binding EGF-
like growth factor (HB-EGF), betacellulin (BTC) and epiregulin (ERG) (2). In addition, four 
neuregulins (NRG 1-4) with multiple splice variants have been identified as the major ligands for the 
ErbB-3 and ErbB-4 receptors, while no ligand has been assigned yet to ErbB-2 (9-14).  
Upon ligand binding, EGF-like growth factors are able to activate their receptors by inducing ErbB 
dimerisation, after which phosphorylation of the receptors in trans occurs. ErbB receptors can 
dimerise with all other ErbB receptor members, in which heterodimers with the orphan ErbB-2 
receptors are preferred (15-17). In general heterodimer formation results in enhanced binding affinity 
(18, 19) and stronger biological responses, since a larger variety of intracellular signalling pathways 
can be initiated (1, 20). Particularly in the case of ligand binding to ErbB-3, heterodimer formation 
with other ErbB members such as ErbB-2 is essential (21-23), since ErbB-3 receptors have an 
impaired tyrosine kinase domain and as a result ErbB-3 homodimers are biologically inactive (24). It 
has been speculated that EGF-like growth factors such as EGF and NRG-1β may have a bivalent 
character with a high affinity binding site for their primary receptor and a low affinity binding site for 
a second ErbB receptor, thus bridging the two receptors into a heterodimeric complex (25-27).  
Selective action of the above ErbB signalling network requires that EGF-like growth factors contain 
specific amino acids that facilitate binding to specific ErbB members. On the basis of a large number 
of site-directed mutagenesis studies, many residues have been identified in the three looped regions 
and linear C-terminal region of both EGF and TGFα that play an important role in the activity of 
these ligands towards ErbB-1. Among these amino acids, in particular the EGF residues Tyr13, Leu15 
and His16 around the second cysteine, as well as Tyr37, Arg41, Gln43 and Leu47 around the sixth 
cysteine and in the linear C-terminal region are highly conserved between ErbB-1 binding ligands 
(28-30). NMR analyses on EGF and TGFα have indicated that these conserved residues are located in 
close distance to each other, from which it has been postulated that these residues in EGF may well be 
part of a non-linear ErbB-1 receptor binding epitope (7, 31, 32). Additional information for 
understanding the selectivity of receptor binding comes from recent observations that BTC, HB-EGF 
and ERG do not only bind ErbB-1, but are also high affinity ligands for ErbB-4 (14, 33-37). In cell 
systems with a high expression level of ErbB-4 also EGF appears to have moderate affinity for this 
receptor (17). In addition, others and we have shown that besides NRG-1 also EGF and BTC are able 
to activate ErbB-2/ErbB-3 heterodimers, although only at super physiological concentrations (38,39). 
It is currently unclear, however, which elements in these broad activating ligands determine the 
selectivity of binding to distinct ErbB receptors. 
In the present study we have exploited EGF/TGFα chimeras to study the amino acid requirements for 
binding of EGF-like growth factors to ErbB-2/ErbB-3 heterodimers, using a gain-of-function 
approach. In previous studies we have provided evidence that chimeras between human (h)EGF and 
Interaction of EGF with ErbB-2/ErbB-3 heterodimers   
 57
hTGFα can be powerful tools to study the structure-function relationship of these ligands, under 
conditions that EGF and TGFα exert distinct biological responses (40,41). In contrast to EGF, TGFα 
is fully unable to activate ErbB-2/ErbB-3 heterodimers (39). Here we show that various EGF/TGFα 
chimeras are powerful activators of ErbB-2/ErbB-3 heterodimers, with near similar activity to NRG-
1β. On the basis of additional mutagenesis studies we show that introduction of only two amino acids 
from the linear N-terminal region of TGFα into EGF is sufficient to make EGF not only a potent 
ligand for ErbB-1, but also for ErbB-2/ErbB-3 heterodimers. In addition, we provide evidence that 
amino acids in the B-loop of EGF and TGFα may either contribute to or impair activation of ErbB-
2/ErbB-3 receptors. Interestingly, the amino acids thus identified as involved in interaction with 
ErbB-2/ErbB-3 heterodimers are located on the opposite site of the molecule in comparison with 
those proposed to be involved in binding to ErbB-1, making EGF potentially a ligand with two faces 
directed to different ErbB receptors for high affinity interaction.  
 
 
Figure 1 Induction of cell proliferation and phosphorylation of 32D cells co-expressing ErbB-2 and ErbB-3 (D23 cells) by 
NRG-1β and EGF/TGF-α chimeras. A Alignment of the amino acid sequences of human EGF, human TGF-α and the EGF-
domain of human NRG-1β (177-226). Numbering of the conserved cysteine residues in bold face is according to EGF. 
Schematic representation of the most relevant EGF/TGF-α chimeras used in this study, created by exchanging inter-
cysteine domains. EGF sequences are indicated as white bars, black boxes represent TGF-α sequences. B Dose reponse 
of ligand-induced proliferation of D23 cells by NRG-1β (■), EGF (+), TGF-α (◊), T1E (Ο), T3E (▼), T3E4E (♦), T4E (▲) and 
E4T (∆). Cells were deprived of IL-3 prior to treatment with the indicated ligands, and the extent of cell proliferation and 
survival was determined 24 h after addition of growth factors by using the calorimetric MTT assay. Results are presented 
as fold induction over control untreated cells and are mean of two independent experiments performed in duplicate. C 
Induction of tyrosine phosphorylation in D23 cells determined by immunoblotting (IB) of whole cell lysates with an antibody 






EGF/TGFα chimeras can be strong activators of ErbB-2/ErbB-3 heterodimers 
Using interleukin 3-dependent myeloid 32D cells transfected with both the ErbB-2 and ErbB-3 
receptor (D23 cells), we have previously shown that EGF is a low affinity activator of ErbB-2/ErbB-3 
heterodimers, while TGFα is fully inactive (39). In the present study we have used EGF/TGFα 
chimeras to determine the requirements for interaction of EGF-like growth factors with ErbB-2/ErbB-
3 heterodimers. The chimeras were constructed by exchanging domains between the conserved 
cysteine residues of human (h)EGF and hTGFα, resulting in ligands with similar high binding affinity 
for the ErbB-1 receptor as wild-type hEGF and hTGFα (42). Figure 1A gives a survey of the most 
relevant EGF/TGFα chimeras tested in this study, as well as the amino acid sequences of hEGF, 
hTGFα and hNRG-1β, the natural activator of ErbB-2/ErbB-3 heterodimers. Following conventions 
used before, a ligand designated T1E is composed of TGFα sequences N-terminal and EGF sequences 
C-terminal of the first cysteine.  
We have examined the ability of various EGF/TGFα chimeras to promote cell survival of D23 cells 
using the MTT-assay, which measures mitochondrial activity. Figure 1B shows that EGF, TGFα, E4T 
and T4E were not active or required superphysiological concentrations of more than 100 ng/mL to 
induce cell survival of D23 cells. In contrast, the chimeras T3E4T, T3E and T1E showed, in this 
order, an increasing potency to stimulate D23 cells, with a half maximum concentration that in the 
case of T1E (1 ng/mL) is only slightly less than that of NRG-1β (0.5 ng/mL). Next, the same 
chimeras were analysed for the ability to induce receptor phosphorylation in D23 cells (Fig. 1C). T1E 
induced receptor tyrosine phosphorylation in these cells to a similar extent as NRG-1β, while the 
chimeras T3E and T3E4T were clearly more potent inducers than EGF and TGFα. As a control it is 
shown that all EGF/TGFα chimeras tested induced similar levels of tyrosine phosphorylation of 
ErbB-1 in 32D cells expressing human ErbB-1 (D1 cells).  
In conclusion, unlike the wild-type ligands EGF and TGFα, certain EGF/TGFα chimeras are potent 
activators of ErbB-2/ErbB-3 heterodimers. Since EGF and T1E differ only in the sequence of the N-
terminal linear region, the strong difference in potency between these two ligands clearly indicates 
that specific residues in this region are involved in binding to ErbB-2/ErbB-3 heterodimers. 
Moreover, the clear difference in potency between the chimeras T3E and T4E, as well as between 
T3E4T and TGFα, reveals that also the region between the third and fourth cysteine (B-loop) in EGF 
contains sequences important for interaction with ErbB-2/ErbB-3 heterodimers. As a result chimeras 
containing the N-terminal linear region of TGFα in combination with the B-loop of EGF are strong 
activators of such heterodimers. The small difference between the activities of T4E and TGFα in 
Figures 1B and 1C suggests that also the region C-terminal of the fourth cysteine may slightly 
contribute to ErbB-2/ErbB-3 selectivity. 
 
Neuregulin-like activity of T1E in human breast cancer cells  
To study the effects of EGF/TGFα chimeras on cells expressing endogenous ErbB-2 and ErbB-3 
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receptors, we measured their ability to induce proliferation and differentiation of the human breast 
cancer cell lines MCF-7 and MDA-MB-453. Many human breast cancer cells show overexpression of 
ErbB receptors, in particular ErbB-2, and in these cells ErbB-2/ErbB-3 heterodimers form a major 
receptor signalling complex. MCF-7 cells can be stimulated to proliferate upon addition of externally 
added growth factors such as insulin-like growth factor-1 and NRG-1β, while EGF is only a poor 
mitogen for these cells (9, 46). Figure 2A shows that T1E, and to a lesser extent T3E, are potent 
activators of MCF-7 cell proliferation, with half-maximum concentrations that are 10- and 100-fold, 
respectively, higher than for NRG-1β but still orders of magnitude lower than observed for the wild-
type ligands EGF and TGFα.  
Since MCF-7 cells express all ErbB members, we next investigated which ErbB receptors are 
activated in immunoprecipitates of specific ErbB receptors. In agreement with the above data, both 
NRG-1β and T1E are able to induce tyrosine phosphorylation of ErbB-2 and ErbB-3 receptors, while 
EGF and TGFα are ineffective (Fig. 2B). Low levels of ErbB-1 phosphorylation were observed upon 
treatment with EGF, TGFα and T1E, but not with NRG-1β. Tyrosine phosphorylation of ErbB-4 was 
also observed upon treatment with NRG-1β and to a lesser extent by T1E (data not shown). In 
conclusion, the ErbB-2/ErbB-3 heterodimer seems the major receptor complex involved in the action 
of T1E on MCF-7 cells. Since ErbB-3 contains several consensus binding sites for the p85 subunit of 
phosphatidylinositol 3-kinase (PI3K), and PI3K activity is strongly induced upon activation of ErbB-3 
(48, 49), we additionally measured ligand-induced recruitment of PI3K by the activated ErbB-3 
Figure 2 Effect of EGF/TGF-α chimeras on the growth of the human mammary carcinoma cell line MCF-7. A Dose-
response growth curve by NRG-1β (■), EGF (+), TGF-α (◊), T1E (Ο) or T3E (▼). Cells were serum starved before 
addition of serial dilutions of the indicated ligands, and growth was monitored by measuring incorporation of [
3
H] 
thymidine between 8 and 24 h. Results are presented as percentages of control (10 % NCS) and give mean values ± 
SEM of three independent experiments performed in triplicate. B Activation of ErbB receptors after 
immunoprecipitation with antibodies directed against the indicated ErbBs upon stimulation with the indicated ligands 
(100 ng/ml), as determined by immunoblotting with an antibody against phosphorylated tyrosine. ErbB-1 activation 
was determined in whole cell lysates by a monoclonal antibody directed against the activated form of ErbB-1. C Co-
immunoprecipitation of the p85 subunit of PI3-K with antibodies against ErbB-3 upon stimulation with NRG-1β, T1E, 




receptor. Figure 2C shows that the p85 regulatory subunit of PI3K co-immuno precipitates with the 
stimulated ErbB-3 receptor upon treatment of MCF-7 cells with NRG-1β and T1E, but not with EGF 
and TGFα. With respect to both biological activity and induced second messengers, T1E therefore 
behaves on MCF-7 cells as a neuregulin-type of ligand. 
MDA-MB-453 human mammary cancer cells, which lack ErbB-1 but overexpress ErbB-2 and ErbB-3 
(34), undergo cellular differentiation in response to NRG-1β, resulting in growth arrest, cell flattening 
and the appearance of neutral lipid-containing droplets. Figure 3 shows that T1E mimics the response 
of NRG-1β and induces phenotypic differentiation with higher potency than EGF, which was 
previously shown to exert this activity only at superphysiological concentrations (39). Taken together, 
these data together show that also in non-transfected cells EGF/TGFα chimeras such as T1E 
specifically activate ErbB-2/ErbB-3 heterodimers resulting in neuregulin-like biological responses. 
 
 
T1E binds to ErbB-2/ErbB-3 heterodimers, but not to ErbB-3 alone 
To investigate if the neuregulin-like biological activity of EGF/TGFα chimeras is paralleled by high 
affinity binding to ErbB-2 and ErbB-3 receptors, we performed radiolabelled ligand binding studies 
on 32D sublines expressing either ErbB-1 alone (D1 cells) or ErbB-3 alone (D3 cells), or a 
combination of ErbB-2 and ErbB-3 (D23 cells). Figure 4A (upper panel) shows that [
125
I]-T1E 
binding to ErbB-1 can be competed equally well by unlabelled EGF, TGFα and T1E, while NRG-1β 
is inactive on this receptor. This confirms earlier observations that in general EGF/TGFα chimeras 
have a similar binding affinity for ErbB-1 as their wild-type ligands. [125I]-T1E also binds well to D23 
cells, with half-maximum competition by NRG-1β at 1.5 ng/mL, by unlabelled T1E at 5 ng/mL and 
by T3E at 200 ng/mL, while no competition by EGF was observed at concentrations below 1 µg/mL 
(Fig. 4A, lower panel). No significant binding of [
125
I]-T1E was observed on D3 cells, indicating that 
the relative affinity of T1E for ErbB-3 alone is very low (data not shown).  
In contrast to radiolabelled T1E, [
125
I]-NRG-1β readily bound to D3 cells (Fig. 4B, upper panel), from 
which it could be competed by unlabelled NRG-1β at a half-maximum concentration of 5 ng/mL, 
while in the case of T1E more than 500 ng/mL were required. On D23 cells, [125I]-NRG-1β binding 
was competed by NRG-1β at a half-maximum concentration of 4 ng/mL and by T1E at 12.5 ng/mL  
 
 
Figure 3 Induction of cellular differentiation 
of MDA-MB-453 human mammary tumour 
cells. Cells were grown for four days in 
presence or absence of the indicated 
ligands (100 ng/ml), and subsequently 
stained with Oil red O to visualise neutral 
lipid vesicles.  
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 (Fig. 4B, lower panel). Thus, introduction of the linear N-terminal region of TGFα into EGF results 
in a ligand with strongly increased affinity for ErbB-2/ ErbB-3 heterodimers, but not for ErbB-3 
alone. 
 
Amino acids in the N-terminal linear region involved in ErbB-2/ErbB-3 activation 
In contrast to EGF, T1E is a potent activator of ErbB-2/ErbB-3 heterodimers, implying that amino 
acids in the N-terminal linear region of TGFα favour binding to this receptor combination. To 
pinpoint the relevant amino acids involved in ErbB-2/ErbB-3 activation, we made a set of additional 
EGF mutants by exchanging residues between the N-terminal linear regions of EGF and TGFα, as 
schematically depicted in Fig. 5A. First the two N-terminal mutants T1E/I and T1E/II were examined 
 
TABLE  I 
Relative binding affinity of EGF/TGFα chimeras to HER-14 cells that express ErbB-1a 
EGF/TGFα chimera Relative binding affinity 
T1E 82 % 
T1E/I 80 % 
T1E/II 92 % 
T4E/III 89 % 
T4E/IV 56 % 
a 
Relative binding affinity = IC50 (mEGF)/ IC50 (mutant) x 100%, as measured by displacement of [
125I]-mEGF on HER-14 
cells by RP-HPLC purified ligands. 
 
 
Figure 4 Ligand displacement analysis of EGF/TGF-α chimeras on 32D cells expressing different subsets of ErbB receptors.
A Displacement of [
125
I] T1E by unlabeled growth factors was performed on 32D cells expressing ErbB-1 (D1 cells, upper
panel) or ErbB-2 and ErbB-3 (D23 cells, lower panel). B Displacement of [
125
I] NRG-1β was performed on 32D cells
expressing ErbB-3 alone (D3 cells, upper panel) or D23 cells (lower panel). Cells were incubated for 2 h at 4C in the
presence of increasing amounts of the ligands NRG-1β (■), EGF (+), T1E (○) or T3E (▼). Unbound ligand was removed by
centrifugation the cell suspension through a serum cushion, after which radioactivity was determined in the cell pellet. The





for their binding affinity to ErbB-1, as measured by the ability to displace radiolabelled mEGF from 
HER-14 cells. Similar to all other hEGF/hTGFα studied previously (40), these mutants showed a 
relative binding affinity close to wild-type EGF (see Table I), indicating that these substitutions did 
not significantly affect ErbB-1 binding. To allow rapid screening of mutant ligands, we examined 
whether these EGF mutants could be tested in functional assays as fusion proteins with protein A, 
since all recombinant ligands used in this study were initially produced as N-terminally tagged protein 
A-fusion proteins. The activity of these fusion proteins was determined by measuring their ability to 
compete with radiolabelled mEGF for binding to HER-14 cells. By using natural mEGF as a standard, 
the activity was subsequently expressed as mEGF binding equivalents. In agreement with previous 
data (50) we found that protein A-tagged T1E and untagged, HPLC-purified T1E induce similar 
mitogenic responses in both D1 cells (data not shown) and D23 cells (compare Figs. 5B and 5C). This 
indicates that the presence of a large N-terminal extension does not hamper receptor interaction with 
either ErbB-1 or ErbB-2/ErbB-3 heterodimers.  
Figure 5B shows that EGF in which the first two N-terminal amino acids have been replaced by the 
four corresponding residues of TGFα (T1E/I), had similar low activity in stimulating D23 cells as 
wild-type EGF. By contrast, the mutant with the first three amino acids of EGF replaced by the five 
 
Figure 5 Identification of amino acids within the linear N-terminal region responsible for 
activation of ErbB-2/ErbB-3 heterodimers. A Schematic presentation of the N-terminal region of 
EGF, TGF-α and the additional chimeric molecules used in this figure. EGF sequences are 
indicated as white squares, black squares represent TGF-α sequences. As in T1E, sequences 
C-terminal of the first cysteine are of EGF. B and C Proliferative capacity of the presented N-
terminal EGF/TGF-α chimeras on D23 cells as determined in a MTT assay. Increasing amounts 
of the following ligands were used: T1E (Ο), EGF (+), T1E/I (υ), T1E/II (•), T1E/III (□) and T1E/IV 
(■). In B the ligands used were all HPLC-puried untagged growth factors, whereas in C the 
ligands used were tested as protA-tagged fusion proteins. Each point represents the mean of a 
duplicate determination
Interaction of EGF with ErbB-2/ErbB-3 heterodimers   
 63
corresponding residues of TGFα (T1E/II) induced a similar high response as T1E. This suggests that 
introduction of the Phe residue at position 3 in EGF is of crucial importance for ErbB-2/ErbB-3 
activation. Next this Phe residue was introduced into EGF either alone (T1E/IV) or in combination 
with the neighbouring His residue at position 2 (T1E/III), which is conserved in all neuregulin 
sequences, and the mitogenic potential of these mutants was tested on D23 cells as protein A-tagged 
ligands. Figure 5C shows that introduction of only the Phe residue at position 3 of EGF does not 
result in improved mitogenic activity. In contrast, introduction of both His and Phe is sufficient to 
make EGF a similarly potent activator of ErbB-2/ErbB-3 heterodimers as T1E. In conclusion, wild-
type EGF appears a weak activator of ErbB-2/ErbB-3 heterodimers because it lacks two specific 
amino acids in its linear N-terminal region. 
 
Amino acids in the B-loop involved in ErbB-2/ErbB-3 activation 
The difference in proliferative activity on D23 cells between the intermediate activator T3E and the 
weak activator T4E prompted us to further identify the involved amino acids in the region located 
between the third and fourth cysteine (so-called B-loop). An additional set of EGF/TGFα chimeras 
was generated in which TGFα residues in the B-loop of T4E were substituted for the corresponding 
 
Figure 6 Identification of amino acids with the EGF B-loop, located between the third and fourth conserved cysteine, 
involved in ErbB-2/ErbB-3 activation. A Schematic view of the B-loop region of EGF, TGF-α and the additional chimeras 
used in this figure. EGF sequences were introduced pair-wise in both strands of the β-sheet into the TGF-α B-loop of T4E. 
B and C Capacity of the different B-loop mutants to induce proliferation of D23 cells was determined using the MTT 
assay. The following EGF/TGF-α chimeras were tested: T3E (▼), T4E (▲), T4E/I ( ), T4E/II (Ο), T4E/III (□), T4E/IV (■) 





amino acids of EGF, as depicted in Figure 6A. The 10 amino acid B-loop, which is composed of two 
mutually interacting β-strands linked by a β-turn, was therefore subdivided into three subdomains and 
amino acids were exchanged in a pairwise manner on both strands of the β-sheet. The B-loop mutants 
were analysed for proliferative activity on D23 cells as protein A-fusion proteins. Figure 6B shows 
that exchange of amino acids next to the conserved cysteines (T4E/I) slightly increased the potency of 
T4E to activate ErbB-2/ErbB-3 heterodimers, while exchange of four residues in the hydrophobic 
middle part of the B-loop (T4E/II) was without effect. However, exchange of the four amino acids 
(Val-Gln-Glu-Asp) around the tip of the B-loop into EGF sequences (Glu-Ala-Leu-Asp) resulted in a 
chimera (T4E/III) with a potency near similar to that of T3E. More detailed mutational analysis 
showed that the chimera in which the Gln-Glu sequence at the tip of the B-loop was exchanged for the 
Ala-Leu (T4E/IV) and the chimera in which only Glu was exchanged for Leu (T4E/V) were both as 
active as T3E in stimulating D23 cells (see Fig. 6C). Taken together, these results suggest that the 
hydrophobic Leu26 in EGF contributes to ErbB-2/ErbB-3 activation, and that the corresponding 






Signalling through ErbB receptors involves a complex network of multiple ligands and mutually 
interacting receptors, that give rise to the induction of receptor-specific intracellular second 
messengers (1). Selectivity of such a network requires that the various ligand molecules involved 
show distinct receptor binding specificity (2, 51). Since the overall structure of the EGF-like growth 
factors is very similar, it can be postulated that specific amino acids facilitate binding to individual 
ErbB members, in addition to residues that prevent binding to the other ErbB receptors. The aim of 
the present study was to examine the specific amino acids in EGF-like growth factors that are 
involved in selective activation of ErbB-2/ErbB-3 heterodimers. Here we show that EGF is unable to 
bind ErbB-2/ErbB-3 heterodimers with high affinity, because it lacks crucial amino acids in the N-
terminal linear region, such as the His and Phe that are present in TGFα. In contrast, TGFα is unable 
to bind ErbB-2/ErbB-3 heterodimers in spite of the presence of the proper amino acids in the linear N-
terminal region, particularly because interaction is impaired by an acidic Glu-residue at the tip of the 
B-loop. This Glu is conserved in TGFα from different species, although there is no indication from 
site-directed mutagenesis studies that it is essential for binding to ErbB-1 (28). Interestingly BTC, a 
high affinity ligand for both ErbB-1 and ErbB-4 but only a weak activator of ErbB-2/ErbB-3 
receptors, shares with TGFα not only the His-Phe motif in the N-terminal linear region, but also the 
negatively charged Glu in the B-loop. In combination, these data indicate that EGF-like growth 
factors indeed contain evolutionary conserved residues that contribute to their receptor specificity by 
preventing binding to multiple ErbB members.  
The present observation that introduction of the N-terminal linear region of TGFα into EGF results in 
a chimera (T1E) with high affinity for ErbB-2/ErbB-3 heterodimers, is in line with previous studies 
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by Barbacci et al. (52). These authors showed that introduction of the linear N-terminal region of 
human NRG-1 into hEGF results in a chimera, designated biregulin, which binds to both EGF and 
neuregulin receptors present on human breast cancer cells. In a subsequent study it was shown that 
biregulin binds with high affinity to ErbB-2/ErbB-3 heterodimers, but not to ErbB-3 alone (27). Our 
data show highly similar binding characteristics for the EGF/TGFα chimera T1E, demonstrating that 
neuregulin sequences are not essential for ligand binding to ErbB-2/ErbB-3 heterodimers. Comparing 
the sequences of the linear N-terminal regions of hEGF, hTGFα and NRG-1 (see Fig.1), it is tempting 
to speculate that the Ser and His residues, which are conserved between TGFα and NRG-1 but absent 
in EGF, are involved in the interaction of T1E and biregulin to ErbB-2/ErbB-3. Barbacci et al. (52) 
showed that truncation of the N-terminal Ser-His motif from biregulin indeed impaired the interaction 
with neuregulin receptors. Our study indicates, however, that in the case of T1E not the N-terminal 
Ser-residue, but the adjacent His and Phe are important for activation of ErbB-2/ErbB-3 heterodimers. 
NRG-1 contains a hydrophobic Leu at position 3, which may play a similar role in ErbB-2/ErbB-3 
binding as the Phe-residue in T1E.  
The present study shows that not only amino acids in the linear N-terminal region, but also in the B-
loop are important for activation of ErbB-2/ErbB-3 heterodimers by EGF-like growth factors. The B-
loop of EGF containing Leu26 is very well suited for binding to ErbB-2/ErbB-3, while the B-loop of 
TGFα containing a Glu-residue at the equivalent position is not. It should be noted that the chimeric 
approach used in this study does not allow identification of residues involved in receptor binding that 
are conserved between hEGF and hTGFα, such as Asp27, Lys28 and Ala30. In comparison with 
EGF, the B-loop of NRG-1 is elongated by three amino acids, resulting in an irregularly formed so-
called Ω-loop at the site of the β-turn. Mutagenesis studies have shown that these additional amino 
acids are not required for binding to ErbB-3 and ErbB-4 receptors, since truncation of the B-loop of 
NRG-1α to the same length as EGF does not affect its binding affinity towards ErbB-3 (53). 
Moreover, replacement of the complete Ω-loop of NRG-1α by the corresponding β-turn of EGF even 
resulted in a ligand with enhanced binding affinity for neuregulin receptors (54). By contrast, binding 
of EGF-like growth factors to ErbB-1 requires a B-loop region with a length that is restricted to 8-10 
amino acids, which suggests that the Ω-loop may have a role as a negative regulatory element by 
preventing NRG-1 binding to ErbB-1 (55, 56). A recent study reported that introduction of TGFα 
sequences into the linear N-terminal region of NRG-1α results in a chimeric ligand with strongly 
reduced binding affinity for neuregulin receptors (54). Subsequent structural studies revealed that in 
this TGFα/NRG-1 chimera the side chain packing between  the linear N-terminus and B-loop is 
disturbed (57), suggesting that a chimera with the linear N-terminal region of TGFα is unable to fold 
properly in combination with an elongated B-loop. 
Multi-dimensional NMR analyses have revealed that the N-terminal linear region of EGF is less 
structured than that of NRG-1α and TGFα, where it tends to form a triple β-sheet with the two anti-
parallel strands present in the B-loop (7, 58-60). Since both the N-terminal linear region and B-loop of 
T1E are involved in ErbB-2/ErbB-3 interaction, it is tempting to speculate that also in this chimera a 




of such a triple β-sheet, with Leu3, Phe21, Val23 and Leu33 on one side, and Val4, Met22 and Tyr321 
on the other side (61). On the basis of these data, Tzahar and coworkers have postulated that the 
former cluster of hydrophobic amino acids together with the N-terminal hydrophilic residues Ser and 
His may form the primary receptor binding domain of NRG-1β to ErbB-3 (27). An alanine scanning 
study on NRG-1α confirmed the importance of His2 and Leu3 in the linear N-terminal region for 
binding to ErbB-3, but also indicated a lack of freedom for mutation of specific amino acids in the A- 
and C-loop (61). In addition, mutation of positively charged amino acids, particularly Arg32 in the B-
loop and Lys35 in the hinge region, affected binding of NRG-1α to ErbB-3 (61). Extrapolation of 
these data to T1E, while neglecting the contribution of the Ω-loop, would suggest that in this chimera 
His2 and Phe3 in the N-terminal linear region and Met21, Ile23 and Ala30 in the B-loop are involved 
in binding to ErbB-3, whereas also a basic Lys-residue is found at position 28, equivalent to Arg32 in 
NRG-1. The acidic Glu-residue present in TGFα is in close proximity to this cluster of residues (58), 
which may explain its inhibitory effect on ErbB-2/ErbB-3 activation.  
 It has been shown that particularly amino acids around the second and sixth cysteine of EGF and 
TGFα are involved in binding to ErbB-1, while amino acids in the N-terminal linear region can be 
freely mutated without an effect on receptor binding. The contribution of individual amino acids in 
the B-loop for ErbB-1 binding is still controversial, since this region is merely believed to have a 
scaffold function for presentation of the receptor binding epitope (7,28-30). In contrast, we show in 
the present study that amino acids in the N-terminal linear region and the B-loop of EGF-like growth 
factors are directly involved in ErbB-2/ErbB-3 activation, which suggests that T1E uses different 
amino acids for binding to ErbB-1 than for interaction with ErbB-2/ErbB-3. Figure 7 shows a 
representation of the three-dimensional structure of hEGF, in which the amino acids involved in 
binding of EGF-like growth factors to ErbB-1 and to ErbB-2/ErbB-3 are indicated. The fact that these 
residues are located on opposite sides of the EGF molecule, would suggest that T1E is a bifacial 
ligand, which can recognise a specific ErbB receptor with one face and another ErbB receptor with a 
second face. This hypothesis may seem in contradiction with the results of the alanine scanning of 
NRG-1α, from which it was concluded that many residues in the A-loop and C-loop important for 
neuregulin binding correspond to critical residues in EGF and TGFα for binding to ErbB-1 (61). 
Alanine mutation studies do, however, not discriminate between residues that are important for the 
proper conformation of the growth factors and residues that are directly involved in receptor binding 
(62). Recently it was shown that in the crystallographic structure hEGF is present as an asymmetric 
dimer, in which the identified residues in the A-loop and C-loop are part of the ligand-ligand interface 
(63). This may indicate that these residues are involved in ligand dimerisation, as a prerequisite for 
proper ligand-receptor complex formation, and are not part of the ligand-receptor interface. Crystal 
structures of the EGF/ErbB-1 complex are still lacking, but NMR studies on TGFα in interaction with 
the extracellular domain of ErbB-1 have provided evidence for specific immobilisation of residues in 
the A-loop and the C-terminal linear region (32,64).  
                                                     
1
 Numbering based on the EGF-domain of NRG-1 
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The observation that both biregulin and T1E bind with high affinity to ErbB-2/ErbB-3 heterodimers 
but not to ErbB-3 alone implies that these chimeras require the additional presence of ErbB-2 for 
stabilisation of the heterodimeric complex. In work to be published elsewhere we have obtained EGF 
mutants by a phage display approach On the basis of random mutation of the N-terminal linear region, 
which bind with high affinity to both ErbB-2/ErbB-3 heterodimers and ErbB-3 alone (see chapter 3). 
This indicates that residues in the N-terminal linear region of EGF-like molecules are directly 
involved in binding to ErbB-3. The dependence of these chimeras on ErbB-2 for high affinity ErbB-
2/ErbB-3 binding may suggest that they contain in addition a secondary binding site for ErbB-2, in 
analogy with the postulated bivalency model of NRG-1 (27). Since ErbB-2 is unable to bind ligand 
molecules on its own, ErbB-2/ErbB-3 heterodimeric complexes are presumably composed of one 
ligand molecule per receptor dimer, or alternatively of two ligand molecules per receptor tetramer 
(65). This is clearly different from the homodimeric complex formed upon binding of EGF (and most 
likely also T1E) to ErbB-1, which has been shown to contain two ligand molecules in complex with 
two receptor molecules (25). In conclusion, EGF and related growth factor are versatile signalling 
molecules with multiple potential receptor binding domains that are restricted in their activity by the 





Materials- Recombinant NRG-1β (EGF domain) was obtained from R&D Systems Europe (Abington, 
Oxon, UK). Natural murine EGF (mEGF) was from Bioproducts for Science Inc. (Indianapolis, IN). 
Radioactive materials were purchased from Amersham (Buckinghamshire, UK). Oligonucleotides 
were obtained from Eurogentec (Servaing, Belgium). 
 
 
Figure 7: Representation of the human EGF structure showing the relative postions of Ser2, Asp3, and
Leu26, as well as residues around the second and sixth cysteine described to be important for the







DNA Constructs- Recombinant human EGF, human TGFα and the majority of the EGF/TGFα 
chimeras were constructed as previously described (42). The genes were linked at the 5’-end to an 
IEGR encoding peptide sequence corresponding to the recognition sequence for the proteolytic 
enzyme Factor X and subsequently coupled to the sequence encoding two synthetic protein A-derived 
IgG-binding domains (so-called Z domains) by cloning into the expression vector pEZZ18 
(Pharmacia, Uppsala, Sweden)(40). The gene constructs encoding the EGF/TGFα chimeras 
designated T1E and T1E/I were produced by means of splice overlap extention PCR using pfu 
polymerase (New England Biolabs Inc., Beverly, MA)(43). The obtained products were purified, 
digested with the endonucleases Bam-HI and Sal-I and cloned into pEZZ18. Additional mutations in 
the N-terminal linear region were introduced using the QuickChange
TM
 site-directed mutagenesis 
(Stratagene, La Jolla, CA) approach, using either pEZZ/FX/T1E/I or pEZZ/FX/EGF as a template. 
Mutations within the B-loop region, located between the third and fourth cysteine, were introduced by 
the same method, using the EGF/TGFα encoding chimera T4E (pEZZ/FX/T4E) as a template. The 
exact sequence of the various mutants was verified by cycle sequencing (Perkin Elmer, Foster City, 
USA).  
 
Expression and purification of mutant growth factors- Recombinant growth factors were expressed 
and purified as described (40). Briefly, mutant growth factors were expressed as protein A-tagged 
fusion proteins in the protease K-deficient Escherichia coli strain KS474 and isolated from the 
periplasmic space. Growth factors were purified by means of affinity chromatography using IgG-
Sepharose, followed by Factor X cleavage, an additional round of affinity chromatography to remove 
the protein A-tag and a final reverse phase (RP)-HPLC purification step to remove disulphide bridge 
mismatches. The amount of growth factor was calculated from the peak area (absorption at 229 nm) 
in the RP-HPLC chromatogram, using natural mEGF as a standard. The affinity for ErbB-1 was 
routinely measured in a [
125
I]-mEGF binding assay on NIH3T3 cells transfected with the human 
ErbB-1 receptor (HER-14 cells). Some of the mutants were analysed as protein A-fusion proteins 
without further purification following acetone precipitation of the periplasmic fraction, and their 
activity to bind ErbB-1 was measured by [
125
I] mEGF binding competition in comparison with natural 
mEGF (40). The amount of active fusion protein thus obtained was subsequently calculated and 
expressed as ng mEGF-equivalents. 
 
Cell lines- Interleukin (IL)-3 dependent murine 32D haematopoietic progenitor cells transfected with 
the various human ErbB-encoding viral vectors or plasmids (a generous gift of Dr Y. Yarden, 
Rehovot, Israel) were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated foetal 
bovine serum (FCS, GibcoBRL, Paisley, Scotland) and 0.25 ng/mL mIL-3 (Promega, Madison, WI). 
The 32D sublines used, D1 (containing 1.8 × 104 ErbB-1 receptors/cell), D3 (containing 1.1 × 104  
ErbB-3 receptors/cell) and D23 (containing ErbB-2 and 1.3 × 104 ErbB-3 receptors/cell), were kept 
under continuous selection using 0.6 mg/mL G418 (Calbiochem, La Jolla, CA) and, in the case a 
second ErbB receptor was coexpressed, 0.4 mg/mL hygromycin B (Sigma, Zwijndrecht, The 
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Netherlands), as described (44). The human mammary carcinoma cell lines MCF-7 and MDA-MB-
453 were cultured in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 medium 
(DF) supplemented with 10% FCS. HER-14 cells (4.0 × 105 ErbB-1 receptors/cell) were cultured in 
gelatinised flasks in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
newborn calf serum (45). 
 
Cell proliferation assays- D23 cells were washed to deprive them from IL-3 and resuspended in 
RPMI 1640 medium supplemented with 0.1% bovine serum albumin (BSA). Subsequently cells were 
seeded into 96-wells plates at a density of 5.0 × 104 cells/well in 0.1 mL, together with serial dilutions 
of recombinant growth factors. In absence of IL-3 cell proliferation and survival can be obtained 
through activation of the expressed ErbB receptors. Cell survival was determined after 24 hours of 
incubation at 37 °C using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay, as previously described (44).  
 
Mitogenic assays- DNA replication of MCF-7 cells upon ligand stimulation was monitored through 
[
3
H]-thymidine incorporation. Cells were seeded in 24-wells plates at a density of 1.5 × 104 cells/well 
in 1 mL DF medium supplemented with 10% FCS. After 24 hours the medium was replaced by DF 
medium lacking phenol red, but supplemented with 30 nM Na2SeO3, 10 µg/mL human transferrin and 
0.5% BSA. Cells were serum starved for an additional 24 hours of incubation, and subsequently serial 
dilutions of growth factors were added in 50 µl of DMEM/BES/0.1% BSA, pH 6.8, basically as 
described (46). Eight hours later 0.5 µCi [3H]-thymidine was added in 50 µl Ham’s F12 medium and 
incorporated thymidine was determined 24 hours after growth factor addition. After fixation and 
permeabilisation in ice-cold 10% trichloroacetate (TCA) for 15 min at 4 °C, the cells were rinsed 
three times with 5% TCA to remove non-incorporated thymidine, and subsequently lysed by addition 
of 1 mL 2N NaOH for one hour at 37°C. Radioactivity was determined by liquid scintillation 
counting.  
 
Immunocytochemistry- MDA-MB-453 cells were seeded on gelatinised glass slides at a density of 1.0 
× 105 cells/well in 1 mL of DF medium supplemented with 10% FCS and grown for 4 days in absence 
or presence of the respective growth factor (100 ng/mL). Cells were stained with red-O oil to visualise 
neutral lipids as previously described (47). 
 
Immunoprecipitation and Western Blotting- MCF-7 cells were grown to confluence in DF medium 
with 10% FCS and serum starved for 16 hours prior to stimulation. D23 and D1 cells were serum 
starved for 2 hours prior to stimulation. Cells were exposed to the indicated growth factors (100 
ng/mL) for 7 min at 37 °C, rinsed three times with ice-cold phosphate-buffered saline (PBS) and lysed 
in RIPA buffer containing freshly added protease inhibitors (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 
1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 1.5 mM EGTA, 1.5 mM MgCl2, 1 mM PMSF, 5 




cleared by centrifugation and either analysed directly by SDS-PAGE or subjected to 
immunoprecipitation using 1 µg of the polyclonal antibodies 1005 (anti-EGFR), Neu (anti-ErbB-2) or 
C17 (anti-ErbB-3), all from Santa Cruz Biotechnology (Santa Cruz, CA). After one hour of 
incubation at 4 °C, protein A-Sepharose (Pharmacia, Uppsala, Sweden) was added and the incubation 
was continued for at least three more hours. Precipitates were centrifugated and rinsed three times 
with RIPA buffer, the proteins resolved on 7.5% SDS-poly acrylamide gels and electrophoretically 
transferred to nitrocellulose. Membranes were incubated for two hours in TBST (10 mM Tris-HCl pH 
7.5, 150 mM NaCl and 0.05% Tween-20) containing 1% low fat milk, probed with 0.5 µg/mL anti-
phosphotyrosine monoclonal antibodies (Upstate Biotechnology Inc., Lake Saranac, NY), or anti-p85 
antiserum (a generous gift from Dr. M. Ouwens, University of Leiden, Netherlands) for two hours, 
and subsequently incubated with a peroxidase-linked secondary antibody. Immunoreactive bands 
were visualised using enhanced chemi-luminescence (ECL, Boehringer, Mannheim). 
 
Ligand displacement experiments- Recombinant NRG-1β and the EGF/TGFα chimera T1E were 
radiolabelled using the Iodogen method (Pierce, Rockford IL) according to the manufacturer’s 
protocol for indirect labelling, resulting in a specific activity of 50-100 µCi/µg protein. Ligand 
displacement analyses were performed using 2.0 × 106 D1 cells, D3 cells or D23 cells. Cells were 
washed once with binding buffer (RPMI supplemented with 0.5% BSA) and subsequently incubated 





I]-T1E. Cells were then washed once with binding buffer and loaded onto a serum cushion to 
remove the unbound label. Subsequently cells were quickly spun down at 2000 rpm and cell surface-
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Epidermal growth factor (EGF) binds with high affinity to the EGF receptor, also known as ErbB-1, 
but upon replacement of the N-terminal linear region by neuregulin (NRG)-1 or transforming growth 
factor (TGF) α sequences it gains in addition high affinity for ErbB-2/ErbB-3 heterodimers. However, 
these chimeras only weakly bind to ErbB-3 alone. To further dissect the ligand binding selectivity of 
the ErbB network, we have applied the phage display technique to examine the role of the linear N-
terminal region in EGF for interaction with ErbB-2/ErbB-3 heterodimers. A library of EGF variants 
was constructed in which residues 2, 3 and 4 were randomly mutated, followed by selection for 
binding to intact MDA-MB-453 cells that overexpress ErbB-2 and ErbB-3 but lack ErbB-1. Analysis 
of the selected phage EGF variants revealed clones with high binding affinity to ErbB-2/ErbB-3 while 
maintaining high affinity to ErbB-1. In these variants, Trp (or alternatively His) was almost 
exclusively present at position 2, while specific combinations of hydrophobic, basic and small 
residues were found at positions 3 and 4. The mitogenic activity of the phage EGF variants 
corresponded with their relative binding affinity. Two of the selected EGF variants, EGF/WVS and 
EGF/WRS, were further characterised as recombinant proteins. In contrast to previously characterised 
chimeras of EGF with NRG-1 or TGFα, these variants did not only show high binding affinity for 
ErbB-2/ErbB-3 heterodimers, but also for ErbB-3 alone. These data show that the linear N-terminal 





The ErbB family of receptor tyrosine kinases includes the epidermal growth factor receptor (EGFR or 
ErbB-1), ErbB-2 (or Neu), ErbB-3 and ErbB-4. Activation of the intrinsic kinase activity occurs upon 
ligand binding and subsequent receptor dimerisation, during which both homodimeric and 
heterodimeric receptor complexes can be formed. ErbB receptors play an important role in 
oncogenesis, particularly as a result of their overexpression in many epithelial tumor cells (1, 2). 
Moreover, the ErbB signalling network is currently one of the most direct targets in the development 
of anti-tumor drugs.  
Soluble ligands for mammalian ErbB receptors can be divided into three groups depending on their 
receptor selectivity. The growth factors EGF, transforming growth factor (TGF) α and amphiregulin 
specifically bind ErbB-1, while betacellulin, epiregulin and heparin-binding EGF-like growth factor 
can interact with both ErbB-1 and ErbB-4. Finally, the numerous isoforms of neuregulin (NRG)-1 to 
4 specifically bind to ErbB-3 and/or ErbB-4 (3-5). No soluble ligand has yet been identified for the 
ErbB-2 receptor.  
All ligands share a conserved structural EGF-like motif of around 50 amino acids, characterised by 
six conserved cysteines and two glycines which define a three-looped structure (A, B and C-loop, 
respectively) with flexible N- and C-terminal linear regions. Structural analysis of human EGF 
Chapter 3 
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revealed a major anti-parallel β-sheet in the B-loop region, and a minor anti-parallel β-sheet in the C-
loop (6, 7). Although several ligands contain extended sequences at the N- and C-terminal ends, the 
EGF-domain of ErbB ligands is sufficient for receptor activation. Receptor binding specificity of 
EGF-like growth factors is achieved by the presence of amino acids that facilitate binding to a specific 
ErbB receptor in addition to amino acids that impair interaction with other ErbB members (8). In the 





 conserved cysteine, including Tyr13, Leu15, His16, Tyr37, Arg41 and Leu47, are crucial for 
binding to ErbB-1, presumably by forming a non-linear binding domain (see Figure 1). While 
substitutions in the B-loop region were also found to affect ErbB-1 binding, its role is controversial 
and this region is believed to serve primarily as a scaffold for maintaining the proper conformation (6, 
9-12). By contrast, a combination of alanine scanning and structural analysis has shown that binding 
of NRG-1 to ErbB-3 involves a set of hydrophobic residues clustered in the linear N-terminal region 
and the B-loop (13, 14), suggesting that EGF-like growth factors may use distinct regions for binding 
to different ErbB receptors. Further evidence for an important role of the linear N-terminal region of 
EGF-like growth factors in ErbB-3 binding specificity is derived from the observation that exchange 
of the linear N-terminal region of EGF by NRG-1 or TGFα sequences results in chimeras, designated 
biregulin and T1E respectively, that not only show high binding affinity for ErbB-1 but also for ErbB-
2/ErbB-3 heterodimers (8, 15). Notably, residues in the linear N-terminal region in EGF are not 
involved in ErbB-1 interaction (15). In contrast to NRG-1, however, these chimeras were unable to 
bind ErbB-3 alone, suggesting that a low affinity interaction of these ligands with ErbB-3 is stabilised 
by subsequent binding of ErbB-2. 
Essential for the activity of the ErbB signalling network is the ability to undergo ligand-induced 
receptor dimerisation. ErbB-2 augments signalling through the ErbB network by acting as the 
preferred dimerisation partner to the other members of the family (16-18), resulting in enhanced 
ligand binding affinity and a higher diversity in second messenger signalling (19-21). Particularly in 
the case of ErbB-3 heterodimer formation with ErbB-2 is essential, since ErbB-3 receptors have an 
impaired tyrosine kinase domain and as a result ErbB-3 homodimers are biologically inactive (22, 
23). This mutual dependence makes the ErbB-2/ErbB-3 heterodimer a good model system to study 
ErbB receptor heterodimerisation. Although the precise mechanism of ligand-induced ErbB 
dimerisation is still unclear, it has been postulated that EGF-like growth factors may have a bivalent 
character and directly bridge two receptors into a dimeric complex (24-26). 
To gain more insight into the manner of interaction between EGF-like ligands and heterodimeric 
ErbB-2/ErbB-3 receptors, we focussed on the role of the linear N-terminal region in EGF for receptor 
binding. In a previous report we have shown that replacement of only two amino acids in the linear N-
terminal region of EGF by their TGFα equivalent (S2H and D3F) is sufficient to make EGF a high 
affinity ligand for ErbB-2/ErbB-3 dimers (8). In addition, mutagenesis studies on the EGF-domain of 
NRG-1β have indicated the importance of Val4 (14). In the present study we have optimised the 
binding of EGF to ErbB-2/ErbB-3 heterodimers by random mutation of positions 2, 3 and 4 in the N-
terminus using a phage display approach. Phage display has been shown to be a powerful technique to 
Selection of EGF variants binding to ErbB-2/ErbB-3 
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study receptor-ligand interactions, as it is an efficient method to rapidly select binders with enhanced 
affinity or altered selectivity to a target molecule (27). Variants with enhanced affinity to ErbB-
2/ErbB-3 were selected by binding to MDA-MB-453 cells expressing ErbB-2 and ErbB-3 but which 
are devoid of ErbB-1. Functional characterisation of the selected clones was obtained by binding and 
growth stimulation assays on 32D cells transfected with ErbB-2 and ErbB-3. Our data show that the 
EGF variants identified in this way show, unlike biregulin and T1E, not only high binding affinity for 
ErbB-2/ErbB-3 heterodimers, but also for ErbB-3 alone. These data are interpreted in terms of the 





Construction of the EGF/234 phage library  
To further elucidate the requirements for ErbB-3 binding and heterodimerisation with ErbB-2, the 
linear N-terminal region of human EGF was randomised at positions Ser2, Asp3 and Ser4. An 
alignment of the sequences of human EGF, the EGF/TGFα chimera T1E and the EGF-domain of 
human NRG-1β is given in Figure 1. In previous work we have shown that exchange of Ser2 and 
Asp3 of EGF for the corresponding His and Phe residues present in TGFα results in a ligand with 
high affinity for ErbB-2/ErbB-3 heterodimers, indicating that amino acids at these positions are 
important for selective binding to this heterodimer (8). Moreover, studies on NRG-1 have identified 
Val4 as part of the binding domain to ErbB-3 (14, 15). Therefore we have constructed the EGF/234 
library in which at positions 2, 3 and 4 all 20 amino acids were allowed, resulting in a complexity of 
8.0 × 103 different amino acid combinations. The completeness of the library was estimated from the 
number of independent transformants (1.2 × 106), while sequencing of an aliquot of the phage library 
Figure 1: Structure and sequence of 
EGF and related molecules. 
Representation of the human EGF 
structure showing the relative positions 
of Ser2, Asp3 and Ser4 randomised in 
the EGF/234 library, and the three 
disulphide-bridges formed by the six 
conserved cysteines. The figure was 
generated from the NMR coordinates of 
egf28.pdb available at 
www.ocms.ox.ac.uk/idc/ structures/egf 
(6). The alignment of the sequences of 
human EGF, the chimera T1E and 
human NRG-1β177-226 is given with 
numbering of the conserved cysteines 





confirmed the genetic diversity and the expected amino acid distribution (data not shown). 
Design of the selection procedure 
In order to select EGF variants with improved binding affinity for ErbB-2/ErbB-3 heterodimers, we 
first generated a T1E phage to serve as a positive control in addition to the previously described EGF 
phage (28) as a negative control. T1E was displayed on pIII minor coat protein using the type 3 vector 
fUSE5. Both T1E phage and EGF phage bound well to NIH 3T3 cells clone 2.2 transfected with 
human ErbB-1 (2.2/HER), but not to untransfected parental cells (Figure 2), which is indicative for 
receptor specific phage binding. T1E phage and EGF phage were also equally potent in ErbB-1 
receptor activation (data not shown), as measured by the induction of luciferase activity in 2.2/HER 
cells transfected with an SIE-luciferase construct (28). 
In order to find the best cell line for ErbB-2 /ErbB-3 selection, several cell lines expressing ErbB-2 
and ErbB-3 receptors were analysed for selective binding of T1E phage versus EGF phage and control 
phage expressing a non-related protein, using an ELISA assay on cells in suspension (Figure 2). D23 
cells, haematopoietic 32D cells lacking endogenous ErbB receptors transfected with both ErbB-2 and 
ErbB-3, were found to discriminate well between T1E and EGF phages. MCF-7 cells, which contain 
all four ErbB receptors to a different extent, did not discriminate between binding of T1E and EGF 
phage. By contrast, MDA-MB-453 cells, which have high expression levels of ErbB-2 and ErbB-3 
but have no detectable levels of ErbB-1 nor ErbB-4, clearly favoured binding of T1E phage over EGF 
phage. Thus, both D23 and MDA-MB-453 cells are appropriate candidates for selection of phages 
targeting ErbB-2/ErbB-3 receptors. To test the selection procedure for cells in suspension, these cell 
lines were next subjected to a mixture of T1E phage and negative control phages in a 1:1000 ratio 
followed by washing and acid elution of bound phages. The D23 cells did not survive the extensive 
washing procedure, resulting in very low output levels. The MDA-MB-453 cells were found to select 
T1E phages well (~65% of eluted phages represented T1E phage, indicating >500 fold enrichment), 
























Figure 2: Whole cell ELISA of phage 
on cells expressing different ErbB 
receptors. Differential binding of T1E 
phage (black bars), EGF phage 
(hatched bars) and control phages 
(white bars) (2-4 × 108 tu/100 µL) was 
determined on clone 2.2 NIH3T3 
fibroblasts and 2.2/HER cells (4 × 105
cells), or MDA-MB-453, MCF-7, 32D 
parental cells and 32D/23 cells 
expressing ErbB-2/ErbB-3 (2 × 106
cells). Amount of bound phage to cells 
in suspension was visualised by 
peroxidase-conjugated anti-M13 
antibodies. Data represent the mean ±
S.D. of two independent experiments 
performed in duplicate. 
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selection individual phage clones were screened in an ELISA on 32D parental versus D23 cells to 
confirm specific ErbB-2/ErbB-3 binding. 
 
Selection of EGF variants on MDA-MB-453 cells expressing ErbB-2 and ErbB-3 
The library of EGF/234 phages was subjected to three rounds of selection on MDA-MB-453 cells in 
suspension. After each selection round the pool of eluted phages was analysed for ErbB-2/ErbB-3 
binding in ELISAs on D23 cells. Already after the first selection round a clear improvement in 
binding was observed in comparison with the initial phage EGF/234 library, which is indicative for 
specific phage selection. Enrichment was also indicated by increased input/output ratios (data not 
shown). 
After selection individual phage clones were tested for specific ErbB-2/ErbB-3 binding by ELISAs on 
D23 cells versus parental 32D cells, and the sequence of clones able to bind ErbB-2/ErbB-3 was 
subsequently determined. Table I lists the sequence and the frequency of occurrence of the amino acid 
 
TABLE 1












Group 1 WRR 
e 
5 ++ 3 
WKR 2 ++ 2,3 
Group 2 WVR 
e 
5 ++ 2,3 
WVK 1 ++ 3 
WIK 1 ++ 3 
Group 3 WTR 
e 
6 ++ 2,3 
WTK 1 + 3 
WGR 1 + 3 
HGR 1 + 2 
Group 4 WVL 1 ++ 2 
WLL 1 ++ 2 
WWV 1 + 3 
HVV 1 + 3 
Group 5 WRT 2 ++ 2,3 
WRS 1 ++ 3 
WRG 2 ++ 2,3 
Group 6 WVS 2 ++ 2 
WVG 2 + 3 
WVA 1 ++ 3 
HVA 1 + 3 
WIS 1 + 3 
WIA 2 + 3 
WLS 1 + 3 
HWS 1 + 2 
Miscellaneous WMQ 1 + 3 
SWV 1 + 3 
HWE 1 + 2 
MTE 1 + 2 
Consensus   WVR   
a 
  
EGF variants were grouped according to the type of residue (basic, hydrophobic, small) found at positions 3 and 4 in 
combination with T rp2 or His2 (see Figure 3B). EGF variants chosen as representative clone for a given category are 
shown in  bold face   
b 
Total number of positive clones identified in phage ELISA n=47
c
Clones were identified as 
intermediate  (+), or high (++)affinity bin ders in phage ELISA on D23 cells in suspension. (+ )   Signal intensity  ≥60% 
compared to  T1E phage, (++) signal  > 80% compared to T1E phage
d
 
Clones were isolated after 2 or 3 selection 
rounds on MDA - MB - 453 cells 
e 




combinations on position 2, 3 and 4 of the selected EGF variants. EGF variants were subdivided into 
a group of high affinity binders (n=30) and of intermediate binders (n=17) according to the signal 
intensity in ELISAs using T1E phage as a positive control. No exclusive convergence was observed 
after three rounds of selection, indicating that multiple substitutions in EGF result in enhanced ErbB-
2/ErbB-3 binding. However, analysis of the occurrence of amino acids per position showed that 85% 
of the selected EGF variants contained Trp at position 2, while the remaining variants had 
predominantly a His residue (11%), indicating that an aromatic amino acid is preferred at this position 
(see Figure 3A). At position 3 mostly hydrophobic residues (43%), predominantly Val, were 
observed, although basic residues were also frequently found (26%). At position 4 the majority of 
clones contained a basic residue (49%), but also small residues as Ser and Thr (19.1%) or Gly and Ala 
(14.9%) were regularly found. It is important to note that 60% of all selected clones contained at least 
one basic residue at position 3 or 4, which indicates that there is a selection in favour of a positively 
charged residue in this region, although the precise position seems of less importance. Relatively more 
His residues were found at position 2 in the intermediate binders (25%) in comparison with the high 
affinity binders (3.3%). Intermediate binders also contained more small residues at positions 3 and 4 
at the cost of basic residues. In general the diversity of isolated clones was not clearly reduced in 
round 3 compared to the clones isolated in round 2. 
 
Selected EGF variants fall into six categories 
 The selected EGF variants can basically be grouped in six categories according to the type of amino 
acid (basic, hydrophobic, small) found at positions 3 and 4, combined with Trp or His at position 2. 
Figure 3B depicts the most frequently observed sequences found in each category, hereafter referred 
to as representative clones. These data imply that selection occurred for distinct combinations of 
 
Figure 3: Schematic representation of the amino acid distribution in selected EGF/234 variants. A Frequency of 
occurrence of amino acids at positions 2, 3 and 4 in selected EGF variants. Both high and intermediate affinity binders, 
as determined in phage ELISAs on D23 cells, were used (n=47). Grey area represents residues other than depicted
(see Table I). B Categorisation of selected EGF variants according to the combination of amino acids found at positions 
3 and 4, in addition to an aromatic (W or H) residue at position 2. The y-axis depicts the type of residue according to 
biochemical properties found at position 3, and the x-axis at position 4. The indicated sequence corresponds to the most 
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residues following the aromatic Trp2. A hydrophobic residue at position 4 was only observed in 
combination with a hydrophobic residue at position 3 (WVL), but not with a basic or small residue. In 
contrast, at position 4 a basic residue seems to be favoured, independent of the residue present at 
position 3. The highest diversity of sequences was found in the category of the WVS type, although 
many clones in this group represent intermediate affinity binders. Interestingly, the corresponding 
sequences present in T1E (HFN) and EGF/S2H-D3F (HFS) were not observed. In conclusion, 
although many different sequences seem to confer ErbB-2/ErbB-3 binding, all selected sequences fit 
into a strict pattern of combinations of residues. 
 
Mitogenic potency of EGF phage variants correlates with their binding 
To assess the biological potency of the EGF variants selected for enhanced ErbB-2/ErbB-3 binding, 
representative phage clones of each of the six categories were propagated on a larger scale. The titers 
of the PEG-purified and subsequently filter-sterilised phages were estimated on the basis of 
spectrometry, titration and phage ELISA. Figure 4A depicts the binding of the representative EGF 
variants measured in ELISA on D23 cells in a dose-response experiment. Each of these phage clones 
bound D23 cells at least as well as T1E phage, with only slight differences between distinct EGF 
variants. Phage EGF served as a negative control. Next the same phage clones were analysed for the 
potential to induce proliferation of D23 cells using the MTT assay, which measures mitochondrial 




























































































Figure 4: Comparison of cell binding and 
mitogenic activity of representative EGF 
variants on cells coexpressing ErbB-2 and 
ErbB-3. A Cell binding of the different 
representative EGF variants was measured 
in phage ELISA on D23 cells in suspension. 
B The potency of the representative EGF 
variants to induce proliferation of D23 cells 
was determined by the MTT assay, which 
measures mitochondrial activity in living 
cells. Cells were deprived of IL-3 and 
subsequently incubated at 37 °C in 
absence or presence of serial dilutions of 
filter-sterilised phages for 24 hours. In both 
experiments EGF phage and T1E phage 
served as controls. Phage EGF (+), T1E 
(Ο), EGF/WRR (♦), EGF/WVR (◊), 
EGF/WTR (□), EGF/WVL (▲), EGF/WRS 
(●), EGF/WVS (∆). Results of the MTT 
assay are presented as fold induction in 
treated cells versus untreated cells. 
Experiments were performed three times in 




D23 cells in comparison with EGF phage, and were all at least as potent as T1E phage. The mitogenic 
activity of the representative EGF variants on D23 cells corresponded in general well with their 
relative cell binding ability (Figure 4B). Thus, in a phage format selected EGF variants showed 
improved capacity to bind and activate ErbB-2/ErbB-3 heterodimers when compared to wild-type 
EGF.  
 
The influence of Trp versus His residues at position 2 in EGF/234 variants 
Several EGF variants identified as intermediate binders were found to contain a His residue at 
position 2, while most high affinity binders contain a Trp at this position. Remarkably, in the natural 
growth factors often His, but never Trp is observed at the equivalent position. To examine whether the 
preference for Trp2 was due to true affinity enhancement and to exclude possible selection bias for 
Trp-residues, we compared various phage clones which differed only in Trp or His at position 2 with 
respect to D23 cell binding and proliferation. Figure 5 shows that at similar concentrations, variant 
EGF/WVA shows more cell binding (left panel) and mitogenic activity (right panel) on D23 cells than 
EGF/HVA, although the differences are relatively small. More pronounced differences were observed 
in the case of phage clone EGF/WGR, which was found superior to EGF/HGR in both cell binding 
and proliferation, while EGF/VGR failed to bind D23 cells and had a similar low activity as EGF 
phage. The representative clone of this category, EGF/WTR, exceeds EGF/WGR in binding and 
activation, suggesting that the most abundantly isolated clone represents the strongest binder within 
this category. Taken together these data show that the abundant occurrence of Trp at position 2 in 
selected EGF/234 variants results directly from their enhanced affinity for ErbB-2/ErbB-3. 
 
Characterisation of recombinant EGF mutants for binding to distinct ErbB receptors  
Phage display of randomised EGF variants is a useful method to identify the sequences involved in 
selective ErbB-2/ErbB-3 binding, but it is inappropriate for the determination of accurate receptor 
binding affinity of the various variants. Since each phage may potentially display 2-5 copies of each 
ligand, multivalent receptor interactions may occur, resulting in an increased apparent affinity or 
Figure 5: Comparison of cell binding and mitogenic activity of EGF variants containing either Trp or His
residues at position 2. Left panel, Binding of distinct phage EGF variants to D23 cells was measured by 
ELISA on cells in suspension. Right panel, Ligand-induced proliferation of D23 cells by the same phage 
EGF variants was determined in the MTT assay after 24 hours incubation. In both assays the concentration
of phage used was 1 × 1010 tu. Experiments were performed two times in triplicate and a representative
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avidity effect. Therefore we have expressed two representative EGF variants as soluble recombinant 
proteins in Escherichia coli. Since in the selected EGF variants the wild-type Ser4 residue was 
regularly observed, we focussed on the contribution of Trp2 in combination with either Val3 or Arg3. 
The variants EGF/WVS and EGF/WRS, respectively, were further characterised as mutant proteins 
after RP-HPLC purification with respect to their relative binding affinities and mitogenic potencies to 
different ErbB receptors. 
First, the recombinant EGF mutants were analysed for ErbB-1 binding by displacement of [
125
I] 
mEGF binding on HER-14 cells overexpressing human ErbB-1 receptors. Figure 6A shows that the 
ErbB-1 receptor binding capacity of EGF/WVS and EGF/WRS was completely retained in 
comparison with EGF and T1E. These data confirm previous observations that residues in the N-
terminal linear region of EGF are not relevant for in ErbB-1 interaction (15). 
Second, the EGF mutants were analysed for binding to ErbB-2/ErbB-3 expressing cells. Figure 6B 
shows the ability of the various ligands to compete with [
125
I] NRG-1β binding to D23 cells. 
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Figure 6: Ligand displacement 
analysis of recombinant EGF mutants 
on cells expressing different subsets 
of ErbB receptors. A Displacement of 
[
125
I] mEGF binding on HER-14 cells 




binding on 32D cells coexpressing 
ErbB-2 and ErbB-3 (D23 cells) or, C 
on 32D cells expressing ErbB-3 alone 
(D3 cells). Cells were incubated for 2 
h at 4 °C in the presence or absence 
of serial dilutions of the unlabelled 
ligands EGF (+), NRG-1β (■), T1E 
(Ο), EGF/WRS (●) or EGF/WVS (∆). 
In case of the 32D cells, unbound 
ligand was removed by centrifugation 
of the cells through a serum cushion, 
after which radioactivity was 
determined in the cell pellet. Results 
are presented as mean ± sem of at 
least three independent experiments 
performed in duplicate.  
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the affinity of EGF/WVS was 5–fold higher than the affinity of T1E, nearly similar to NRG-1β. Wild-
type EGF competed under these conditions only at concentrations above 500 ng/mL (36). 
Third, the two EGF mutants were analysed for binding to 32D cells expressing ErbB-3 alone (D3 
cells). We have previously shown that T1E binds with high affinity to ErbB-2/ErbB-3 complexes, but 
only weakly to the ErbB-3 receptor alone (8). A similar observation has been made for the NRG-
1/EGF chimera biregulin (25). Interestingly, both EGF/WVS and EGF/WRS showed a ten-fold higher 
relative binding affinity than T1E in a competition experiment with [
125
I] NRG-1β on D3 cells, with 
an apparent affinity 10-fold lower than NRG-1β (Figure 6C). Taken together, these data indicate that 
the substitution of WVS and WRS into EGF specifically enhances the binding affinity for ErbB-3, 
leaving the ErbB-1 binding unaffected. This results in ligands that not only strongly bind to ErbB-1 
and ErbB-2/ErbB-3 receptors, but that also bind to ErbB-3 alone.  
 
Mitogenic activity of recombinant EGF mutants through distinct ErbB receptors 
Finally the EGF mutants were analysed for the ability to activate distinct ErbB receptors by measuring 
both ligand-induced tyrosine phosphorylation and the mitogenic activity in 32D cells expressing 
specific ErbB receptor members. Figures 7A+C show that EGF/WVS and EGF/WRS are equally 






















































































































Figure 7: Activation of different ErbB receptor members by recombinant EGF mutants. A, B Induction of cell 
proliferation of 32D cells expressing ErbB-1 (D1 cells) and D23 cells by EGF (+), NRG-1β (■), T1E (Ο), EGF/WVS (∆) 
or EGF/WRS (●) as measured in a MTT assay after 24 hours. Data points represent the average of two experiments 
performed in duplicate. C, D Induction of tyrosine phosphorylation in D1 cells or D23 cells after stimulation for 7 
minutes at 37 °C with the indicated ligands at 100 ng/mL determined by immunoblotting (IB) with anti-phosphotyrosine 
(PY) antibodies following SDS-PAGE of whole cell lysates. Western blots were reprobed after stripping with anti-ErbB-
1 or anti-ErbB-3 antibodies. The 180 kDa marker protein is indicated. 
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ErbB-1 (D1 cells). In addition, both mutants resembled wild-type EGF in inducing proliferation of D1 
cells. Next the activation of ErbB-2/ErbB-3 heterodimers was examined by measuring tyrosine 
phosphorylation of ErbB-2 and ErbB-3 receptors in whole cell lysates of D23 cells. As shown in 
Figure 7D, EGF/WVS was similarly potent as NRG-1β in inducing receptor tyrosine phosphorylation 
of D23 cells, while EGF/WRS and T1E were slightly less active. The same order of potencies was 
observed in a mitogenic assay on D23 cells, where EGF/WVS was also a stronger mitogen than 
EGF/WRS (Figure 7B). These data show that potent receptor activation and cellular stimulation 






In order to understand the selectivity of ligand binding to different members of the ErbB receptor 
family, we have studied the role of the linear N-terminal region of EGF-like ligands for interaction 
with ErbB-2/ErbB-3 heterodimers. In a previous study we have shown that exchange of the linear N-
terminal region of EGF for TGFα sequences results in a ligand (T1E) with high affinity for ErbB-
2/ErbB-3 heterodimers, but low affinity for ErbB-3 alone. Similar results were obtained with a ligand 
in which only two amino acids of TGFα (S2H and D3F) were incorporated into EGF (8). In the 
current study we have used a phage display approach to optimise the binding of EGF to ErbB-2/ErbB-
3 heterodimers by random mutation of the residues at positions 2, 3 and 4. Using whole cell selection 
several EGF variants with strong ErbB-2/ErbB-3 binding capacity were obtained, leading to a clear 
view of the sequence determinants that convert receptor specificity of EGF. Moreover, our results 
demonstrate that the selected EGF clones result in ligands that do not only have increased affinity for 
ErbB-2/ErbB-3 heterodimers, but also for ErbB-3 alone.  
Comparison of the NMR solution and crystal structures reveals that the N-terminal linear region of 
human EGF is completely flexible, while in NRG-1α it forms the third strand of a triple β-sheet with 
the B-loop (6, 7, 13, 37, 38). TGFα has a slightly more structured N-terminus than EGF (39). In the 
structure of NRG-1α two patches of hydrophobic and positively charged residues are exposed on 
opposite sites of the major triple β-sheet (13). One of these hydrophobic clusters of residues 
comprising Leu3, Phe21, Val23 and Leu33 has been implicated for ErbB-3 binding in an alanine 
scanning mutagenesis study, suggesting it may form the ErbB-3 binding site, although also mutation 
of residues in other regions affected the binding capacity (14). Our results subscribe the idea that 
sequences in the N-terminal linear region directly participate in ErbB-3 receptor binding. In case the 
N-terminus is improved for ErbB-3 binding, as in EGF/WVS and EGF/WRS, these ligands are 
capable to form both ErbB-3 homodimers and ErbB-2/ErbB-3 heterodimers. In case the N-terminal 
sequences are sub-optimal for ErbB-3 binding, as in the chimeras T1E (HFN) and biregulin (HLV), 
the weak ErbB-3 binding can nevertheless be stabilised by subsequent heterodimer formation with 
ErbB-2. Previously Tzahar and coworkers (25) postulated that NRG-1β contains two separate binding 
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sites for two receptors, including a specific, high affinity binding site for ErbB-3 and a broad specific, 
low affinity binding site for another ErbB member such as ErbB-2. If EGF-like growth factors indeed 
may be bivalent ligands, this would imply that T1E and biregulin should contain a good secondary 
binding site for ErbB-2, but not for ErbB-3. In contrast, the improved primary ErbB-3 binding site of 
the EGF/WVS and EGF/WRS mutants in combination with the poor secondary binding site for ErbB-
3 may already be sufficient to stabilise the dimer, although dimerisation with ErbB-2 still seems 
preferred.  
Phage display has been shown to be a powerful technique to achieve altered selectivity or enhanced 
binding for target molecules after randomisation of ligand epitopes (27, 40-42), and has been applied 
successfully for binding optimisation of EGF-like growth factors (43-45). Moreover, selection of 
phage libraries performed on cell surface-expressed receptors has the advantage that the natural 
conformation is conserved, although other reports also described successful selection using purified 
receptor molecules (45, 46). The most prominent amino acid residue present in the isolated EGF-
variants with ErbB-2/ErbB-3 binding capacity was the Trp residue at position 2, implying that this 
residue is mainly responsible for the gain in binding affinity. In a phage display study for optimisation 
of NRG-1β binding to ErbB-3-IgG fusion proteins, Trp was exclusively found at position 1 in the 
randomised N-terminus, in combination with different hydrophilic residues at position 2 (45). Since 
the Trp residue is located at the signal peptide cleavage site, the authors could not exclude the 
possibility of expression bias. The enrichment for Trp-residues could also result from a length 
requirement to extend beyond a possible steric inhibition of the pIII molecule. However, these 
arguments do not seem relevant for the present study, since the fUSE5 vector used here contained an 
N-terminal extension of three residues between the signal peptide cleavage site and the ligand, which 
makes the possibility of a phage artefact unlikely. The observation that a Trp-residue is abundantly 
recruited at position 2 of EGF therefore most likely indicates that this aromatic residue strongly 
enhances ErbB-3 binding.  
In the selected EGF variants hydrophobic residues were particularly abundant at position 3, in 
agreement with the presence of Leu in NRG-1 and Phe in the chimera T1E. However, the frequent 
occurrence of basic residues (WRR- and WRS-categories) indicates that there is no absolute need for 
hydrophobicity at this position. This suggests that the presence of Trp2 may already provide sufficient 
hydrophobic packing. On the other hand, the difference in binding affinity between the WVS and 
WRS mutants indicates that the additional hydrophobicity derived from Val3 results in higher affinity 
to ErbB-2/ErbB-3. Residues with a hydrophilic character, either the basic Arg or small hydrophilic 
Ser and Thr, seem to be preferred at position 4. In contrast, in randomised NRG-1 selected for binding 
to ErbB-3-IgG fusion proteins the hydrophobic residues were predominantly found at postions 3 
(Leu) and 4 (Val) (45). Interestingly, in the present study EGF variants with hydrophobic residues at 
position 4 (WVL-category) were found in only 4 out of 47 clones. Taken together, our results indicate 
that for optimal binding to ErbB-2/ErbB-3 receptors, EGF should preferentially contain an aromatic, a 
hydrophobic and a positively charged amino acid at its positions 2, 3 and 4, although the exact 
position of these distinct residues may not be very strict. 
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Since the N-terminal linear region of EGF is unstructured, while in NRG-1 it forms a β-strand, the 
selected sequences may very well reflect a structural requirement for ligand binding to ErbB-3. This is 
in agreement with the observation that substitutions in the N-terminus of EGF selectively affect ErbB-
3 but not ErbB-1 binding. Besides having a function in direct receptor interaction, selected 
hydrophobic and aromatic residues in the N-terminus might contribute to hydrophobic packing with 
residues in the B-loop of EGF. The selected EGF variants are enriched for β-branched amino acids 
such as Thr and Val, and for amino acids with a tendency to support β-strand formation, as expressed 
in the Chou-Fasman algorithm (47). For instance, at each position Trp was preferred above His, Thr 
above Ser, and Arg above Lys. This suggests that the selected sequences may also favour stabilisation 
of the N-terminal linear region of EGF into a β-strand as a structural requirement for EGF-like growth 
factors to bind ErbB-3. Determination of the NMR solution structure of T1E or any of the EGF 
variants selected here should reveal whether the proposed enhanced stabilisation of the N-terminal 
linear region has indeed occurred. 
When comparing the present results with those on optimisation of NRG-1β binding to ErbB-3 (45), it 
should be realised that the studies have been carried out in an entirely different background of 
adjacent amino acids. By random mutation of only positions 2, 3 and 4, compensatory sequences can 
be selected that are not relevant for other ligand molecules. For instance, the presence of basic 
residues in 60% of all selected EGF variants at either position 3 or 4 could be due to compensation of 
the presence of the acidic Asp5 in EGF, whereas NRG-1 contains a basic residue Lys5. Alternatively, 
since the B-loop of NRG-1 is enriched for basic residues (Lys24, Arg31, Lys35) in comparison with 
EGF (Lys28), the selected basic residues may compensate for the lack of positive charge in the 
adjacent B-loop. The importance of the local structure for receptor interaction is also illustrated by the 
report that exchange of the linear N-terminal region of NRG-1α with TGFα sequences strongly 
impaired the ability to bind ErbB-2/ErbB-3, while introduction of similar sequences into EGF (T1E) 
strongly enhanced this ability (8, 48). In comparison with EGF, the B-loop of NRG-1 is extended by 
three residues, which form an irregular Ω-loop. It would be interesting to study whether the presence 
of the Ω-loop plays a role in this controversy. Recently it has been shown that a chimera in which the 
linear N-terminal region of NRG-1 is introduced into TGFα is unable to activate ErbB-2/ErbB-3 
heterodimers, thus emphasising the importance of the presence of appropriate amino acids in the B-
loop region (49). 
The present data indicate that a Trp-residue in the N-terminal linear region of EGF-like growth factors 
strongly enhances the binding affinity for ErbB-3. It is therefore intriguing that most natural ErbB-3 
binding ligands have the less efficient His-residue at this position. Among them are NRG-1 (residues 
HLV), NRG-2 (residues HAR) and the viral Shope fibroma growth factor (residues HVK), but also 
the ErbB-1 binding ligands TGFα (residues HFN) and betacellulin (residues HFS)(8, 15, 36, 50-52). 
Intriguingly, Myxoma growth factor with the sequence RIK at these positions has been reported as a 
selective activator of ErbB-2/ErbB-3 heterodimers (50). This suggests that natural ligands are not 
necessarily optimised for high binding affinity to their receptor. This is also indicated by the 
observation that a high affinity ligand such as NRG-1β could be further optimised more than 50-fold 
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for ErbB-3 binding (45). Data from our group (unpublished results) and others (53) indicated that the 
mitogenic activity of EGF for ErbB-1 containing cells is limited by internalisation and degradation of 
the receptor-ligand complex before cells are triggered to enter S-phase. As a consequence EGF 
mutants with a lower affinity for ErbB-1 were found to be at least as mitogenic as EGF itself. This 
suggests that an intermediate binding affinity coupled to strict receptor selectivity is most appropriate 
for the biological activity of natural ligands, especially under conditions where multiple ErbB 
members are coexpressed. EGF-like growth factors are also widely used to target toxins or other drugs 
to cells overexpressing ErbB receptors (54, 55). The present observation that EGF with only two 
mutations (S2W, D3V/R) is a high affinity ligand for ErbB-1, ErbB-3 and ErbB-2/ErbB-3 
heterodimers, makes this type of pan-ErbB ligands interesting candidates for targeting toxins to cells 





Construction of the human EGF/234rand library -A library of phage-EGF randomly mutated at 
positions 2, 3 and 4 was constructed by a PCR-based approach using a degenerate oligonucleotide 
primer (forward primer: 5’-GCGGTACCGGCCGACAANNSNNSNNSGAGTGTCCGTTGAGT 
CACGAC -3’, reverse primer: EGFback (28)) using fUSE5/hEGF as template. The PCR fragments 
were cloned into the phage fd fUSE5 vector (29) using the Eag-I and Sfi-I sites. Ligation products 
were electroporated into Escherichia coli TG-1 cells for phage production. The number of 
transformants was calculated and used to determine the size of the library. Randomly picked clones 
from the library were sequenced by cycle sequencing (Perkin-Elmer) to confirm diversity of codon 
use. 
 
Cell lines -Interleukin (IL)-3 dependent murine 32D haematopoietic progenitor cells transfected with 
the various human ErbB-encoding viral vectors or plasmids were cultured in RPMI-1640 medium 
supplemented with 10% heat-inactivated fetal calf serum (FCS, GibcoBRL, Paisley, Scotland) and 
0.25 ng/mL mIL-3 (Promega, Madison, WI). The 32D sublines used, designated D1 (ErbB-1, 1.8 × 
10
4
 receptors/cell), D3 (ErbB-3, 1.1 × 104 receptors/cell) and D23 (ErbB-2 and ErbB-3, 1.3 × 104 
ErbB-3 receptors/cell), were kept under continuous selection using 0.6 mg/mL G418 (Calbiochem, La 
Jolla, CA) and, in the case a second ErbB receptor was coexpressed, 0.4 mg/mL hygromycin B 
(Sigma, St Louis, MO, USA) as described (30). The human mammary carcinoma cell lines MDA-
MB-453 and MCF-7S were cultured in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and 
Ham’s F12 medium (DF) supplemented with 10% FCS. Murine NIH-3T3 clone 2.2 cells devoid of 
endogenous ErbB-receptors, and two different NIH-3T3 clones transfected with hErbB-1, 2.2/HER 
and HER-14 cells (both 4.0 × 105 human ErbB-1 receptors/cell), were cultured in gelatinised flasks in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% newborn calf serum (31). 
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Preparation of phage -Phage preparations were carried out as described (32). For ELISAs, small scale 
phage preparations were used. Bacterial clones were grown at 30 °C in 1.5 mL of 2xTY medium 
containing 12.5 µg/mL tetracycline. To the culture supernatant polyethylene glycol (PEG) 8000 was 
added to precipitate the phages. Phages were finally resuspended in 100 µL phosphate-buffered saline 
(PBS: 136 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) typically resulting in 
phage titers of 1-5 × 1010 tu/mL. 
 
Selection on cells in suspension -The procedure for panning on whole cells in suspension was adapted 
from Watters et al. (33). MDA-MB-453 cells were harvested by trypsination, washed in PBS 
supplemented with 10% FCS, centrifuged for 4 min at 1200 rpm, resuspended in selection buffer 
(PBS supplemented with 0.1 % bovine serum albumine (BSA), 1 mM CaCl2 and 2 mM MgCl2) and 
pre-incubated for 30 min at room temperature. Phage selections were carried out by incubation of 2 × 
107 cells together with 3 × 108 phages of the EGF/234 library in 3 mL selection buffer for 1 hour at 
room temperature with gentle agitating. Unbound phages were removed by washing the cells ten 
times with 10 mL PBS containing 0.1% Tween 20, by spinning the cells for 4 min at 1000 rpm 
followed by resuspension. Two subsequent washes were performed with PBS. During the washing 
procedure, cells were transferred twice to clean tubes to get rid of phages non-specifically bound to 
the plastic. Cell-bound phages were harvested by 8 min incubation in acid elution buffer (0.1 M 
HCl/glycine pH 2.2) followed by neutralisation of the eluate by adding an equal volume of 1 M Tris-
HCl pH 8.0. The eluate was transferred to an Eppendorf tube and spun for 5 min at 13000 rpm to 
eliminate cell debris, after which the supernatant was transferred to a fresh tube. Eluted fractions were 
used for phage titration and infection of logarithmic cultures of Escherichia coli strain TG-1. 
 
Whole cell phage ELISA -The procedure for ELISA using phage on whole cells in suspension was 
adapted from Hoogenboom et al. (34). Phage solutions were prepared in PBS/2% BSA. Cells were 
harvested, washed and resuspended in phage-binding buffer (RPMI, 10 mM HEPES, 2% BSA). Cells 
were seeded in 96-well microtiter plates with V-shaped bottom (Greiner 651101) at 1 × 106 cells per 
well in 0.15 mL and pre-incubated for 30 min at room temperature on a rowing-boat shaker, after 
which they were spun for 4 min at 1000 rpm. Cell pellets were carefully resuspended in phage mix. 
After incubation for 1 h at room temperature with gentle agitation, cells were spun for 4 min at 1000 
rpm, after which the supernatant was removed and cells washed three times with 0.18 mL PBS/well. 
For detection of cell-bound phage, cells were incubated for 1 h at room temperature with peroxidase-
conjugated anti-M13 antibody in PBS/1% BSA (Pharmacia Biotech,
 
Uppsala, Sweden). Cells were 
spun for 4 min at 1000 rpm and washed three times with PBS followed by addition of substrate, 0.1 
ml 0.4 mM 3,3’5,5’-tetra methyl benzidine (Sigma, St Louis, MO, USA) and H2O2 in 0.11 M citrate 
buffer pH 5.5. Reaction was terminated after 4 min by addition of 0.05 mL 2N H2SO4. Cells were 
spun for 4 min at 1000 rpm, and 0.12 mL of supernatant was transferred to a new 96-wells plate. 




Construction and production of recombinant EGF/234 mutants -Mutants EGF/WVS and EGF/WRS 
were constructed by introduction of the respective mutations in pEZZ/FX/EGF vector (35) using 
QuickChange
TM
 site-directed mutagenesis (Stratagene, La Jolla, CA). The exact sequence was verified 
by cycle sequencing (Perkin Elmer, Foster City, USA). Recombinant growth factors were expressed 
and purified as described (35). Briefly, mutant growth factors were expressed as protein A-tagged 
fusion proteins in the protease K-deficient Escherichia coli strain KS474 and isolated from the 
periplasmic fraction. Growth factors were resolved by means of affinity chromatography using IgG-
Sepharose, followed by Factor X cleavage of the tag, an additional round of affinity chromatography 
to remove the protein A-tag and a final reverse phase (RP)-HPLC purification step. The amount of 
growth factor was calculated from the peak area (absorption at 229 nm) in the RP-HPLC 
chromatogram, using natural murine (m)EGF as a standard. The proper molecular sizes of EGF/WRS 
and EGF/WVS were verified by MALDI-TOF analysis. 
 
Ligand Displacement Experiments -Natural mEGF (Bioproducts for Science Inc., Indianapolis, IN) 
and recombinant human NRG-1β177-246 (R&D Systems, Minneapolis, MN) were radiolabelled using 
the Iodogen method (Pierce) according to the manufacturer’s protocol for indirect labelling, resulting 
in a specific activity of 50-80 µCi/µg protein. Binding displacement on HER-14 cells was performed 
as described (35). Ligand displacement analyses on 32D cells were performed using 1.5 × 106 D23 
cells, or 2 × 106 D3 cells as described (30). Cells were washed once with binding buffer (RPMI 1640 
supplemented with 20 mM HEPES pH 7.4 and 0.5% BSA) and subsequently incubated for 2 hours at 
4 °C with serial dilutions of unlabelled ligand in the presence of 1 ng/mL [
125
I]-NRG-1β. Cells were 
washed once with binding buffer and loaded onto a 0.6 mL serum cushion to remove the unbound 
label. Subsequently cells were centrifuged at 2000 rpm and cell surface-bound radioactivity was 
determined by γ-counting. 
 
Cell proliferation assays -32D cells were washed in RPMI 1640 medium to deprive them of IL-3. 
Subsequently cells were seeded into 96-well tissue culture plates at a density of 5.0 × 104 cells/well in 
0.1 ml RPMI supplemented with 0.1% BSA, together with serial dilutions of filter-sterilised phages or 
recombinant growth factors. Cell survival was determined after 24 hours of incubation at 37°C using 
the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide (MTT) assay, as previously 
described (30).  
 
Western blotting -32D cells were serum-starved for 2 hours prior to stimulation. Cells were exposed to 
the indicated growth factors (100 ng/mL) for 7 min at 37 °C, rinsed three times with ice-cold PBS and 
lysed in RIPA buffer containing freshly added protease inhibitors (50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 1.5 mM EGTA, 1.5 mM MgCl2, 1 mM PMSF, 5 
µg/mlml pepstatin A, 0.15 units/mL aprotinin, 5 µg/mL leupeptin, 2 mM Na3VO4). Lysates were 
cleared by centrifugation and resolved by SDS-polyacrylamide electrophoresis (SDS-PAGE) using 
7.5% gels and electrophoretically transferred to nitrocellulose (Schleicher & Schuell, Germany). 
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Membranes were incubated for two hours in TBST (10 mM Tris-HCl pH 7.5, 150 mM NaCl and 
0.05% Tween-20) containing 5% low fat milk, probed with 0.1 µg/mL anti-phosphotyrosine (Upstate 
Biotechnology Inc., Lake Saranac, NY), anti-EGFR 1005 or anti-ErbB-3 C17 (both from Santa Cruz 
Biotechnology, CA) antibodies for two hours, washed twice with TBST and subsequently incubated 
with a peroxidase-linked secondary antibody. Immunoreactive bands were visualised using enhanced 
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Certain chimeras of EGF related growth factors can specifically interact with both ErbB-1 receptors 
and ErbB-2/ErbB-3 heterodimers, but the regions involved in receptor interaction appear to be located 
at opposite faces of the ligand. By substitution of two residues critical for ErbB-1 binding in the 
chimera T1E by the corresponding residues of the natural ErbB-2/ErbB-3 agonist NRG-1β, we aimed 
to selectively interfere with ErbB-1 interaction while preserving the ErbB-2/ErbB-3 binding affinity. 
However, T1E appears less sensitive to L15V and L47M mutation than EGF, as both mutants retained 
similar binding affinity for ErbB-1 and ErbB-2/ErbB-3 receptors as wild-type T1E. The L15A 
substitution strongly reduced the binding affinity of T1E for both ErbB-1 and ErbB-3 expressing 
cells, indicating that hydrophobicity at position 15 is a general requirement for ErbB interaction. The 
introduction of the entire C-terminal region of NRG-1β into T1E strongly affected the ErbB-1 affinity 
resulting in a five-fold reduction compared to T1E. This impairment could only be attributed in part to 
the loss of Leu47, and emphasises the influence of residues spatially adjacent to Leu47 in ErbB-1 
binding. While in the structure of the EGF-bound ErbB-1 complex Leu47 strongly contacts residues 
in domain III of ErbB-1, its contribution to the ErbB-1 interface of T1E appears much less 
pronounced. Our findings indicate that Leu15 and Leu47 within the T1E molecule do not directly 





The complex network of multiple EGF-like growth factors and the four members of the ErbB family 
of receptor tyrosine kinases plays a major role in mediating pleiotropic biological responses such as 
proliferation, differentiation, chemotaxis and neuronal outgrowth. The importance of a strict 
regulation of this network is illustrated by the implication of both receptor and ligand overexpression 
in several human cancers (1). Selective regulation of the ErbB-mediated biological action requires 
specificity of receptor-ligand interaction. 
Ligand binding induces dimerisation of the ErbB receptors, whereby besides homodimeric also 
heterodimeric complexes can be formed. While EGF-related growth factors share a structurally 
conserved EGF-domain dictated by three disulphide bridges, their sequence homology is only limited 
and growth factors display pronounced receptor specificity. EGF and six other growth factors 
amongst which transforming growth factor α (TGFα) bind and activate ErbB-1, while the neuregulins 
(NRG) 1-4 are the natural ligands for complexes of the ErbB-3 receptor and/or ErbB-4 (reviewed in 
2,3). Although no known soluble ligand directly binds to ErbB-2, this receptor serves as the preferred 
dimerisation partner for all three other ErbB receptors. Heterodimerisation with ErbB-2 is of 
particular importance for ErbB-3, which has impaired kinase activity and thus depends on a 
coreceptor for biological activity (4).  Heterodimerisation with ErbB-2 augments the signaling 
diversity and transformation potential of an ErbB receptor, and enhances the binding affinity by 
decelerating the ligand dissociation rate (5-9).  
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To achieve selective receptor binding, EGF-like ligands combine positive elements for interaction 
with one ErbB receptor with negative sequences to avoid interaction with other ErbB members (10). 
The receptor specificity of ligands is not discrete, but ligands have differential abilities to interact with 
multiple ErbB receptors albeit with strong differences in binding affinity (2,11). For instance, the 
growth factor betacellulin is a bispecific, high affinity ligand for both ErbB-1 and ErbB-4 (12). 
Likewise, EGF is a high affinity ligand for ErbB-1, but can also function as low affinity mitogen for 
ErbB-2/ErbB-4 and ErbB-2/ErbB-3 heterodimers (13-15). We and others have shown that two 
chimeras of EGF, in which the linear N-terminal region has been replaced for sequences of the ErbB-
1 ligand TGFα (T1E) or the ErbB-3/4 ligand NRG-1 (biregulin), have high binding affinity for both 
the ErbB-1 receptor and ErbB-2/ErbB-3 heterodimers, although their affinity for the ErbB-3 receptor 
alone is weak (16,17).  
The binding determinants of the chimera T1E for interaction with ErbB-1 and for interaction with 
ErbB-2/ErbB-3 heterodimers appear to be different. In previous work we have identified residues in 
both the linear N-terminal (His2, Phe3; numbering according to EGF) and B-loop (Leu26) region 
of T1E that confer specificity towards ErbB-2/ErbB-3 complexes (17). Moreover, by the use of a 
phage display approach the ErbB-2/ErbB-3 binding affinity of EGF could be enhanced by 
modification of N-terminal residues, emphasising their role in ErbB-3 binding (18). On the contrary, 
mutagenesis studies revealed that residues in the linear N-terminal region of EGF-like ligands are not 
important for ErbB-1 binding, while the contribution of hydrophobic residues in the B-loop region 
including Leu26 to ErbB-1 interaction is not without controversy (19,20). Instead, the requirement of 
EGF residues surrounding the second (Tyr13, Leu15, His16) and sixth cysteine (Tyr37, Arg41) and in 
the C-terminal linear region (Leu47) for ErbB-1 binding is widely acknowledged, and structural NMR 
data indicated that these residues are in close proximity at one side of the ligand (21,22). It thus 
appears that T1E contains independent binding sites for interaction with distinct ErbB members 
located at opposite faces of the molecule. 
To test this assumption, we set out to selectively impair the ability of the bispecific chimera T1E to 
bind ErbB-1 while preserving the binding capacity to ErbB-2/ErbB-3 heterodimers. Thereto two 
residues in T1E that are part of the ErbB-1 interface, Leu15 and Leu47, were substituted for the 
equivalent residue in NRG-1β (Val15 and Met50, respectively) to minimise the occurrence of 
concomitant effects on ErbB-2/ErbB-3 binding and activation. Since the NRG-1 counterpart for 
Leu15 is the biochemical similar Val residue, an additional mutant containing the L15A substitution 
was employed. The respective point mutations of these two residues in EGF or TGFα have been 
reported to result in reduced ErbB-1 binding affinity (23-26). We show that these substitutions within 
the T1E molecule do not strongly affect its ability to interact with ErbB-1, suggesting that T1E may 
bind ErbB-1 in a slightly different manner than the parental growth factors EGF and TGFα.  
 




Expression and purification of recombinant T1E mutants 
In the present study we have substituted residues involved in ErbB-1 binding to examine whether the 
ErbB-3 binding site in T1E is independent of the ErbB-1 binding site. Basically residues lacking a 
conformational role were targeted for mutation to the corresponding residue in NRG-1β, the natural 
activator of ErbB-2/ErbB-3 heterodimers. NMR analysis of EGF/L15A revealed only minor structural 
alterations in the growth factor compared to wild-type EGF, therefore Leu15 has been substituted by 
the NRG-1β residue Val (24). Given the high degree of similarity between the sidechain of Val and 
Leu, differing only in a CH2 group, an additional Ala substitution was performed. Previous studies 
have shown that L15V and L15A substitutions in EGF resulted in mutants with relative ErbB-1 
binding affinities of 18% and 0.9-2.4%, respectively, compared to wild-type (24,25,30-32). Another 
key residue conserved among ErbB-1 ligands across species that has been implicated in ErbB-1 
binding is Leu47 in EGF (25,26,32-34). Alteration of the size and geometry of the sidechain already 
reduced the ErbB-1 affinity of EGF, as illustrated by the L47V, L47I and L47M mutants with 1%, 
17% and 10% relative binding affinity. Structural determination of Leu47 replacements in both EGF 
and TGFα confirmed that this residue is not implicated in structural maintenance (33,35,36). All T1E 
mutants were expressed as fusion proteins with a proteinA-tag in Escherichia coli, and purified by 
 
Figure 1: Displacement of [
125
I] mEGF by 
distinct T1E mutants on ErbB-1 
expressing HER-14 cells. Monolayers 
were incubated in presence of 1 ng/ml 
radiolabelled mEGF with varying 
concentrations of each ligand: mEGF (+), 
T1E (Ο), T1E/L15A (▲), T1E/L15V (∆) 
and T1E/L47M (□).Data are given as % 
compared to the blanc control and each 
point represents the average of at least 
three experiments performed in duplicate.
 
 
Figure 2: Displacement of [
125
I] T1E by 
distinct T1E mutants on 32D cells 
expressing ErbB-2 and ErbB-3 (D23 
cells). Cells were incubated for 2 h at 4 
°C with radiolabelled ligand (2 ng/ml) in 
presence of serial dilutions of unlabelled 
NRG-1β (■), T1E (Ο), T1E/L15A (▲), 
T1E/L15V (∆), or T1E/L47M (□). Unbound 
ligand was removed by sedimentation of 
the cells through a serum cushion. Data 
represent mean of three independent 




































































affinity chromatography steps before and after cleavage of the tag. Recombinant T1E proteins were 
obtained after final reverse-phase HPLC purification and the proper size was verified by matrix-
absorbed laser diffraction index TOF analysis and (in case of T1E/L47M) by electrospray 
massaspectrometry. In several cases the HPLC chromatogram showed two major elution peaks with 
similar ErbB affinity; the peak with the highest hydrophobicity corresponded to the protein with the 
expected molecular size, while the other contained a truncated form corresponding to the respective 
T1E mutant missing the two N-terminal valines. Only the peaks containing the full-length proteins 
were used for further characterisation. 
 
Binding ability of T1E mutants to cells expressing ErbB-1 and ErbB-2/ErbB-3 
The effects of the replacement of Leu15 and Leu47 on the ability of T1E to bind ErbB-1 was 
addressed by binding competition on HER-14 cells, transfected murine NIH 3T3 fibroblasts that 
express 1-2 × 105 human ErbB-1 receptors per cell. Figure 1 shows the displacement of [125I] mEGF 
by each T1E variant, using unlabelled mEGF as a standard. The relative ErbB-1 binding affinity of 
T1E/L15A was 3.8% compared to native mEGF, in line with the diminished binding to 2.4% of 
EGF/L15A reported (24). However, the relative binding affinity of L15V was in the similar range as 
T1E with 62.4% of mEGF. Surprisingly, the L47M replacement in T1E did not reduce the relative 
ErbB-1 binding affinity, despite the findings by other groups that Leu47 substitutions completely 
abrogated the binding of EGF. Likewise, the effect of these point mutations in T1E on its ErbB-3 
binding ability was assessed by binding competition of 32D cells coexpressing ErbB-2 and ErbB-3 
(D23 cells). In figure 2 is shown that the L15V and L47M substitutions hardly affected the relative 
binding affinity of T1E towards ErbB-2/ErbB-3 heterodimers. By contrast, the L15A substitution 
resulted in a ligand with only 2.5% binding affinity of wild-type T1E for ErbB-2/ErbB-3 expressing 





























Figure 3: Ligand-induced proliferation of 32D cells expressing ErbB-1 (D1) and ErbB-2 and ErbB-3 (D23). The 
relative mitogenic activity of EGF (+), NRG-1β (■), T1E (Ο), T1E/L15A (▲), T1E/L15V (∆), T1E/L47M (□) was 
assessed by using the calorimetric MTT assay after 24 hours incubation and compared to unstimulated control
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ErbB-3 interaction of T1E, while the conserved L15V and L47M substitutions in T1E did not affect 
interactions with either receptor. 
 
Effect of leucine substitutions in T1E on the activation of ErbB expressing 32D cells 
We next examined the effect of the various substitutions in T1E on its ability to activate ErbB-1 and 
ErbB-2/ErbB-3 receptors. Since ErbB-expressing 32D sublines depend on the corresponding ligand 
for their growth and survival in absence of IL-3, the proliferative activity mediated by the T1E 
mutants was measured in the calorimetric MTT assay. Despite the low affinity for ErbB-1, the 
T1E/L15A mutant still exerted relatively high activity on 32D cells expressing ErbB-1 (D1 cells), 
while it was only a weak inducer of proliferation of D23 cells (Figure 3). The other mutants 
T1E/L15V and T1E/L47M induced similar cellular proliferation as wild-type T1E on both D1 and 
D23 cells, concomitant with their retained binding affinity.  
In addition, receptor activation was measured following ligand-induced tyrosine phosphorylation of 
specific ErbB receptors in the same cell lines, as well as in 32D cells coexpressing ErbB-1 and ErbB-3 
(D13 cells). Figure 4 indicates that at saturating concentrations (100 ng/mL) all T1E mutants were 
able to phosphorylate ErbB-1 in D1 cells to a similar extent as EGF and wild-type T1E, with a 
slightly lower induction by T1E/L15A. In D23 cells the ErbB-3 receptor was found to be 
phosphorylated by T1E/L15V and T1E/L47M but not by T1E/L15A. In the D13 cells strong 
phosphorylation of the ErbB-3 receptor was only observed in response to NRG-1β, while T1E/L15V 
and T1E/L47M induced a low amount of receptor phosphorylation. Interestingly, wild-type T1E did 
not show any ErbB-3 phosphorylation signal in these cells, suggesting that in spite of having similar 
binding affinities for ErbB-3 these mutants were more efficient inducers of ErbB-3 phosphorylation 
than T1E. On the contrary, the ErbB-1 receptor in D13 cells was readily phosphorylated by EGF, 
T1E, and all T1E mutants tested, most likely as a result of ErbB-1 homodimer formation. NRG-1β 
induced only a faint ErbB-1 phosphorylation signal in D1 cells, in agreement with previous 
observations (28,37). Taken together, the substitution of the T1E leucines 15 and 47 to the equivalent 
Figure 4: Ligand-induced ErbB 
phosphorylation in 32D cells 
expressing ErbB-1 alone (D1 cells), 
ErbB-2 and ErbB-3 (D23 cells) and 
ErbB-1 and ErbB-3 (D13 cells). 
Serum-starved cells were stimulated 
for 7 mins at 37 ºC with 100 ng/ml of 
the indicated ligands. ErbB proteins 
were immunoprecipitated from the 
cell lysates with anti-ErbB-1 (528) 
and anti-ErbB-3 (C-17) antibodies, 
and analysed on 8% SDS gels. 
Immunoblots were probed with anti-


















































residues found in NRG-1β did not affect the ability to signal through ErbB-1, nor through ErbB-3 
receptors. The mutation of Leu15 to alanine, however, abolished the activity of T1E on cells 
expressing ErbB-1 as well as ErbB-2/ErbB-3. 
 
Replacement of the entire linear C-terminal region in T1E affects ErbB-1 binding 
Work by different groups indicated that the presence of Leu47 in EGF (or the equivalent Leu48 in 
TGFα) is of crucial importance for ErbB-1 interaction, while within the EGF/TGFα chimera T1E the 
L47M substitution appears to have little effect on ErbB-1 binding and activation. To further examine 
the role of Leu47 in this chimera, we analysed several previously constructed T1E variants containing 
different C-terminal linear tails for ErbB-1 interaction (38). In these variants, the T1E residues 
following the sixth cysteine were exchanged by TGFα residues (EHADLLA), NRG-1β (QNYVMA) 
and a NRG-1 variant optimised for ErbB-3 binding (QHYVIA) (39). Figure 5 shows the relative 
binding affinity of the resulting chimeras T1E6T, T1E6N and T1E6N
opt
 for ErbB-1 using [
125
I] mEGF 
competitive binding analysis on HER-14 cells. The relative binding affinity of T1E6N for HER-14 
cells was decreased to 10% of mEGF, that of T1E6N
opt
 to 20-24% of mEGF, yet T1E6T retained full 
binding affinity for ErbB-1 similar to most other EGF/TGFα chimeras (40). Thus, while the single 
L47M substitution did not significantly alter the ErbB-1 binding and mitogenic properties of T1E, the 
additional mutation of the adjacent residues to NRG-1β sequences impaired the interaction with the 
ErbB-1 receptor. When Leu47 was replaced by a an isoleucine (as in optimised NRG-1) instead of a 
methionine, the impairment was less strong, suggesting that the decrease in ErbB-1 binding of T1E6N 
could be attributed only in part to the loss of Leu47. Furthermore, examination of the ability to induce 
proliferation of D1 cells revealed that all T1E mutants were equally strong mitogens, with the 
exception of T1E6N
opt
 which induced a ~10-fold stronger response (Figure 6). These findings are in 
agreement with previous observations where a decrease in ErbB-1 binding affinity did not correlate 






Figure 5: Ligand displacement analysis 
of T1E variants in which the entire 
linear C-terminal region is replaced for 
TGFα, NRG-1β or optimised NRG-1 
sequences. Displacement of 
radiolabelled mEGF by unlabelled 
ligands was performed on HER-14 cells 
expressing ErbB-1. EGF (+), T1E (Ο), 
T1E6T (●), T1E6N (∆), T1E6Nopt (□). 
Data represent the means of three 
independent experiments performed in 











































In the present study we have investigated whether two leucine residues in EGF that are critical for 
ErbB-1 interaction are also involved in specific ErbB-3 binding. By substitution of these residues in 
T1E by the corresponding residues of NRG-1β, the natural ErbB-2/ErbB-3 activator, we aimed to 
selectively interfere with the ErbB-1 interaction while preserving the ErbB-2/ErbB-3 binding affinity. 
Our findings indicate that although the presence of leucine or valine at position 15 is required for 
interaction of T1E with either ErbB-1 or ErbB-3 receptors, this residue does not contribute to 
specificity for different ErbB members.  Moreover, within T1E also the leucine at position 47 does 
not seem absolutely required for ErbB-1 binding and activation, in sharp contrast to the effects of 
EGF Leu47 substitutions reported by others. Moreover, the L47M substitution did neither improve 
nor impair the ability of T1E to bind and activate ErbB-3 heterodimeric receptors, and therefore 
seems not critical for specificity towards ErbB-3. 
The molecular basis for ErbB-1 specificity has recently been elucidated by determination of  the 
crystal structure of the ErbB-1 extracellular domain bound by EGF or by TGFα (42,43). In the 2:2 
receptor-ligand complex the ligand simultaneously binds to subdomain I and III of a single ErbB-1 
molecule, resulting in the conformation-induced exposure of an extended ‘dimerisation’ loop within 
domain II. This dimerisation loop mediates inter-receptor contacts with the other ErbB receptor and 
thereby stabilises the ligand in a high affinity complex. Most likely this mechanism serves as a 
paradigma for homodimerisation of ErbB-3 and ErbB-4 complexes (44). In the ErbB-1 homodimeric 
complex, the B-loop region of both ligands interacts with domain I, while residues surrounding the 
second and sixth cysteine interact with domain III. In particular, the side-chain of Leu15 in EGF has a 
 
Figure 6: Ligand-induced proliferation of 32D cells expressing ErbB-1 (D1) and ErbB-2 and ErbB-3 (D23). The 
relative mitogenic activity of EGF (+), NRG-1β (■), T1E (Ο),T1E6T (●), T1E6N (∆), T1E6Nopt (□) was assessed by 
using the calorimetric MTT assay after 24 hrs incubation and compared to unstimulated control cells. Results are 

























































hydrophobic contact with Val350 in domain III of ErbB-1 (43). Notably, at the equivalent position in 
ErbB-3 and ErbB-4 Thr347 is found, suggesting that, assuming a similar receptor-ligand interaction as 
for ErbB-1, hydrophobicity may not be required for ErbB-3 binding. Besides providing hydrophobic 
contact, Leu15 in EGF is additionally involved in preserving the correct position of Arg41, thereby 
facilitating its salt-bridge formation with Asp355 in domain III of ErbB-1. The hydrophobic 
sidechains at positions 13 and 15 and the Arg at position 41 are indeed conserved for ligand-receptor 
interactions among the ErbB and EGF families, including the NRGs, the viral EGF-like growth 
factors and the Drosophila EGF receptor agonists. In line with this additional function, the 
hydrophobic character and γ-branched “leucine-type” geometry of the sidechain at position 15 in EGF 
seem important features, as in EGF substitutions to the β-branched valine results in reduced ErbB-1 
binding affinities to18% (25). However, the L15V substitution in T1E left the ErbB-1 binding affinity 
unaltered compared to wild-type T1E. The importance of hydrophobicity at position 15 for interaction 
with either ErbB-1 or ErbB-3 was confirmed by the strongly reduced binding affinity of T1E/L15A, 
in good agreement with the reported reduced ErbB-1 affinity of EGF/L15A (24,30,31). The effects on 
mitogenicity were less evident for T1E/L15A on D1 cells, but is in line with the partial uncoupling of 
ErbB-1 binding from ErbB-1 activation observed for the EGF/L15A analog and other low affinity 
ligands including EGF/L47V (24,34,41,45). Notably, alanine mutation of Val15 in NRG-1β has also 
been shown to reduce the ErbB-3 affinity, although this residue was not assigned to the primary 
binding site (46). Therefore, it appears that Leu15 in EGF and Val15 in NRG-1β mainly have a 
general role in ErbB receptor-ligand interaction to position the critical receptor-interaction of Arg41.  
In EGF complexed with the ErbB-1 extracellular domain, Leu47 largely contributes to the total buried 
surface area, which is indicative for its important role in receptor recognition and stabilisation. The 
equivalent Leu48 in TGFα in conjunction with the ErbB-1 ectodomain is completely buried in the 
same hydrophobic pocket in domain III comprising Leu382, Gln408, His409, Phe412, Val417, Ile438 
centered over Ala415 (42,43). These structural data are in line with the high degree of conservation of 
this leucine among ErbB-1 ligands (except for amphiregulin), but not in the NRGs, and confirm 
earlier mutagenesis results. The present seemingly contradictive results suggest that the chimera T1E 
is less susceptible for mutations at position 47 than EGF and TGFα, and may indicate that the 
receptor contacts with domain III of ErbB-1 are less efficient for this ligand.  
One possible explanation for these puzzling findings could be that T1E interacts differently with 
ErbB-1 domain I than EGF and TGFα. While the interaction of EGF with domain I of ErbB-1 is 
solely formed by hydrophobic residues in the B-loop region (e.g. Leu26, Ile23), in TGFα also charged 
residues in both the B-loop (Gln26, Asp27) and the N-terminus (His4, Phe5) contribute to the receptor 
interface. Since the chimera T1E combines the N-terminal region of TGFα with the B-loop region of 
EGF, either an intermolecular conflict or a synergy between the residues involved in ErbB-1 
recognition may occur. The altered binding to domain I may change the orientation of the ligand 
within the cleft between domains I and III of ErbB-1, and thereby prevents efficient contact of the 
linear C-terminal region of T1E with the hydrophobic residues in domain III. Notably, of all 
EGF/TGFα chimeras analysed T1E exerts the lowest relative affinity for ErbB-1 (62% of 
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mEGF)(17,40). The stronger effects of the replacement of the entire C-terminal tails on the ability of 
T1E to interact with ErbB-1 could as well be explained by a cumulatively reduced contact with 
domain III residues. In TGFα the sidechain of Leu49 adjacent to Leu48 contacts both domain I and 
III, and thereby may define the final position of the two domains in the complex.  
It is unresolved if ligand binding to subdomains I and III differs between distinct ErbB receptors, and 
whether both subdomains contribute equally to ligand binding. NRG-1β can directly bind an ErbB-3 
proteolytic fragment containing only domain I (47), while EGF can bind an ErbB-1 fragment 
encompassing domain III (48), and therefore it appears that the site of primary interaction may be 
different for ErbB-3 ligands and ErbB-1 ligands. How the bispecific ligand T1E initially binds to 
ErbB-3 remains to be determined. Previous work has identified critical residues for ErbB-2/ErbB-3 
interaction in the N-terminal and B-loop region (His2, Phe3, Leu26) of T1E, and in analogy with the 
ligand-bound ErbB-1 structure it seems most likely that these residues mediate the interaction with 
residues in domain I of ErbB-3 (17). Interestingly, the N-terminal region in the receptor-bound TGFα 
molecule forms the third strand of a triple β-sheet with the B-loop region, unlike the conformation of 
the TGFα molecule in solution (42,49). Likewise a tendency to β-sheet formation has been observed 
for the N-terminal region of T1E in solution as determined by 2D NMR spectroscopy (Wingens et al., 
prepress JBC), which may indicate that a triple β-sheet may also be stabilised in T1E upon ErbB 
interaction. Alanine scanning mutation of NRG-1 implicated several discontinuous hydrophobic and 
charged residues in the N-terminus and B-loop which form a patch on one face of the major β-sheet in 
ErbB-3 binding (46). In addition, the substitution of V15A and M50A in NRG-1β has also been found 
to reduce the ErbB-3 binding affinity, indicating that these regions may also involve ErbB-3 
interaction. In conclusion, it appears likely that the T1E residues involved in interaction with ErbB-3 
display overlap with the determinants for ErbB-1 binding, mediating contacts with residues in both 





Materials- Carrier-free recombinant NRG-1β177-246 was obtained from R&D Systems Europe 
(Abington, Oxon, UK). Wild-type murine EGF (mEGF) was from Bioproducts for Science Inc. 
(Indianapolis, IN). Oligonucleotides were obtained from Eurogentec (Servaing, Belgium). Polyclonal 
anti-ErbB-3 antibodies (C17) and monoclonal anti-ErbB-1 antibodies (225) were from Santa Cruz, 
while monoclonal anti-phoshotyrosine antibodies G410 were derived from Upstate Biotech. Inc.   
 
Mutagenesis- Point-mutations were introduced in the EGF/TGFα chimera T1E using Quickchange 
site-directed mutagenesis (Stratagene, la Jolla, CA) on vector pEZZ18/Fx/T1E. The following 
complementary oligonucleotides containing the desired mutation (underlined) were used: 
T1E/L15Asense 5’-CAT GAT GGC TAC TGC GCA CAC GAC GGT GTA TGC-3’, T1E/L15V 
sense 5’-CAT GAT GGC TAC TGC GTG CAC GAC GGT GTA TGC-3’, T1E/L47Msense 5’-GC 
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CAG TAC CGC GAC ATG AAA TGG TGG GAG C-3’. Integrity of the T1E mutants was verified 
by automated cycle sequencing (Beckmann CEQ2000). Production and purification of recombinant 
proteins was essentially performed as previously described (17). Briefly, growth factors were 
expressed as proteinA-IEGR fusion proteins in Escherichia coli and purified by affinity 
chromatography on IgG-coupled Sepharose beads. After proteolytic cleavage by Factor Xa, the 
proteinA-tag was removed by a second round of chromatography on the same column. Disulphide 
bridge mismatches and inactive forms of the ligands were removed by a final reverse phase high 
performance liquid chromatography (HPLC) step. The amount of pure growth factor was estimated 
from the HPLC peak area using native mEGF as a standard.  
 
Cell lines- HER-14 cells, murine NIH 3T3 fibroblasts engineered to express human ErbB-1 (4.0 x 10
5
 
ErbB-1 receptors/cell), were cultured in gelatinised flasks in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% newborn calf serum (27). Murine 32D haematopoietic progenitor 
cells engineered to express human ErbB receptors were cultured in RPMI-1640 medium 
supplemented with 10% heat-inactivated foetal calf serum (FCS, GibcoBRL) and 0.25 ng/ml mIL-3 
(Promega, Madison, WI). The 32D sublines used, D1 (ErbB-1, 1.8 × 104 receptors/cell), D3 (ErbB-3, 
1.1 × 104 receptors/cell) and D23 (ErbB-2 and ErbB-3, 1.3 × 104 ErbB-3 receptors/cell), were kept 
under continuous selection using 0.6 mg/ml G418 (Calbiochem, La Jolla, CA) or 0.4 mg/ml 
hygromycin B (Sigma)(28). Human breast cancer MCF-7 cells were cultured in a 1:1 mixture of 
DMEM and Ham’s F12 medium supplemented with 10% FCS.  
 
Ligand Displacement Experiments- Recombinant NRG-1β, T1E and natural mEGF were radiolabelled 
using the Iodogen method (Pierce) according to the manufacturer’s protocol for indirect labelling, 
resulting in a specific activity of 50-100 µCi/µg protein. The ErbB-1 binding affinity was measured in 
a [
125
I]-mEGF binding competition assay on HER-14 cells seeded in gelatinised 24-wells plates as 
described (29). Other ligand displacement analyses were performed using 2.0 × 106 D3 cells or D23 
cells. Cells were washed once with binding buffer (RPMI/0.5% BSA) and subsequently incubated for 





I]-T1E. Cells were then washed once with binding buffer and loaded onto a serum cushion to 
remove the unbound label. Subsequently cells were quickly spun at 2000 rpm and cell surface-bound 
radioactivity was determined by γ-counting.  
 
MTT assays- 32D cells were deprived from IL-3 by rinsing and resuspension in RPMI 1640 medium 
supplemented with 0.1% bovine serum albumin (BSA). Cells were seeded into 96-wells plates at a 
density of 5.0 × 104 cells/well in a total volume of 0.1 ml, in presence or absence of serial dilutions of 
recombinant growth factor. Cell survival was determined after 24 hours incubation at 37 °C using the 
calorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (28). 
Mitochondrial activity in viable cells convert the lactam-ring into purple crystals. Two hours after the 
addition of 50 µg/well MTT, cells were lysed in 0.1 ml acidic isopropanol and carefully resuspended. 
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Plates were read at 550-655nm, and duplicate data points were plotted as fold induction over 
untreated control wells. 
 
Immunoprecipitation and Western blotting- The various 32D sublines were deprived of IL-3 and 
serum for 4 hours in RPMI supplemented with 0.1% BSA prior to stimulation. Ligands were 
lyophilised in 1 M HAc/0.1% BSA. Incubation was started by addition of 10 x 10
6
 cells to the tubes 
containing the ligands to a final concentration of 100 ng/ml. After incubation for 7 min at 37 °C in a 
water bath, the tubes were transferred to ice and 0.5 ml of ice-cold PBS was added. Cells were 
pelleted for 4 min at 1000 rpm at 4 °C, rinsed a second time, and lysed by addition of 1 ml RIPA 
buffer with freshly added protease inhibitors for 15 min on ice. Lysates were cleared by centrifugation 
for 15 min at 14000 rpm at 4 °C. The respective ErbB proteins were precipitated by incubation of 1 
µg of antibody for at least 4 hours at 4 °C while tumbling, and captured by the addition of proteinA-
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EGF-like growth factors activate their ErbB receptors by promoting receptor-mediated 
homodimerisation, or alternatively by the formation of heterodimers with the orphan ErbB-2 through 
an as yet unknown mechanism. To investigate the selectivity in dimer formation by ligands, we have 
applied the phage display approach to obtain ligands with modified C-terminal residues that 
discriminate between ErbB-2 and ErbB-3 as dimerisation partner. We used the EGF/TGFα chimera 
T1E as template molecule, since it binds to ErbB-3 homodimers with low, and ErbB-2/ErbB-3 
heterodimers with high affinity. Many phage variants were selected with enhanced binding affinity for 
ErbB-3 homodimers, indicating that C-terminal residues contribute to the interaction with ErbB-3. 
These variants were also potent ligands for ErbB-2/ErbB-3 heterodimers, in spite of negative selection 
for such heterodimers. In contrast, phage variants positively selected for binding to ErbB-2/ErbB-3 
heterodimers, but negatively for binding to ErbB-3 homodimers, can be considered as “second best” 
ErbB-3 binders, which require ErbB-2 heterodimerisation for stable complex formation. Our findings 
imply that EGF-like ligands bind ErbB-3 through a multi-domain interaction, involving at least both 
linear endings of the ligand. Apparently the ErbB-3 affinity of a ligand determines whether it can 
form only ErbB-2/ErbB-3 complexes or also ErbB-3 homodimers. As no separate binding domain for 
ErbB-2 could be identified, our data support a model in which ErbB heterodimerisation occurs 





The recent determination of the crystal structure of the extracellular domain of ErbB-1 in complex 
with its ligands epidermal growth factor (EGF
1
) or transforming growth factor α (TGFα) has provided 
evidence for the formation of homodimeric ErbB-1 complexes through a receptor-mediated 
dimerisation mechanism (1,2). Ligand binding to both domains I and III of the extracellular domain of 
the receptor involves the transition of ErbB-1 from a ‘closed’ to an ‘open’ state, which then permits 
dimerisation with another liganded ErbB-1 through interaction of domain II residues within these 
receptors. Most likely this mechanism can serve as a paradigm for homodimerisaton of other liganded 
ErbB receptors, such as ErbB-3 and ErbB-4. However, it is well established that EGF-like growth 
factors preferentially signal through heterodimers of their cognate receptor with the orphan ErbB-2. 
The mechanism by which EGF-like growth factors bind their receptors in heterodimeric receptor 
complexes remains an open question.  
Dimerisation of ligand-bound receptor tyrosine kinases is a mechanism that is thought to activate the 
intrinsic kinase domain, followed by transphosphorylation and subsequent docking of cellular signal 
transducing proteins. As a consequence, ligand binding serves as a potential site for regulation of cell 
proliferation in diseases where ErbB receptors are overexpressed, as has been observed for ErbB-1 
and ErbB-2 in multiple human cancers (3). ErbB-2 has no known ligand, but by decelerating the 
ligand dissociation rate it serves as a preferred dimerisation partner for all other ErbB members (4-6). 
Chapter 5 
 110
Heterodimer formation with ErbB-2 is especially important in the case of the ErbB-3, which together 
with ErbB-4 forms the natural receptor for the different neuregulins (NRGs). ErbB-3 contains a 
defective kinase and hence ErbB-3 homo-dimers are biologically inactive (7,8). The ErbB-2/ErbB-3 
heterodimer, however, is the most prominent and strongest transforming signaling complex activated 
by NRG-1 (9-12) and provides an attractive model system to study the mechanism of ligand-induced 
ErbB heterodimerisation. 
EGF-like growth factors share a structurally conserved EGF motif, characterised by three disulphide-
bonded loops (the A-, B- and C-loop), in addition to a linear N-terminal and C-terminal region. 
Structural and mutational analyses have shown that residues in the A-loop, C-loop and C-terminal 
linear region of EGF and TGFα primarily bind to domain III of ErbB-1, followed by an interaction of 
residues in their B-loop with domain I of the receptor (1,2,13-16). By contrast, NRG-1β has been 
shown to bind with high affinity to a proteolytic fragment of ErbB-3 containing only domain I (17). 
Moreover, NRG binding to ErbB-1/ErbB-4 chimeras requires the presence of domain I of the latter 
receptor, suggesting that ligand binding to NRG receptors primarily involves interaction with domain 
I of the receptor (18). Alanine scanning of NRG-1β revealed that hydrophobic and charged residues in 
the linear N-terminal region and the B-loop, that form a surface patch on one site of the triple β-sheet, 
are the major determinants in ErbB-3 binding (19,20). On the other hand, also residues in the C-
terminal region of NRG may play a role in receptor binding, since the natural α- and β- isoforms of 
NRG-1 and NRG-2, which only vary in sequences C-terminal of the fifth cysteine, strongly differ in 
their ability to bind and activate distinct ErbB combinations (21-24). Exchange studies between NRG-
1α and NRG-1β have shown that particularly the linear C-terminal region determines the binding 
properties and mitogenic potential of these isoforms (25). Therefore it has been proposed that NRGs 
may have a bivalent character and interact with both ErbB-3 and ErbB-2 through separate binding 
sites (26). 
To evaluate the contribution of residues in the linear C-terminal region of EGF-like ligands for 
selective dimer formation, we applied the phage display technique to select ligands that discriminate 
between ErbB-2 and ErbB-3 as dimerisation partner in ErbB-3 complexes. In earlier work we and 
others showed that EGF chimeras in which the linear N-terminus was replaced by either NRG 
(biregulin) or TGFα (T1E) residues gained high binding affinity to ErbB-2/ErbB-3 heterodimers, 
while they bound only weakly to ErbB-3 alone (27,28). Unlike NRG-1β, both T1E and biregulin seem 
dependent on subsequent binding of ErbB-2 to stabilise their low affinity interaction with ErbB-3. In a 
previous study we could attribute the weak ErbB-3 interaction of the chimera T1E in part to the 
presence of sub-optimal sequences in the linear N-terminus. Based on a phage display approach we 
enhanced the binding affinity for ErbB-3 relative to T1E by substitution of only two residues in EGF 
(D2W and S3V/R)(29). In the present study we have used the same approach to subject five residues 
in the linear C-terminal region of T1E for randomisation and selection for altered receptor selectivity 
and affinity. The targeted residues in T1E correspond to the positions in the NRG isoforms that have 
been implicated in the differential activation of ErbB dimers. Here we show that T1E can be strongly 
optimised for binding to ErbB-3 by the current phage display approach, indicating that residues in the 
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linear C-terminal tail contribute to the ability of ligands to bind ErbB-3 homodimers. Moreover, in 
spite of negative selection protocols we consistently observed a direct relation between the ability of 
T1E variants to bind ErbB-3 and their ability to induce ErbB-2/ErbB-3 heterodimers. Since no 
sequences selective for ErbB-2 heterodimerisation could be identified, our findings support a model in 






The linear C-terminal region of T1E influences the ErbB-2/ErbB-3 binding efficiency 
Previous work showed that the chimeric EGF-like ligands biregulin and T1E bind only weakly to 
ErbB-3, due to sub-optimal sequences in the N-terminal linear region (26,29). The observed high 
affinity binding of T1E and biregulin for cells expressing both ErbB-2 and ErbB-3 thus appears to 
depend critically on additional stabilisation of the complex by ErbB-2. The strong dependence on 
ErbB-2 as dimerisation partner makes this type of molecules a good model system for identifying 
residues that mediate the selective recruitment of ErbB-2 versus ErbB-3 as dimerisation partner.  
In this study we have examined whether sequences in the C-terminal linear region of T1E play a 
direct role in the formation of ErbB-3 homodimeric and ErbB-2/ErbB-3 heterodimeric complexes, as 
suggested by a comparison of the different NRG isoforms. Thereto we initially exchanged the C-
terminal linear tail of T1E, composed of EGF sequences, for the corresponding sequences of TGFα 
(Glu44-Ala50), NRG-1β (Gln45-Ala51) and an optimised NRG-1β mutant. This latter mutant has 
been obtained from a previous phage display study on NRG-1β by selection for high affinity binding 
to ErbB-3 ectodomains, and contains the mutations N47H and M50I compared to the wild-type NRG-
1β EGF domain (30). The TGF-α C-terminus was included because it shows the highest sequence 
similarity with optimised NRG-1β, and because previous studies have indicated that introduction of 
TGF-α C-terminal residues into NRG-1α strongly enhances binding affinity for ErbB-2/ErbB-3 
heterodimers on SK-BR-3 cells (35). The nomenclature used for the T1E mutants follows previously 
used conventions, in which T1E6N is a chimera containing TGFα sequences up to the first cysteine, 
followed by EGF sequences up to the sixth cysteine and NRG-1β residues in the C-terminal tail 
(Figure 1A). All T1E mutants were expressed as recombinant peptides in Escherichia coli, finally 
purified by reverse-phase HPLC and verified for the appropriate molecular weight by MALDI-TOF 
analysis.  
The biological activity of the various T1E mutants was assessed by competitive binding analysis on 
stable transfectants of 32D cells that express defined ErbB combinations (12). Figure 1B shows clear 
differences in the ability of the T1E mutants tested to displace radiolabelled T1E from 32D cells 
coexpressing ErbB-2 and ErbB-3 (D23 cells). The IC50 of both T1E6N and T1E6T (50-60 ng/ml) was 
increased compared to T1E itself (6.7 ng/ml), whereas T1E6N
opt
 bound D23 cells with enhanced 
affinity (3 ng/ml) comparable to wild type NRG-1β (2 ng/ml). Similar differences were observed in 
the ability of these T1E mutants to stimulate proliferation of D23 cells and the neuregulin-responsive 
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MCF-7 human breast cancer cells, indicating that their relative binding affinity corresponded to the 
ability to activate ErbB-2/ErbB-3 complexes (data not shown). Thus, changes in the C-terminal 
sequences of T1E strongly affect its ability to interact with ErbB-2/ErbB-3 heterodimers. Despite the 
fact that NRG-1β is the natural activator for ErbB-2/ErbB-3 heterodimers in vivo, its C-terminal 
sequences do not appear beneficial for the interaction with ErbB-2/ErbB-3 in a T1E environment. In 
this respect the EGF residues present in T1E appear more effective in stabilising ErbB-2/ErbB-3 
complexes than the corresponding NRG-1β and TGF-α sequences. 
To further evaluate the role of the linear C-terminus in binding to ErbB-3, the binding affinity of the 
T1E mutants was assessed by [
125
I] NRG-1β displacement on 32D cells solely expressing ErbB-3 
receptors (D3 cells). In agreement with crosslinking analyses, we assume that NRG-1β is able to 
induce homodimeric ErbB-3 complexes in D3 cells (12,26). Figure 1C shows that all T1E mutants 
have an affinity for ErbB-3 alone that is at least 50-fold lower than that of NRG-1β. Compared to 
T1E, T1E6N
opt
 shows increased binding affinity, while T1E6N and T1E6T have almost similar 
binding affinity. Thus, replacement of the C-terminal tail of T1E for NRG-1β sequences did not 
significantly improve the weak binding of T1E to the ErbB-3 receptor. By contrast, introduction of the 
C-terminal tail of the optimised NRG-1β variant increased the relative binding affinity of T1E for 
both homo-and heterodimeric ErbB-3 complexes, indicating these residues improve the recruitment of 
ErbB-2 and ErbB-3 independent of the context of the NRG molecule. Together these findings 
Figure 1: Exchange of the linear C-terminal region in the EGF/TGFα chimera T1E affects the binding to specific
ErbB combinations. (A) Amino acid sequences of the T1E variants used in this study, aligned with human EGF
and the EGF-domain of human NRG-1β. Numbering of the conserved cysteines in bold face is according to T1E.
(B) Displacement of [
125
I] T1E binding on 32D cells coexpressing ErbB-2 and ErbB-3 (D23 cells). (C)
Displacement of [
125
I] NRG-1β binding on 32D cells expressing ErbB-3 (D3 cells). Cells were incubated for 2 hrs
at 4 °C with radiolabelled ligand (2 ng/ml) in presence of serial dilutions of unlabelled NRG-1β (closed squares),
T1E (open circles), T1E6T (closed circles), T1E6N (open squares), or T1E6N
opt
(open diamonds). Unbound
ligand was removed by sedimentation of the cells through a serum cushion, after which cell-bound radioactivity
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demonstrate that residues in the C-terminal region of T1E indeed contribute to the ligand preferences 
for distinct receptor complexes.  
 
Design of the T1E
46-50
 phage library and selection strategy 
To assess the precise contribution of individual residues in T1E to the recruitment of ErbB-2 or ErbB-
3 into dimeric complexes, we randomly mutated five positions in the linear C-terminus of T1E that 
correspond to the positions in the NRG isoforms implicated in differential ErbB binding using a phage 
display approach. By a combination of positive and negative selection strategies and specific elution 
methods, we subsequently selected variants that discriminated between binding to ErbB-3 
homodimers and to ErbB-2/ErbB-3 heterodimers. To this end we used homodimeric ErbB-3-IgG 
fusion proteins in addition to MDA-MB-453 cells, human breast carcinoma cells with overexpression 
of ErbB-2 and ErbB-3, which we have previously employed for affinity optimisation of EGF variants 
to ErbB-2/ErbB-3 heterodimers (29). Figure 1A shows the sequence of the phage library of T1E 
variants. The Gln45 residue adjacent to Cys44 is conserved between EGF and NRG-1β, and therefore 
the adjacent five residues (Tyr46-Lys50) were targeted for mutation. Because the randomised area is 
localised in close proximity to the fusion point with the pIII minor coat protein, a flexible linker was 
introduced into the fUSE5 phage vector to minimise possible steric effects. The resulting phages each 
display 2-5 copies of the fusion proteins (32). The completeness of the T1E
46-50 
phage library was 
estimated from the number of independent transformants yielding 1.45 ×107, thereby covering five 
times the theoretical diversity of 3.1 ×106 possible different amino acid combinations. Sequence 





clones isolated for preferential ErbB-3 homodimer formation  
Phage T1E variants that preferentially bind to ErbB-3 homodimers but not ErbB-2/ErbB-3 
heterodimers were isolated using alternating selection rounds on homodimeric ErbB-3-IgG fusion 
proteins and whole MDA-MB-453 cells. During the selection on cells the ErbB-2 dependent phage 
clones were depleted from the cell surface by competitive elution with anti-ErbB-2 antibodies that are 
known to impair ligand binding (34). Subsequently the remaining phage clones bound to ErbB-3 
receptors on the cell surface were harvested by acid elution. The alternation between exposure to 
soluble and cell-bound ErbB-3 receptors reduced non-specific background binding of phages and 
excluded a possible selection advantage offered by the preformed dimeric ErbB-3-IgG compared to 
the monomeric cell-expressed receptors. 
Individual phage clones were randomly picked after four selection rounds and subsequently analysed 
for binding to ErbB-3 ectodomains in phage ELISA. Table 1 gives a survey of the sequences of 16 
T1E
46-50
 clones selected for preferential binding to ErbB-3 homodimers (ErbB-3 selectants) with their 
corresponding binding properties. Binding ability of the clones to ErbB-2/ErbB-3 heterodimers was 
determined in ELISAs on intact cells (D23 versus parental 32D cells) and on heterodimeric ErbB-23-
IgG fusions. Since these heterodimeric IgG fusion proteins were generated by cotransfection of the 
expression vectors encoding the respective receptors, experiments were carried out on a mixture of 
ErbB-23-IgG heterodimers and ErbB-2-IgG and ErbB-3-IgG homodimers. As positive control 
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EGF/W2V3 phage was used, a previously characterised EGF variant with high affinity for ErbB-3 
homodimers and ErbB-2/ErbB-3 heterodimers (29). Wild-type T1E phage and EGF phage were used 
as additional controls. Table 1 indicates that all ErbB-3 selectants displayed strong binding to ErbB-3-
IgG, with concomitant strong binding capacity to both ErbB-23-IgG ectodomains and D23 cells. 
Thus, despite the negative selection for ErbB-2 dimers, the T1E clones selected by this approach had 
not lost their ability to bind to ErbB-2/ErbB-3 heterodimers. In other words, the ErbB-3 selectants are 
unable to discriminate between ErbB-2 and ErbB-3 as dimerisation partner.  
 
TABLE  1 
Sequences and binding characteristics of ErbB-3 selectants 





  46 47 48 49 50 n=16 D23 ErbB-23-IgG ErbB-3-IgG 
3.1  Ile Phe Asp Trp Ala 5 ++ ++ ++ 
3.2  Ile Phe Asp Phe Leu 1 ++ ++ ++ 
3.3  Ile Tyr Asp Val Asp 1 ++ ++ ++ 
3.4  Thr Tyr Asp Phe Pro 1 ++ ++ ++ 
3.5  Tyr Tyr Asp Ile Asp 1 ++ ++ ++ 
3.6  Tyr Ile Gln Leu Ser 2 ++ ++ ++ 
3.7  Ile Ala Asp Val Gly 2 ++ ++ ++ 
3.8  Ile Ala Asp Ile Gln 1 ++ ++ ++ 
3.9  Ile Ala Asn Met Met 1 ++ ++ ++ 
3.10  Ile Trp Asp Phe Pro 1 ++ ++ ++ 




 X     
 
 
a Single phage clones were screened for binding in phage ELISA on D23 cells versus parental 32D cells, and on ErbB-IgG 
fusion proteins. Relative binding was measured in comparison to the posive control phage EGF/WV. (++), signal intensity > 
100%; (+) signal > 80%; (+/-) signal ≥ 50%; (-) signal < 50% of control. b Preferential selection of aromatic(10/16) or 
hydrophobic residues. Consensus sequence is based on a frequency occurrence of ≥50%.  c Preferential selection of 
residues with an aromatic(8/16) or hydrophobic character. 
 
 
The most striking result in the sequences obtained was the abundant selection of Asp48 in 81% of the 
ErbB-3 selectants, which is the corresponding residue in both EGF and TGF-α. Substitutes found on 
positions 46, 47 and 49 tended to be similar in character, being predominantly large and hydrophobic, 
although at position 46 a preference for Ile was observed (75%). At position 47 residues Tyr and Phe 
were found in more than half of the ErbB-3 selectants, indicating that aromatic side-chains seem to be 
favoured. The most frequently selected T1E
46-50 
clone, designated 3.1, contained IFDWA sequences 
(5/16 times). The overall consensus sequence for T1E
46-50 
ErbB-3 selectants, based on the frequency 
of occurrence of a certain (type of) amino acid detected at the respective position in ≥ 50% of all 





 clones isolated for selective ErbB-2/ErbB-3 heterodimer formation 
In an inverse strategy, phage T1E variants were isolated that selectively bound to ErbB-2/ErbB-3 
heterodimers but failed to bind to ErbB-3 homodimers. Thereto negative selection on homodimeric 
ErbB-3-IgG fusion proteins was performed prior to the selection on MDA-MB-453 cells. Ligands that 
ultimately depended on ErbB-2 for high affinity binding were eluted from the cell surface by 
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treatment with ErbB-2 antibodies. Control cell pannings confirmed the specific elution of wild-type 
T1E phages by this method (data not shown). After four rounds of selection, single clones were 
sequenced and analysed for binding properties in ELISAs in a similar way as described above for the 
ErbB-3 selectants (Table 2). All T1E clones selected for preferential ErbB-2/ErbB-3 binding (ErbB-
23 selectants) were found to bind strongly to both D23 cells and ErbB-23-IgG ectodomains, 
confirming that selection had been achieved. When the ErbB-23 selectants were analysed for their 
ability to bind to ErbB-3 homodimers, half of the clones lacked detectable binding for ErbB-3-IgG, 
similar to phage T1E (group 1), while the remaining were still able to bind with gradual affinity to 
ErbB-3 homodimers (group 2). Thus, only a fraction of the ErbB-23 selectants was able to 
discriminate against ErbB-3 as dimerisation partner in the ErbB-3 complex.  
 
 
TABLE  II 






 46 47 48 49 50 D23 ErbB-23-IgG ErbB-3-IgG
 1 23.1 Phe Leu Thr Val Asp + ++ +/- 
 23.2 Tyr Leu Thr Leu Asp ++ ++ +/- 
 23.3 Tyr Leu Ser Thr Asp + ++ - 
 23.4 Tyr Leu Ala Leu His + ++ - 
 23.5 Tyr Leu Gln Met Asn + + - 
 23.6 Tyr Tyr Leu Ile Asp ++ + +/- 
 23.7 Tyr Tyr Gly Phe Asp ++ + +/- 
 23.8 Trp Tyr His Val Asp + +/- - 
 23.9 Ala Tyr Asp Ile Tyr + + - 
 23.10 His Leu Asp Leu Leu + +/- - 
 23.11 Tyr Leu Asp Pro Asn + +/- - 
 23.12 Thr Val Gln Gly Gln  +/- + - 
Consensus Tyr Leu  X Ap 
b
 Asp  
2 23.13 Ile Phe Asp Trp Ala ++ ++ ++ 
 23.14 Ile Phe Asp Trp Leu ++ ++ ++ 
 23.15 Tyr Tyr Asp Ile Asp ++ ++ ++ 
 23.16 Tyr Leu Glu Ile Asp ++ ++ ++ 
 23.17 Tyr Leu Glu Leu Glu ++ ++ + 
 23.18 Tyr Leu Asp Ile Ser ++ ++ + 
 23.19 Tyr Leu Ser Met Trp ++ ++ + 
 23.20 Ala Tyr Asp Ile Pro ++ ++ + 
 23.21 Val Ala Asp Ile Pro ++ + + 
 23.22 Glu Tyr Asp Pro Tyr + ++ ++ 
 23.23 Trp Leu Asp Pro Leu ++ ++ ++ 
 23.24 Trp Asn Asp Pro Gln + ++ + 







 X    
 
a Single phage clones were screened for binding in phage ELISA on D23 cells versus parental 32D cells, and on ErbB-IgG. 
Relative binding was measured in comparison to the positive control phage EGF/WV. (++) Signal intensity > 100%; (+) 
signal > 80%; (+/-) signal ≥ 50%; (-) signal < 50% of control. b Preferential selection of residues with a hydrophobic 
character (9/12). Consensus sequence is based on a frequency occurrence of ≥50%.  c Preferential selection of aromatic 
(8/13) or hydrophobic residues.  
d
 Preferential selection of hydrophobic residues (12/13). 
e
 Preferential selection of 




When comparing the sequences of the two distinct groups of ErbB-23 selectants, both differences and 
similarities became apparent (Table II). The consensus sequence of group 1 ErbB-23 selectants could 
be assigned as Y46-L47-X48-apolar49-D50, while the consensus sequence of group 2 strongly 
resembled that of the ErbB-3 selectants in Table I. The diminished ability to bind to ErbB-3 
homodimers of the group 1 clones correlated with a shift of the acidic Asp from position 48 (72% 
group 2) to position 50 (52% group 1). Predominantly large hydrophobic residues were found at 
positions 46, 47 and 49 in all ErbB-23 selectants, similarly as observed for the ErbB-3 selectants, 
although the exact nature of the side-chains differed. Taken together, the overall consensus sequence 
of ErbB-23 selectants displays remarkable overlap with the consensus sequence for ErbB-3 selectants.  
 
 
Figure 2: Binding characteristics of individual phage T1E
46-50
 variants selected for preferential ErbB-3
homodimer binding (ErbB-3 selectants) or preferential ErbB-2/ErbB-3 heterodimer binding (ErbB-23
selectants). (A, B) Phage ELISA on ErbB-23-IgG fusion proteins. (C, D) Phage ELISA on homodimeric
ErbB-3-IgG fusion proteins. Binding of ErbB-3 selectants is depicted in panel (A, C), ErbB-23
selectants in panel (B, D). Phage clones used were T1E
46-50 
variants IFDWA (grey squares), IADIQ
(grey triangles), YYDID (grey diamonds), YLEID (closed circles), YLDIS (closed squares), YLQMN
(closed triangles), YLTLD (crosses), YLALH (open diamonds), and YLSTD (open squares), while
phage T1E (open circles), phage EGF/W2V3 (open triangles), and phage EGF (plusses) were used as
positive and negative controls, respectively. Results are presented as mean of two experiments
performed in duplicate. 
 




 variants display gradual differences in ErbB-3 binding  
To gain further insight into the relative contribution of specific amino acids to the ability of ligands to 
bind ErbB-3, we subjected a number of selected T1E
46-50
 phage variants to extended analysis using 
dose-response experiments. Based on the similarity and divergence from the consensus sequences, 
individual T1E
 
selectants that harbour acidic Asp residues (at position 48, 50, or at both positions) 
combined with distinct hydrophobic residues were chosen and produced as large-scale cultures. Phage 
T1E served as a positive control for ErbB-2/ErbB-3 binding, phage EGF/WV as a positive control for 
ErbB-3 homodimer binding, while phage EGF was used as a negative control.  
While no absolute binding affinities could be determined by the used multivalent phage display 
system, the relative affinities could readily be compared between the distinct clones. All clones, 
invariably whether they were isolated as ErbB-3 selectants (Figure 2A) or as ErbB-23 selectants 
(Figure 2B), were found to bind with similar strong affinity to heterodimeric ErbB-23-IgG complexes. 
The binding of wild-type T1E to the ErbB-23-IgGs was relatively low in comparison to all other T1E 
variants and EGF/WV. This may be attributed to the flexible linker region which is present in the 
T1E
46-50
 phages but absent in the wild-type T1E phage. Conversely, the binding affinity of the various 
T1E
46-50
 clones to ErbB-3-IgGs showed strong variation between the clones, and in general the ErbB-
3 selectants (Figure 2C) were superior to the ErbB-23 selectants (Figure 2D). Interestingly, the ErbB-
3 selectants with C-terminal sequences IFDWA, IADIQ and YYDID showed significantly higher 
affinity for ErbB-3 than the positive control EGF/WV (Figure 2C), indicating that C-terminal 
sequences strongly contribute to enhanced ErbB-3 affinity. When comparing the ErbB-23 selectants, a 
more or less gradual decrease in ErbB-3 binding affinity was observed in the order: YYDID > YLEID 
= YLQMN = EGF/WV > YLDIS > YLTLD > T1E > YLSTD and YLALH >> EGF (Figure 2D). 














































Figure 3: Ability of individual phage clones to induce proliferation of 32D cells expressing ErbB-2
and ErbB-3 (D23 cells). Cells were incubated for 24 hours in IL-3 free medium containing serial
dilutions of filter-sterilised T1E
46-50 
phages selected for ErbB-3 homodimer binding (A) or ErbB-
2/ErbB-3 heterodimer binding (B): IFDWA (grey squares), IADIQ (grey triangles), YYDID (grey
diamonds), YLEID (closed circles), YLDIS (closed squares), YLQMN (closed triangles), YLTLD
(crosses), YLALH (open diamonds), YLSTD (open squares), or phage T1E (open circles), phage
EGF/W2V3 (open triangles), and phage EGF (plusses). Viable cells were determined using the




position 48, and to a lesser extent when present at position 50. Moreover, acidic residues present at 
both positions seem beneficial for ErbB-3 binding, while also the combination of Q48/N50 was 
shown to be efficient. Apparently the depletion of the strongest ErbB-3 binding clones from the pool 
of ErbB-2/ErbB-3 selectants has resulted in the isolation of the “second best” ErbB-3 binding clones.  
In addition, the abilities of the distinct T1E variants to activate ErbB-2/ErbB-3 heterodimers were 
assessed by measuring the IL-3 independent proliferation of D23 cells in an MTT assay. Figure 3 
shows that all T1E variants are equipotent to phage EGF/WV and superior to phage T1E itself in 
inducing proliferative responses in D23 cells, indicating that functional ErbB-2/ErbB-3 heterodimers 
are formed  in response to all selectants. Thus, the ErbB-23 selectants only ineffectively bind to ErbB-
3 homodimers, similar to T1E, but are still strong inducers of ErbB-2/ErbB-3 heterodimers. The 
ErbB-3 selectants effectively bind to ErbB-3 homodimers and ErbB-2/ErbB-3 heterodimers, similar to 
EGF/WV, but this increased ErbB-3 affinity does not result in enhanced mitogenic potency for cells 
expressing ErbB-2 and ErbB-3. Therefore it appears that a low threshold ErbB-3 binding is already 





EGF-like ligands differ in their ability to recruit a dimerisation partner for their cognate receptor, 
resulting in differential potency and mitogenic responses. This suggests that ligands contain specific 
residues that mediate interaction with distinct ErbB complexes, including heterodimers with the 
orphan ErbB-2. To investigate the selectivity in dimer formation by EGF-related ligands, we have 
applied the phage display approach to obtain ligands with modified C-terminal residues that have (i) 
altered selectivity and (ii) enhanced binding affinity. Our findings indicate that EGF-like growth 
factors contain multiple, independent binding domains for ErbB-3, one of which is located in the C-
terminal tail. However, no separate binding domain for ErbB-2 could be identified in this region. 
Instead, ligand-induced ErbB-2/ErbB-3 heterodimerisation appears to occur as a consequence of a low 
affinity interaction with ErbB-3 and subsequent stabilisation by ErbB-2.  
To address the issue of dimer selectivity, distinct combinations of positive and negative selection 
strategies were applied to isolate ligands that were able to discriminate between ErbB-2 and ErbB-3 in 
complex formation with ErbB-3. Two of our present observations argue against the hypothesis that 
the selectivity in recruitment of the dimerisation partner is mediated by sequences in the linear C-
terminal tail of ligands. First, none of the ErbB-3 selectants had impaired ability to form ErbB-
2/ErbB-3 heterodimers, in spite of the negative selection for T1E variants that depended on ErbB-2 
dimerisation for binding. The most likely explanation is that the linear C-terminal region is not 
directly involved in the recruitment of ErbB-2 as dimerisation partner, either because ligands do not 
harbour a separate ErbB-2 binding site, or because such a site is located in a different region of the 
ligand. Hence, our data do not favour a model in which the linear C-terminal tail harbours a secondary 
binding site for ErbB-2, as previously proposed in ligand bivalence models (26,36). 
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Secondly, the incomplete discrimination against ErbB-3 homodimer formation observed for the ErbB-
23 selectants might indicate that ligands require only a low level of ErbB-3 binding affinity to allow 
the efficient formation of ErbB-2/ErbB-3 heterodimers. These ligands can thus be considered as the 
‘second best’ ErbB-3 binders. Moreover, the observation that ligand variants positively selected for 
ErbB-3 binding, but negatively for ErbB-2/ErbB-3 binding, are still potent activators of heterodimers 
also strongly indicates that binding to ErbB-3 is sufficient for heterodimer formation. It thus appears 
that the relative binding affinity to ErbB-3 is indicative for the binding behaviour of ligands to 
dimeric complexes, such that low affinity binders only interact with ErbB-2/ErbB-3 heterodimers, 
while high affinity binders can additionally form ErbB-3 homodimers.  
Our present observations argue for a separate ErbB-3 binding site located in the linear C-terminal tail 
of EGF-like ligands. Previous mutagenesis studies have assigned several non-continuous hydrophobic 
and charged residues in the triple β-sheet formed by the linear N-terminal region and the B-loop 
region of NRG-1 as the major determinants for ErbB-3 binding (19,20,27). It can however not be 
excluded that additional residues in the ligand may contribute to receptor interaction. For instance, 
residues in the β-turn in the A-loop of NRG-1 were also susceptible to Ala mutation, although this 
might be attributed to structural disturbance as well (20). The crucial importance of N-terminal 
residues was further emphasised by two phage display studies, revealing the strong requirement for 
aromaticity (His or Trp) combined with aliphatic or basic side chains for ErbB-3 interaction (29,30). 
Here we show that optimised sequences in the C-terminal linear region also directly contribute to the 
ability of T1E ligands to interact with ErbB-3, and that they can compensate for the presence of 
suboptimal residues in the linear N-terminus of T1E. Notably, the T1E
46-50
 variants selected for 
prefential binding to ErbB-3 homodimers displayed even stronger binding to ErbB-3-IgG than the 
EGF/W2V3 mutant (Figure 2C). Thus, while residues in the N-terminus and B-loop appear to confer 
specificity to ErbB-3 binding, residues in the linear C-terminal tail may further enhance receptor 
affinity, in line with the differential ErbB-3 binding abilities of the distinct NRG-1 isoforms. This 
suggests that both linear regions of the ligand participate independently in receptor binding, such that 
ligand binding to ErbB-3 occurs through a multi-domain receptor interaction.  
The C-terminal sequence requirements for ErbB-3 binding can be deduced from a comparison of the 
consensus sequences of the selected high and low affinity ErbB-3 binding variants. Large 
hydrophobic residues are preferred at positions 46, 47 and 49 in all selected T1E
46-50
 variants, while 
methionine was alternatively allowed at position 49. In particular Ile46 contributes to enhanced ErbB-
3 binding affinity. In addition, the presence of an acidic residue facilitates specific binding to ErbB-3, 
preferentially located at position 48 (for strong ErbB-3 binding), or alternatively at position 50 (for 
weak ErbB-3 binding). Since a combination of the polar residues Gln48 and Asn50 proved also 
sufficient (Figure 2D), we propose that these two side-chains are involved in hydrogen bonding. 
Interestingly, in the structure of receptor-bound TGFα several C-terminal residues interact with both 
domains I and III, among which the corresponding Asp47 in TGFα (1). It has been suggested that 
these residues determine the final position of the two ligand-binding domains in the complex, and 
thereby influence the stability of the dimer. It is tempting to speculate that in the T1E selectants 
Asp48 may serve a similar function when binding to ErbB-3. Furthermore, all T1E variants selected 
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for ErbB-3 binding had maintained their ability to bind to ErbB-1 expressed on 32D cells and ErbB-1-
IgG ectodomains, indicating that the requirements in the C-terminal tail for ErbB-1 and ErbB-3 
interaction may partly overlap (unpublished observations). This observation is remarkable since the 
majority of selected clones lacked a Leu or Ile at position 49 in T1E (Leu47 in EGF), which is strictly 
conserved among ErbB-1 ligands and known to be highly sensitive to site-directed mutagenesis 
(13,14).  
Comparing the consensus sequence of the ErbB-3 selectants with that of the natural ErbB-3 ligands, 
one can conclude that the EGF linear C-terminal region comprising Tyr46-Asp48-Leu49 contributes 
positively to the interaction with ErbB-3. The finding that T1E effectively forms ErbB-2/ErbB-3 
heterodimers but not ErbB-3 homodimers can thus not be attributed to inappropriate C-terminal 
sequences, as previously thought. Rather, it reflects the presence of suboptimal residues in both its N-
terminal and C-terminal region (29). The observation that introduction of the NRG-1β C-terminus 
into T1E did not increase the ErbB-3 binding affinity can be explained by the presence of only two 
out of four required determinants, Tyr47 and Met49, with Met being a less-favoured residue. In 
agreement, mutation of these two residues into alanine was found to reduce the ErbB-3 binding 
affinity of NRG-1β (20). Apparently, natural ligands are not necessarily optimised for high affinity to 
their receptors, which is also indicated by the increase in ErbB-3 binding affinity of optimised NRG-
1β variants (30). Their affinity enhancement was mostly attributed to the Met to Ile substitution in the 
C-terminal tail, as also shown by the T1E6N
opt
 mutant in our study. Interestingly, despite the abundant 
occurrence of Asp residues in the T1E variants optimised for ErbB-3 binding, acidic residues were not 
observed in optimised NRG-1β variants, which may be attributed to differences in the structural 
environment of T1E and NRG-1β (30). We have recently solved the three-dimensional structure of 
T1E
1
, but since that of the NRG-1β isoform is unknown, a direct comparison is impossible. 
Our results imply that specific residues in the C-terminal tail of EGF-related ligands are involved in 
direct interaction with ErbB-3 but not ErbB-2. This makes it unlikely that the formation of 
heterodimeric ErbB complexes is driven through bivalent binding of ligands to two different ErbB 
molecules. Instead, our findings support a receptor-mediated dimerisation mechanism, in which 
ligand binding to ErbB-3 determines the formation of both ErbB-3 homodimers and ErbB-2/ErbB-3 
heterodimers (Figure 4). In a variant of this model, it has been proposed that ligands only induce 
ErbB-3 homodimers, which may subsequently stabilise two ErbB-2 molecules into a tetrameric 
complex (37-40). Based on the analogy of the crystal structures of ErbB-1 and ErbB-3, it is most 
likely that homodimeric ErbB-3 complexes are formed through a conformation-induced mechanism 
with a 2:2 stoichiometry (1,2,41). In this scenario the ligand would bind domain I of ErbB-3 through 
the linear N-terminal and B-loop regions, while its C-terminal residues would interact with receptor 
domain III. In the conformation-induced model, selectivity between the formation of inactive ErbB-3 
homodimers and active ErbB-2/ErbB-3 heterodimers will be achieved through the intrinsic property 
of a ligand to bind ErbB-3 (Figure 4). Ligands with high affinity for domain I and/or III of ErbB-3, 
including NRG-1β and some of the ErbB-3 variants selected here, have a high potency to bring ErbB-
                                                 
1 M. Wingens et al. 2003, prepress JBC. 
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3 into the “open” dimerisation state and will thus induce both ErbB-3 homodimers and ErbB-2/ErbB-
3 heterodimers. Ligands with relatively low affinity for ErbB-3 due to suboptimal interaction with 
domain I or III, such as T1E and NRG-1α, have only a low potency to induce ErbB-3 into the “open” 
state and only in the case the liganded ErbB-3 is complexed by ErbB-2 a stable complex is formed. 
This model presumes that the dimerisation site of ErbB-2 is maintained constitutively in the “open” 
configuration, as an explanation for the preferential heterodimerisation with ErbB-2. From an 
evolutionary point of view this would be a sensible mechanism to enhance the formation of active 
ErbB-2/ErbB-3 complexes and to avoid biologically inactive ErbB-3 homodimers. In this respect 
NRG-1β would be the optimal natural ligand if ErbB-2 is present in excess over ErbB-3, while the 
low affinity NRG-1α isoform would be more effective under conditions that ErbB-3 is present in 
excess over ErbB-2 (21,24). A switch in isoform production thus offers the cell a subtle method of 





Construction of T1E mutants- The construction of T1E has been described previously (28). Residues 
in the linear C-terminal region following the sixth cysteine in pEZZ/Fx/T1E were replaced by the 
corresponding residues of TGF-α and NRG-1β by means of splice overlap extension polymerase 
chain reaction. The initial PCR fragments containing the complementary overhang sequences were 
made using pEZZ/Fx/T1E, pEZZ/Fx/TGF-α and the NRG-1β gene in pNRG8-g3 (a gift from 
Genentech Inc., San Francisco, CA) as templates. The fragment for the C-terminal region of the 
optimised NRG-1β (referred to as NRG-58 (30)) was constructed using oligonucleotide primers 
containing mutations encoding Asn-His and Met-Ile substitutions. Mutant gene products were 
subsequently introduced in the pEZZ vector using the Bam-HI/Sal-I sites and verified by automated 
cycle sequencing. Production, purification and characterisation of recombinant T1E mutants was 



































(middle and right panel)
mechanisms. The ErbB-3 receptor
is shown in white and ErbB-2 in
grey. The orientation of the linear N-
and C-terminal regions of the ligand
is indicated by N and C,
respectively. The middle panel
depicts the ErbB-2/ErbB-3
heterodimeric complex induced by a
ligand with low ErbB-3 affinity, and
the ErbB-3 homodimeric complex
induced by a ligand with high ErbB-




Cell lines- Interleukin-3 dependent murine (m) 32D haematopoietic progenitor cells transfected with 
distinct human ErbB-encoding viral vectors or plasmids were cultured in RPMI-1640 medium 
supplemented with 10% heat-inactivated fetal calf serum (FCS, GibcoBRL Life Technologies, 
Paisley, UK), 0.25 ng/ml mIL-3 (Promega, Madison, WI), and kept under continuous selection using 
0.6 mg/ml G418 (Calbiochem, La Jolla, CA) or 0.4 mg/ml hygromycin B (Sigma, St Louis, MO)(12). 
The human mammary carcinoma cell line MDA-MB-453 was cultured in a 1:1 mixture of Dulbecco’s 
modified Eagle’s medium and Ham’s F12 medium supplemented with 10% FCS. Human embryonic 
kidney 293 cells were cultured in Dulbecco’s modified Eagle’s medium (Gibco BRL) supplemented 
with 10% FCS. 
 
Ligand Displacement Experiments- Recombinant human NRG-1β 176-246 (R&D Systems, Minneapolis, 
MN) and T1E were radioiodinated using the Iodogen method (Pierce) according to the manufacturer’s 
protocol for indirect labelling, resulting in a specific activity of 40-80 µCi/µg protein. Ligand 
displacement analyses on 32D cells were performed as described (28). 
 
Construction of the phage T1E
46-50 
library- A phage library of T1E randomised by mutation to NNS 
codons (N=G/T/A/C, S=G/C) at positions Tyr46, Arg47, Asp48, Leu49 to Lys50 (T1E numbering) 
was constructed by a PCR-based approach using fUSE5/T1E as template (29,31). The randomised 
region in the peptide growth factor was directly followed by the Sfi-I restriction site, thereby omitting 
the EGF residues Trp51 to Arg55. Since the randomised sequence was located in close proximity of 
the pIII fusion point, a flexible (Gly-Gly-Gly-Ser)2 linker sequence was introduced in the wild-type 
fUSE5 vector after the second Sfi-I site prior to the gene encoding pIII. Wild-type fUSE5 contains an 
out-frame stuffer fragment between the Sfi-I sites, thereby eliminating background phage (32). The 
PCR fragments encoding the randomised T1E gene were cloned into the fUSE5/linker phage vector 
using both Sfi-I sites. Ligation products were processed and electroporated into Escherichia coli TG-1 
cells (Stratagene) for phage production. The number of independent transformants was determined by 
titration on tetracycline-containing plates to estimate the size of the library. Randomly picked clones 
from the library were analysed by cycle sequencing (Perkin-Elmer, Applied Biosystems) to confirm 
the diversity of codon use and the expected amino acid distribution. Phage preparations were carried 
out following standard polyethylene glycol 8000/NaCl precipitation procedures. Titers of filter-
sterilised phages were estimated by both titration and spectrophotometrical determination. 
 
Preparation of ErbB-IgG fusion proteins- Gene constructs encoding the extracellular domain of 
human ErbB receptors were fused to the hinge and Fc regions of the human IgG1 heavy chain 
(referred to as ErbB-IgG (33)). Subconfluent HEK-293 cells were transfected with the expression 
vector pCDM7/IgB3 or a mixture of pCDM7/IgB3 with pCDM7/IgB2 using Lipofectamine2000 
(GibcoBRL) according to the manufacturer’s protocol. Conditioned culture supernatants containing 
the soluble dimeric IgG fusion proteins were harvested 5-10 days following transfection, and purified 
by affinity chromatography on a 1 ml Hi-trap Protein A-Sepharose column (Pharmacia Amersham 
Biotech). Purified IgG fusion proteins were eluted with 0.1 M citric acid (pH 4.2) into tubes 
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containing 1 M Tris pH 9.0. ErbB-IgG preparations were quantified by Fc-ELISA using human IgG 
as a standard, while the purity and presence of dimeric species was confirmed by SDS-polyacrylamide 
electrophoresis and immunoblotting with polyclonal antibodies directed against human Fc (Nordic, 
Tilburg, NL).  
 
Phage selection on ErbB-3-IgG fusion proteins- Nunc immunoabsorbant wells were precoated 
overnight at 4°C with 0.2 µg of goat-anti-human Fc-specific IgG (Jackson Immunoresearch 
Laboratories, West Grove, PA) in 100 µl PBS (137 mM NaCl/ 2.7 mM KCl/ 1 mM Na2HPO4/ 2 mM 
KH2PO4). Wells were washed in PBS/0.05% (v/v) Tween20 (washing buffer) and blocked for 1 h in 
0.2 ml PBS/0.2% (w/v) BSA (blocking buffer) at room temperature. Next, wells were coated with 100 
ng ErbB-3-IgG for 2 h in PBS/0.2% BSA/0.05% Tween20 (binding buffer). Wells were rinsed twice 
and incubated with 1-3 ×1010 T1E46-50 phages in 0.1 ml binding buffer. After incubation for 2 h, 
unbound phages were removed by rinsing 12 times with washing buffer. Bound phages were eluted 
by addition of 0.1 ml glycine buffer (50 mM glycine/150 mM NaCl pH 2.7) for 10 min, and the eluate 
was neutralised with 25 µl of 1 M Tris/HCl pH 8.0. The elutate was used for phage titration and 
infection of logarithmic cultures of TG-1 cells. 
 
Whole cell phage selection- Phage selections on MDA-MB-453 cells were carried out by incubation 
of 5-10 × 106 cells in suspension with 1-3 × 1010 tu T1E46-50 phages in 3 ml blocking buffer. In the 
case of ErbB-3-IgG depletion, the phages were subjected to ErbB-3-IgG as described above prior to 
cell selection. The unbound phages from ErbB-3-IgG wells were subsequently transferred to 12 ml 
Falcon tubes, diluted to 3 ml with binding buffer and added to MDA-MB-453 cells. After incubation 
for 2 h on a rowing boat shaker, cells were rinsed seven times in washing buffer by spinning for 4 min 
at 1000 rpm, followed by resuspension and a final wash with PBS. Cells were transferred twice to 
clean tubes to remove phages non-specifically bound to the plastic. Specific elution was performed by 
competition with a 1:1 mixture of the anti-ErbB-2 monoclonal antibodies L26 and L96 (Neomarkers, 
Fremont, CA (34)) at 50 µg/ml in binding buffer for 1 h at 4 °C on a rowing boat shaker. Cells were 
spun and the supernatant was collected as ErbB-2/ErbB-3 phage fraction. The remaining cell-bound 
phages were harvested by a 10 min incubation in 1 ml acid elution buffer, followed by neutralisation 
upon adding 0.2 ml 1 M Tris-HCl pH 8.0. Cells were spun for 5 min at 1200 rpm, and the eluate was 
collected as ErbB-3 fraction. The distinct eluted fractions were used for phage titration and infection 
of logarithmic cultures of TG-1 cells.  
 
Phage ELISA- Small scale phage preparations were used for the screening of individual clones in 
ELISA assays. PEG 8000 precipitates of culture broths of clones grown overnight in 2 ml 2xTY 
supplemented with 12.5 µg/ml tetracyclin in 12-wells plates were resuspended in 100 µl PBS, 
typically resulting in phage titers of 1-5 × 1010 tu/ml. Whole cell ELISAs on 32D sublines in 
suspension were performed as described (29). The procedure for ErbB-IgG ELISA was similar as 
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described (20), with the following modifications: homodimeric ErbB-3-IgG fusion proteins were 
coated at 50 ng/well, and heterodimeric ErbB-23-IgG at 100 ng/well in 0.1 ml of binding buffer.  
 
Cell proliferation assays- 32D cells that coexpress ErbB-2 and ErbB-3 (D23 cells) were washed in 
RPMI 1640 medium to deprive them of IL-3. Subsequently cells were seeded into 96-well tissue 
culture plates at a density of 5.0 × 104 cells/well in 0.1 ml RPMI supplemented with 0.1% BSA, 
together with serial dilutions of filter-sterilised phages or recombinant growth factors. Cell survival 
was determined after 24 hours of incubation at 37 °C using the 3-(4,5-dimethylthiazolyl-2)-2,5-
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Structure-function relationship of EGF-like growth factors 
 
 
Basically, three different mutation strategies have been performed to study the amino acids in EGF-like 
growth factors that are essential for biological activity. These include a) site directed mutagenesis studies 
in which individual amino acids are mutated for chosen other residues, b) phage display studies in which 
individual amino acids or specific domains are randomly mutated and mutants expressed on phage 
selected for high affinity receptor binding, and c) domain exchange studies in which domains are 
exchanged between different EGF-like growth factors. Numerous studies have been performed in which 
individual amino acids in EGF and TGFα are mutated. The results of these studies have been reviewed 
extensively (Groenen et al., 1994; Campion and Niyogi, 1994). From these point mutation studies it has 
become clear that with respect to the binding affinity for ErbB-1 these growth factors contain four 
categories of amino acids: 
i) residues where mutation into any other amino acid leads to a complete loss of activity, because 
they are directly involved in proper protein folding. These include all six cysteines as well as Gly22 and 
Gly39 (EGF numbering) which are conserved in all EGF-like growth factors.  
ii) residues that have only very limited freedom of mutation, and are thought to be involved directly 
in receptor binding. These residues are functionally also highly conserved between the various family 
members. In the case of EGF, these include Tyr13, Leu15 and His16 around the second cysteine, and 
Tyr37, Arg41, Gln43 and Leu47 around the sixth cysteine (see grey residues in Fig.1). Based on NMR 
studies these residues, with the exception of Leu47, are believed to form together the non-linear ErbB-1 
receptor binding domain (Hommel et al., 1992). 
iii) residues that are not conserved between EGF-like growth factors and can readily be mutated, but 
only if additional amino acids are mutated as well. This category implies particularly amino acids in the 
B- and C-loop that are involved in β sheet formation. On the two sites of the β sheet amino acids are 
required with complementary side chain size and ability to form hydrogen bonds. Mutation of Ala30, 
which directly interacts with Met21 in the B-loop of EGF, results in a strong reduction of biological 
activity (Groenen et al., 1994) unless Met21 is mutated as well, such that a combination of amino acids is 
obtained that is also found in other ErbB-1 ligands on these positions.    
iv) residues that can be mutated with no or little effect on the biological activity. These residues are 
mainly located in the N-terminal linear region and towards the turn in the B-loop. These latter residues are 
mainly involved in providing a proper scaffold for the high affinity interaction between directly 
interacting amino acids and the receptor molecule. The requirement for such a scaffold function is also 
indicated by the observation that partial peptide sequences of EGF and TGFα have no or only very 
limited biological activity (Schultz and Twardzik, 1991; Groenen et al., 1994). 
Interestingly, mutation of specific amino acids in EGF-like growth factors can result in strong reduction 
of ErbB-1 binding affinity without affecting their mitogenic potential. This has first been described for a 
EGF/L47V mutant, which has a more than 10-fold lower binding affinity but near similar mitogenic 
activity as wild type EGF (Walker et al., 1990). A similar phenomenon has been observed for EGF/Y13G 
(Reddy et al., 1996) and various chimeras of EGF-like growth factors (see below). The molecular 
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mechanism behind this so-called low affinity/high activity behaviour is still unclear, but has been 
correlated with enhanced proteolytic resistance of the ligand (Walker et al., 1990), altered routing of the 
receptor-ligand complex (Reddi et al., 1996) and with enhanced expression levels of the ErbB-1 receptor 
(Puddicombe et al., 1996). This phenomenon does also not depend on the formation of specific ErbB 
heterodimers, since we have detected this low affinity/ high activity behaviour also in defined cell systems 
which only contain ErbB-1. Also no evidence was found for the involvement of so-called high and low 
affinity EGF receptors (M.L.M. van de Poll, A.E.G. Lenferink and E.J.J. van Zoelen, unpublished 
observation).  
In contrast to the many site-directed mutagenesis studies on EGF and TGFα, much less is known about 
the effects of single amino acid mutations in neuregulins. A notable exception, however, is the detailed 
study of Jones et al. (1998) in which all amino acids in NRG-1β have been mutated individually into 
alanine. Based on such alanine scanning it has been established that mutation of His2 or Leu3 in the linear 
N-terminal region, as well as of specific amino acids in the A-loop, C-loop or linear C-terminal region 
strongly impairs the ability of NRG-1β to bind ErbB-3. Binding to ErbB-4 is particularly impaired by 
mutations in the C-loop. It should be realized, however, that this approach does not discriminate between 
amino acids within the first three categories mentioned above, and gives therefore little information on 
specific amino acids involved in receptor binding. In a parallel phage display study the complete amino 
acid sequence of NRG-1β has been randomly mutated in a segment-wise approach (Ballinger et al., 1998). 
This study showed a very high degree of conservation of particularly Leu3, Val15-Glu19, Val23, Glu39, 
Arg44-Gln46 and Tyr48-Val49 in high affinity mutants for ErbB-3. No comparable studies have been 
performed on EGF and TGFα, but it is striking that the linear N-terminal region appears to be very impor-
tant for ligand binding to ErbB-3, while it is known te be of little importance for ligand binding to 
ErbB-1. Interestingly, by combining the sequence information for high affinity ErbB-3 binding of the 
individually mutated segments into one protein, a NRG-1β mutant has been generated with almost 
fifty-fold higher binding affinity for ErbB-3 than wild type NRG-1β (Ballinger et al., 1998). Besides the 
Figure 1: Primary amino acid sequence of human EGF. The dotted residues
represent the cysteines (C) and glycines (G) that form the basis for the three
dimensional structure of the EGF-like domain, the grey amino acids the 





six cysteines, this superbinding mutant has identical residues as wild type NRG-1β in only 22 out of 44 
positions. The number of phage display studies on EGF and TGFα is very limited, and this approach has 
only been used to provide additional evidence for the important role of specific amino acids in high 
affinity ErbB-1 binding (Souriau et al., 1997; Souriau et al., 1999; Tang et al., 1997).  
 
 
Domain-exchange studies on EGF-like growth factors 
 
 
A) General Considerations 
Due to the presence of three disulphide bridges, EGF-like molecules consist of two linear regions and five 
intercysteine regions, one of which is a single amino acid hinge region and it has been anticipated that 
each of these seven regions may serve a specific function. In order to study the role of these specific 
regions, amino acid stretches bordered by the conserved cysteine residues have been exchanged between 
EGF-like molecules. In a pioneering experiment, Purchio et al. (1987) showed already more than a decade 
ago that a chimera of vaccinia growth factor and TGFα is indeed biologically active. When compared to 
site-directed mutagenesis studies of individual amino acids, domain-exchange studies have a number of 
advantages: 
i) By exchanging domains between two structurally very related molecules, it can be expected that 
the chimeras obtained will have a near similar three-dimensional structure. In the case of single amino 
acid substitutions, however, activity may be lost if as a result of the mutation the protein is unable to fold 
into an active conformation. 
 ii) Site-directed mutagenesis studies have a tendency to focus on amino acids that are conserved 
between structurally related proteins, including the amino acids required for proper protein folding. In 
contrast, a domain-exchange strategy will leave these conserved amino acids unaltered, and focuses on 
amino acids that differ between the proteins investigated. 
iii) A domain-exchange strategy requires a protein with a specific biological activity that is not 
shared by a structurally related second protein. The second protein will now gain biological activity by 
introducing domains from the first protein which are relevant for this biological activity. In contrast to this 
gain-of-function approach, a single amino acid mutation in a functionally active protein generally has 
either no effect on its biological activity if an unrelevant residue is mutated, or results in reduced activity 
if an important residue is mutated. Such a reduction in biological activity can have many different 
reasons, however, including problems with protein expression, processing and folding. This makes it very 
difficult to draw definite conclusions from such loss-of-function approches.      
iv) A final advantage of a domain-exchange approach is that in general only a relatively limited 
number of mutants is required to identify a region important for a specific biological activity. By 
subsequent single amino acid exchanges in the region of interest, the residues of relevance for a biological 
activity can then be identified. In all cases, amino acids have to be exchanged into only a single 
alternative, which contrasts the situation observed during site-directed mutagenesis where in principle 




B) EGF chimeras with mammalian homologues 
Based on the above philosophy we have constructed a set of human (h)EGF/hTGFα chimeras, by 
exchanging domains bordered by the conserved cysteine residues (see Fig.2). In the nomenclature used 
for these ligands, E3T stands for a ligand with hEGF sequences N-terminal of the third cysteine and  
hTGFα sequences C-terminal of this cysteine (Kramer et al., 1994). In our approach these ligands have 
first been made as Protein A-fusion proteins in E. coli, followed by immunopurification on 
IgG-Sepharose, cleavage of the protein A-tag and final purification from incorrectly folded, inactive 
isoforms by reverse-phase HPLC (Van de Poll et al., 1995). In our hands these purified EGF/TGFα 
chimeras all have similar binding affinity for the human ErbB-1 receptor, as tested on NIH3T3 cells 
overexpressing this receptor (Van de Poll et al., 1995). Using this set of chimeras we have tested the role 
of specific domains in these molecules under conditions that EGF and TGFα have distinct activities.  
Human EGF and hTGFα have the same binding affinity for human ErbB-1 and basically induce similar 
responses in cells carrying this receptor. TGFα has been shown to be more potent than EGF in a limited 
number of cell systems, most likely as a result of the above described difference in routing of the receptor 
after ligand-induced internalization. It has been known for some time, however, that EGF and TGFα 
differ considerably in their affinity for chicken (c)ErbB-1, such that TGFα binds with high and EGF only 
with low affinity to this receptor (Lax et al., 1989). When testing the various EGF/TGFα chimeras for 
binding affinity to cErbB-1, the data in Figure 2 show that ligands with TGFα sequences in their 
C-terminal linear region have a high binding affinity for cErbB-1, similar to TGFα, while ligands with 
Figure 2: Structure and activity of EGF/ TGFα chimeras. On the left hand side the structure of various chimeras 
has been indicated relative to the six conserved cysteine residues (C) using a white color for EGF sequences
and a black color for TGFα sequences. On the right hand side the relative affinity of these chimeras is indicated
for the chicken EGF receptor (cErbB-1; data from Kramer et al., 1994), for the human ErbB-1 in the presence of 
the 13A9 antibody (13A9; data from Lenferink et al., 1998) and for activation of ErbB-2/ErbB-3 heterodimers 
(ErbB-2/3; data from Pinkas-Kramarski et al., 1998 and  chapter 2). +++ stands for optimal activity, -- for no 




EGF sequences in this region have a low binding affinity for this receptor, similar to EGF (Kramer et al., 
1994). By subsequent exchange of individual amino acids in this linear C-terminal region, we could show 
that a single point mutation in EGF, R45A, is already sufficient to make EGF a high affinity ligand for 
cErbB-1 (Van de Poll et al., 1995), indicating that Arg45 is part of or very close to the receptor binding 
domain of EGF. Experimental evidence for this hypothesis has been provided by human ErbB-1 with a 
single substitution of Gly441 to Lys, the residue found in the corresponding position in cErbB-1, which 
showed markedly reduced binding to EGF (Elleman et al., 2001). These results illustrate that the gain-of-
function approach used in these domain-exchange studies primarily results in the identification of residues 
that impede a particular activity, more than of residues that promote such activity. 
Although EGF and TGFα bind the human ErbB-1 receptor with similar affinity in a mutually competitive 
manner, there is evidence that the binding characteristics of both ligands are not identical. This is 
illustrated by the observation that the 13A9 anti-ErbB-1 antibody blocks receptor binding of TGFα but 
not of EGF (Winkler et al., 1989). This could either mean that EGF and TGFα bind to distinct, but partly 
overlapping epitopes on the receptor, or that the antibody stabilizes a conformation in ErbB-1 that favours 
binding of EGF but not of TGFα. Using receptor binding studies, we could show (see Figure 2) that in the 
presence of the 13A9 antibody EGF/TGFα chimeras with a linear C-terminal region of EGF are still able 
to bind ErbB-1 with similar affinity as EGF, while chimeras with TGFα sequences in this region are 
unable to bind in the presence of the antibody, similar to TGFα (Lenferink et al., 1998). This indicates 
that the linear C-terminal regions of EGF and TGFα most likely bind to separate sequences on ErbB-1, 
such that the binding domain of TGFα but not that of EGF overlaps with the binding epitope of the 13A9 
antibody.  
When studying the biological activity of the various EGF/TGFα chimeras on cells carrying the human 
ErbB-1 receptor, we observed that in spite of their similar binding affinity they strongly differed in their 
ability to induce mitogenic stimulation (Lenferink et al., 1997). While most of the chimeras shown in 
Figure 2 induced mitogenesis with similar dose dependence as the wild type ligands hEGF and hTGFα, 
three of them, namely E3T, E4T and T3E4T, showed mitogenicity at already a ten-fold lower 
concentration (Lenferink et al., 1997). Although the structural requirements for this so-called 
superagonistic behaviour are still unclear, we have established that these three ligands differ in a number 
of aspects from the other chimeras. First of all, they induce receptor recycling after ligand-induced 
internalisation, similar to TGFα but unlike EGF and the other chimeras tested. Since TGFα is not a 
superagonist, this indicates that receptor recycling may be essential but not sufficient to explain 
superagonistic behaviour (Lenferink et al., 1997). Secondly, we have shown that these superagonists show 
an enhanced rate of both receptor association and receptor dissociation (Lenferink et al., 2000). It is 
currently unclear, however, how differences in binding rate constants may directly influence the 
mitogenic potential of such growth stimulating ligands.   
Intriguingly, chimeras of hTGFα with mouse (m)EGF appear to behave differently from the 
hTGFα/hEGF chimeras described above. In the initial experiments of Lax et al. (1989) it was shown that 
mEGF has a 500-fold lower affinity for chicken ErbB-1 than hTGFα. Our studies indicated that hEGF has 
only 50-fold lower affinity for cErbB-1 than hTGFα, and thus has 10-fold higher affinity for this receptor 
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than mEGF (Kramer et al., 1994). Our data indicated that the difference in affinity between hTGFα and 
hEGF for cErbB-1 is mainly due to sequence differences in the C-terminal linear region. However, 
Richter et al. (1995) showed that a mEGF/hTGFα chimera which in our nomenclature would be referred 
to as mE3T4E, has significantly higher binding affinity for cErbB-1 than mEGF, indicating that the 
difference in binding affinity between mEGF and hEGF for cErbB-1 may be located in the B-loop. In 
addition it has been shown by this group that mE6T has low affinity but high mitogenic potential for cells 
overexpressing hErbB-1 (Puddicombe et al., 1996), which clearly differs from our observations on hE6T, 
which has very similar properties as hEGF (Lenferink et al., 1997). These observations urge for a more 
detailed study on the different behaviour of mouse and human EGF.  
When studying chimeras between EGF and NRG-1β, Barbacci et al. (1995) observed that most of them 
had lost the ability to compete with EGF for receptor binding, but maintained their neuregulin activity. 
Interestingly, a chimera of EGF with only the linear N-terminal region of NRG-1β (in our nomenclature 
referred to as N1E, in which N is used as abbreviation for neuregulin) was shown to be an activator of 
both ErbB-1 and of ErbB-2/ErbB-3 heterodimers. The properties of this so-called biregulin molecule 
suggests that the linear N-terminal region of neuregulin contains important ErbB-3 binding domains 
(Barbacci et al., 1995; Tzahar et al., 1997). Upon systematic introduction of NRG-1β sequences into the 
N-terminal half of EGF it was shown that also N2E but not N3E is able to bind ErbB-1 with high affinity 
(Chau et al., 1996), most likely because the resulting introduction of highly charged amino acids into the 
second part of the A-loop impairs binding of EGF to ErbB-1 (Campion et al., 1997). In comparison, our 
own data indicate that the corresponding chimera obtained by introducing TGFα sequences into EGF 
(T3E) is an activator of both ErbB-1 and of ErbB-2/ErbB-3 heterodimers (see chapter 2). Intriguingly, 
however, introduction of TGFα sequences into the linear N-terminal region of NRG-1α has been shown 
to result in a chimera (T1N) with strongly reduced neuregulin activity (Harris et al., 1998), most likely 
because of perturbations in the triple stranded β-sheet (Adler and Thompson, 1999). Finally, amino acid 
exchange studies between NRG-1α and NRG-1β have indicated that the higher potency of the β-isoform 
resides in a region of seven amino acids in the C-terminal linear region (Whoriskey et al., 1998).   
 
 
C) EGF chimeras with non-mammalian homologues 
The observation that Spitz activates the Drosophila EGF receptor (DER) while Argos antagonizes this 
activity (Wasserman and Freeman, 1998), has initiated domain-exchange between these molecules to 
study where the selectivity in their action is located. In this way it has been shown that both sequences 
within and outside the EGF-like domain determine their specificity (Schnepp et al., 1998; Howes et al., 
1998). Argos exerts its inhibitory action by preventing receptor binding of Spitz and thus by acting as a 
DER antagonist. Based on this concept, chimeras have been made between EGF and Argos with the aim 
to construct antagonists for the human EGF receptor. Lohmeyer et al. (1997) have shown, however, that 
EGF/Argos chimeras generally fail to bind to ErbB-1. The most conspicuous difference between Argos 
and other EGF-like molecules is the length of their B-loop. We have therefore made a chimera of EGF 
and Argos by extending the B-loop of EGF with 10 additional amino acids from Argos (Van de Poll et al., 
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1997). This ligand (E3A4E/B20) showed only low binding affinity to ErbB-1, but was mitogenically as 
active as wild type EGF. No evidence was obtained, however, for antagonistic activity of this chimera.  
The Drosophila Notch gene encodes a receptor-like molecule which plays an important role in controlling 
cell fate during development. In its extracellular domain it contains a large number of EGF-like repeats 
(Wharton et al., 1985), of which repeat #13 shows the highest sequence homology with hEGF, including 
the presence of Arg41 which is known to be essential for ErbB-1 binding (Van de Poll et al., 1998). By 
making chimeras of this Notch repeat with EGF, we have studied the minimum number of amino acids 
from EGF that have to be introduced into Notch (NT) to make it a high affinity ligand for ErbB-1 (Van de 
Poll et al., 1998). Using E1NT6E, which does not interact with ErbB-1, as a starting point we have shown 
that introduction of Tyr13 into Notch is sufficient to make it a high affinity ligand for human ErbB-1, 
provided that a proper amino acid combination for β sheet formation is present in the onset of the B-loop, 
e.g. Met21 and Ala30. Enhanced receptor affinity was obtained by additional introduction of Asn32 and 
Glu40 into this EGF/Notch chimera (Van de Poll et al., 1998). This shows again that only at a limited 
number of specific amino acids are required for high affinity ErbB-1 binding. In addition, many of the 
EGF/Notch chimeras derived in that study showed low receptor binding affinity in combination with high 
mitogenic activity (Van de Poll et al., 1998), as was previously also found for EGF/Argos chimeras and 
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EGF-like growth factors activate the intrinsic tyrosine kinase activity of ErbB receptors by promoting 
receptor homo-and heterodimerisation. As a consequence, ligand binding serves as a potential site for 
regulation of cell proliferation in diseases as cancer where ErbB receptors are overexpressed, and 
makes this event an important target for therapy. Moreover, most EGF-like growth factors 
preferentially signal through heterodimers of their cognate ErbB receptor with the orphan ErbB-2, but 
the precise role of ligands in the formation of heterodimeric complexes is unknown. As ligands differ 
in their ability to recruit a certain dimerisation partner, which directly influences their potency and 
kinetics of signaling, the identification of sequences involved in selective ErbB binding and 
dimerisation is important for the design of new antagonists. 
Although the structure-function relationship of EGF and TGFα for ErbB-1 binding has been widely 
studied (see Appendix), only limited information is available on the determinants for specific 
interaction with ErbB-3 and ErbB-4. This thesis concentrated on the role of ligands in specific 
heterodimer formation between ErbB-2 and ErbB-3 receptors. The ErbB-2/ErbB-3 heterodimer 
provides a good model system to investigate the role of the ligand in ErbB heterodimer formation for 
the following reasons. First, the kinase-defective ErbB-3 depends on ErbB-2 as coreceptor for 
functional signalling, and therefore ligands that induce functionally active heterodimers can easily be 
recognised by their ability to activate cells coexpressing both ErbB members. Secondly, since ErbB-2 
is an orphan receptor, ligands will bind ErbB-3 prior to dimerisation with ErbB-2. Finally, the 
coexpression of ErbB-2 with ErbB-3 has been shown to enhance the binding affinity of a ligand both 
on the cell surface and within preformed ErbB-IgG ectodomains (1,2). We have applied homology 
exchange mutagenesis and phage display to analyse and modify the binding and dimerisation 
properties of EGF-like ligands. The findings are interpreted in terms of different molecular 
mechanisms for ligand-induced ErbB-2/ErbB-3 heterodimerisation. 
 
 
Sequence requirements for specific ErbB-2/ErbB-3 activation 
Homology exchange mutagenesis has proved a useful approach to identify regions within homologous 
proteins with different biochemical properties, for instance in ligands which exert different receptor 
specificities. By typically measuring a gain-of-function in receptor binding ability, this method 
distinghuishes the important residues that confer receptor specificity from those that impair receptor 
binding. Moreover, the exchange of homologous regions prevents the occurrence of large structural 
alterations, since residues involved in conformation maintenance will be preserved. In contrast, 
mutagenesis analysis of the sidechains of natural ligands typically measures a loss-of-function, which 
may result from conformational pertubation. Within the family of EGF-like growth factors many 
different chimeric ligands have been constructed by the exchange of inter-cysteine regions or smaller 
sequences (3-13).  
Early studies had shown that EGF and BTC could act as weak agonists on cells expressing ErbB-2 
and ErbB-3 receptors, in contrast to TGFα, which only activates ErbB-1 (14,15). To identify the 
functional domains involved in ErbB-2/ErbB-3 interaction, we analysed a panel of EGF/TGFα 
chimeras for their ability to activate cells that express defined ErbB combinations on a null 
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endogenous ErbB background. As outlined in chapter 2, various EGF/TGFα chimeras were more 
potent activators of cells expressing ErbB-2 and ErbB-3 receptors than EGF. The strongest agonist for 
ErbB-2/ErbB-3 heterodimers was the chimera T1E, in which the linear N-terminal region of EGF had 
been replaced by TGFα sequences. This chimera mimicked the biological activity of NRG-1β in two 
different human breast cancer cell lines expressing ErbB-2 and ErbB-3 by stimulating cell 
proliferation and differentiation. The binding affinity of T1E on D23 cells was in a similar range as 
that of the natural high affinity ligand NRG-1β, while the ErbB-1 binding affinity was retained. In 
contrast to NRG-1β, T1E bound only weakly to cells expressing ErbB-3 alone, indicating that the 
additional presence of the ErbB-2 receptor is required for high affinity interaction. The overall 
biochemical properties of the chimera T1E strongly resembled those of biregulin, a chimera in which 
the linear N-terminal region of EGF has been replaced by NRG-1 sequences (“N1E”, following our 
nomenclature)(6,16,17). Both chimeras seem pan-ErbB ligands, with binding affinities in the 
nanomolar range for ErbB-1 receptors, ErbB-2/ErbB-3 heterodimers, and ErbB-2/ErbB-4 
heterodimers (17, and chapter 2).  
Comparison of the potencies of distinct EGF/TGFα chimeras led to the identification of  two distinct 
regions involved in this gain-of-function, e.i. the linear N-terminal region of TGFα in conjunction 
with the B-loop region of EGF. More detailed analysis identified His2 and Phe3 within the TGFα N-
terminus as discriminating determinants within T1E for ErbB-2/ErbB-3 activation in D23 cells, 
corresponding to His2 and Leu3 in biregulin. Within the B-loop region the presence of Leu26 in EGF 
facilitates interaction with ErbB-2/ErbB-3 heterodimers, while Glu27 at the equivalent position in 
TGFα impairs binding. It appears that the combination of sequences in the N-terminal region and the 
B-loop is critical for ErbB-2/ErbB-3 interaction, since a chimera in which the linear N-terminus of 
TGFα is followed by NRG-1α sequences (“T1N”) is unable to activate cells expressing ErbB-2 and 
ErbB-3 (9). Note that the B-loop region of NRG-1 is extended by three residues compared to the 
corresponding region in EGF, which is not necessary for binding to the NRG receptors but may 
prevent its binding to ErbB-1 (8,9,12). The structural integrity of the triple β-sheet was indeed 
affected in the T1N chimera (18). In line with these findings, another chimeric ligand in which the 
linear N-terminus of NRG-1 is followed by TGFα sequences (“N1T”) is also unable to activate breast 
cancer cells expressing ErbB-2 and ErbB-3 (13). Together these data stress the role of the local 
context for functional amino acids, and argue that selective ErbB interaction of ligands involves both 




Structural requirement for ErbB-3 specificity? 
The conformation of the N-terminal linear tail of EGF is remarkably different from that of NRG-1α, 
as indicated by the 2D-NMR solution structures. While this region is completely flexible in human 
EGF, in the NRG-1α EGF-domain it forms the third strand of an anti-parallel triple β-sheet together 
with the two strands of the B-loop (19-21). The EGF-domains of BTC and HB-EGF, which bind 
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ErbB-4 in addition to ErbB-1, also exert a tendency to form a triple β-sheet, suggesting that this 
feature may serve as structural requirement for interaction with the two NRG receptors (22,23). As 
residues within both the linear N-terminal region as the B-loop play a major role in ErbB-3 binding 
and ErbB-2/ErbB-3 activation, we speculated that these regions might adopt a similar conformation in 
the chimera T1E. The recent determination of the 2D-NMR structure of T1E in our laboratory did, 
however, not fully subscribe this assumption (M. Wingens, prepress JBC). In here, the linear N-
terminal region of T1E was found to adapt a β-strand conformation only in four out of 36 possible 
configurations, whereas the overall structure of T1E proved very similar to that of human EGF 
(Figure 1). The N-terminal linear region has an elongated shape compared to EGF, due to nuclear 
overhauser exchange contacts between the first two valines and Leu26 located at the tip of the B-loop. 
The impact of this interaction should be taken with caution, since these valines are missing in 
biregulin which nevertheless exerts identical biochemical properties as T1E. Compared to the EGF 
and TGFα structures the orientation of the N- and C-terminal domains appears slightly altered in T1E, 
which may indicate flexibility around the hinge residue (24). In the NMR solution structure of TGFα 
the linear N-terminal region is also disordered, although it is still more structured than that of EGF, 
but in the co-crystal complex with ErbB-1 the linear N-terminus is stabilised within a triple β-sheet 
(25,26). Therefore, the enhanced tendency to triple β-sheet formation of T1E compared to EGF may 
slightly contribute to its ability to interact with the ErbB-3 receptor. 
 
 
Linear N-terminal sequences in EGF mediate binding to ErbB-3 
As the linear N-terminal region plays a major role in conferring specificity towards ErbB-2/ErbB-3 
heterodimers, we have determined the optimal sequence requirements within this region by using the 
phage display method. Affinity optimisation of EGF modified at positions 2, 3 and 4 was performed 
by three rounds of whole cell selection on human breast cancer cells that coexpress ErbB-2 and ErbB-
3, resulting in the isolation of EGF variants with binding affinities up to five-fold higher than that of 





Figure 1: The 44 NMR solution 
structures of human EGF (19) and 
the 36 solution structures of the 
EGF/TGFα chimera T1E (printed 
with permission of M. Wingens). 
The linear terminal regions are 
indicated with N (NH2-terminal 





binding to ErbB-2 and ErbB-3 receptors, the selectants exerted concomitant increased binding affinity 
for cells expressing ErbB-3 alone and homodimeric ErbB-3-IgG ectodomains. Although the ErbB-3 
binding affinity of the EGF variants is still one order of magnitude lower than that of NRG-1β, the 
affinity enhancement strongly implies that residues in the linear N-terminus are involved in direct 
binding to ErbB-3, and not in mediating dimerisation of ErbB-2.  
The consensus sequence of EGF
234
 variants optimised for high ErbB-3 affinity was Trp2/Val3/Arg4: 
While the presence of an aromatic residue at position 2 was absolutely required, basic residues could 
substitute for hydrophobicity at position 3. These findings are largely in agreement with the residues 
identified in a similar phage display study on NRG-1β by Ballinger and coworkers (27). Affinity 
optimisation of the N-terminus of NRG-1β for ErbB-3-IgG binding resulted in NRG-1β1-5 variants 
containing an aromatic Trp at position 1, followed by a polar residue at position 2, while mainly 
hydrophobic residues were found at position 3 and 4 (27). While no preferential selection for basic 
residues was observed, it seems likely that positive charge is provided by compensatory residues 
present in structurally adjacent domains outside the region subjected to analysis (e.g. Lys9 in NRG-
1β). Notably, none of the selected NRG-1β1-5 phage variants exerted enhanced ErbB-3 binding 
compared to wild-type NRG-1β phage, while strong affinity enhancement could be achieved by the 
optimisation of some of the other regions in NRG-1β. Apparently the linear N-terminus of NRG-1β is 
already optimal for ErbB-3 interaction within the context of the NRG-1β molecule. This result also 
emphasises the critical choice of the template molecule for phage display studies that aim to optimise 
the binding affinity or alter the receptor selectivity.  
The similarity in the sequence requirements of EGF234 and NRG-1β1-5 phage variants optimised for 
ErbB-3 binding suggests that these mutant ligands may bind a similar epitope on the ErbB-3 receptor. 
Previously alanine scanning mutagenesis of NRG-1β implicated residues that form a hydrophobic and 
charged surface patch on one side of the triple β-sheet, including His2, Leu3, Val4, Phe21, Val23, 
Arg31, Leu33 and Lys35, as major determinants in ErbB-3 binding (21,28). Within this large surface 
area, it appears that the presence of a aromatic residue located at the N-terminal is absoluty required 
for ErbB-3 specifity, when embedded by hydrophobic and basic or polar residues (chapter 2). 
Combined with the negative role of the glutamate within the TGFα B-loop, we speculate that the 




The linear C-terminal region of EGF-like ligands contributes to ErbB-3 interaction 
The linear C-terminal region of EGF-like ligands also appears to have a role in ErbB-3 and ErbB-4 
interaction. The natural α- and β- isoforms of NRG-1 and NRG-2 strongly differ in their binding 
affinity and ability to activate distinct ErbB combinations, underlying for a great deal the broad range 
in biological responses covered by this growth factor subfamily (15,29-31). The sequence variance of 
the NRG isoforms within the EGF domain is restricted to amino acids following the fifth cysteine in 
the EGF domain. Previous studies using chimeric ligands indicated that particularly residues in the C-
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terminal linear tail critically influence the binding and mitogenic properties of these isoforms (9,10). 
Based on these differences, it has been proposed that NRGs and other EGF-like growth factors may 
have a bivalent character and interact with both ErbB-3 and ErbB-2 through separate binding sites 
(16,32,33).  
As mentioned above, the chimeras T1E and biregulin both depend on ErbB-2 to stabilise their low 
affinity interaction with ErbB-3. Using phage display we have optimised five residues in the linear C-
terminal region of T1E for altered receptor selectivity and affinity, as outlined in chapter 5. With 
respect to the affinity optimisation, we show that T1E can be strongly enhanced for binding to ErbB-3 
homodimers, indicating that also residues in the linear C-terminal tail contribute to the ability of 
ligands to bind ErbB-3. However, T1E
46-50 
phage variants were also potent ligands for ErbB-2/ErbB-3 
heterodimers, in spite of negative selection for such heterodimers. No altered receptor selectivity 
could be achieved by modification of the linear C-terminal residues of T1E. We consistently observed 
a direct relation between the ability of T1E variants to bind ErbB-3 and their ability to induce ErbB-
2/ErbB-3 heterodimers. The T1E variants positively selected for ErbB-2/ErbB-3 binding, but 
negatively for binding to ErbB-3 homodimers, can be considered as “second best” ErbB-3 binders, 
which is also reflected by the high degree of similarity in the consensus sequences of the ErbB-23 and 
ErbB-3 selectants. Since we failed to detect specific residues involved in direct interaction with ErbB-
2, it seems highly unlikely that the linear C-terminal region harbours a separate binding site for ErbB-
2, and that the formation of heterodimeric ErbB complexes is driven through bivalent ligands binding 
to two different ErbB molecules.  
Thus, sequences in the C-terminal linear region of a ligand directly contribute to its ErbB-3 affinity, 
and thereby determine whether only ErbB-2/ErbB-3 heterodimers or in addition homodimers of ErbB-
3 can be formed. The T1E
46-50
 variants with the highest ErbB-3 affinity contained large hydrophobic 
residues at 46, 47 and 49, preferentially having isoleucine at postion 46 and an aromatic residue at 47, 
in combination with Asp at position 48. Interestingly, the optimised C-terminal sequences can 
compensate for the sub-optimal residues present in the linear N-terminus and B-loop of T1E with 
respect to ErbB-3 interaction, since the ErbB-3 binding affinity of many T1E variants was strongly 
enhanced relative to EGF/W2V3S4, the EGF variant with the highest ErbB-3 affinity (chapters 3 and 
5). The ErbB-3 affinity of NRG-1β could be strongly enhanced by modification of residues 46-50 in 
the C-terminal region (corresponding to residues 45-49 of T1E), in particular due to the substitution of 
Met50 by Ile (27). In line with the ErbB-3 optimised T1E
46-50
 variants, aromatic/hydrophobic side-
chains were found in at the equivalent positions in NRG-1β variants. In contrast, no acidic residues 
were preferentially selected in optimised NRG-1β variants, were the wild-type Val49 was conserved 
(27). However, a direct contribution of the aspartate to ErbB-3 interaction is confirmed by the 25-
times enhancement in binding affinity observed for NRG-1α upon replacement of its linear C-
terminus for TGFα sequences (“N1T”). Of the sequences that favour ErbB-3 binding, the TGFα C-
terminus only contains the aspartate and adjacent leucine (9). This differential selection of aspartate 
may be attributed to differences in the structural environment of the ligands, or to a slightly different 
ErbB-3 binding interface. This latter option may also explain why the exchange of the entire C-
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terminal region in T1E for NRG-1 residues strongly affected its ability to bind D23 cells, while the 
single L47M substitution in T1E did not (chapter 5). Residues in the C-terminal region of ligands 
have also been implicated in ErbB-4 selectivity. Sequence exchange of NRG-2α and NRG-2β 
revealed that in particular the presence of Lys versus Phe at position 45 in the NRG-2 EGF-domain 




Multi-domain binding to ErbB-3  
Our findings imply that EGF-like ligands interact with ErbB-3 through a multi-domain binding site, 
involving at least both linear endings of the ligand. However, we cannot exclude the possibility that 
additional sequences contribute to ErbB-3 specificity. The A-loop region may contain minor 
determinants for ErbB-2/ErbB-3 interaction, as we found that the EGF/TGFα chimera T3E had lower 
potency and affinity than T1E (chapter 2). In agreement with these observations, exchange of part of 
the A-loop region in EGF by NRG-1 sequences (“E2N3E”) resulted in a low affinity ligand for ErbB-
2/ErbB-3 heterodimers (6). NRG-1β residues in the two β-turns of the A- and C-loop were sensitive 
to mutation, although these regions are presumably involved in structural maintenance (21,28).  
Figure 2 summarises the residues within T1E that correspond to the ErbB-3 binding determinants 
identified in this thesis. Based on the analogy of the crystal structures of ErbB-1 and ErbB-3, it is 
most likely that homodimeric and heterodimeric ErbB-3 complexes are mediated through a 
conformation-driven dimerisation mechanism (26,34-36). Moreover, the multi-domain interaction 
with ErbB-3 suggests that ErbB-3 ligands bind their receptor in a similar mode as ErbB-1 ligands, 
where the ligand simultaneously contacts domains I and III of one receptor (26,34,35,37). Future 
experiments must reveal whether the introduction of optimal N- and C-terminal residues in EGF will 
synergistically enhance the ErbB-3 binding affinity and result in a ligand with equally high affinity 
for both ErbB-1 and ErbB-3 receptors. Interestingly, the kinetic rate constants may reflect the 
orientation and the ability of a ligand to stabilise the dimerisation conformation state. The EGF/L47V 
and L47M analogues have only low ErbB-1 binding affinity as a result of an increased dissociation 
rate, while the association rate was similar to wild-type EGF (38,39). Since several residues in the 
linear C-terminal tail of receptor-bound TGFα were found to contact both domains I and III (e.g. 
Tyr38, Val39 and Leu49) or with domain I (e.g. Asp47), these residues have been suggested to 
determine the final position of domain I and III in the complex, and thereby influence the stability of 
the resulting dimer (26). Possibly in the optimised T1E variants residues in the linear C-terminus, 
including the aspartate at position 48, may similarly function to position the two ligand-binding 
domains in a conformation that favours dimerisation. As outlined in chapter 4, the residues Leu15 and 
Leu47 that are part of the EGF·ErbB-1 interface do not contribute to the specificity for ErbB-1 and 
ErbB-3 interaction in T1E. While in EGF Leu47 is buried in a hydrophobic pocket in domain III, this 






Figure 2: Residues in T1E involved in ErbB-3 interaction. Residues that were identified by homology exchange 
mutagenesis or which correspond to the consensus sequence for binding to ErbB-3 are encircelled. The other 
residues indicated represent residues that mediate receptor contacts that are conserved between ErbB-1 and 
ErbB-3, as referred to in Table I. Numbering is according to EGF. 
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context of the T1E molecule (chapter 4 and 5). This suggests that the receptor contacts with domain 
III residues are less efficiently mediated by T1E than by EGF, resulting in reduced ErbB-1 affinity, 
and that the relative orientation of T1E in the cleft between domain I and III is slightly different from 
that of EGF or TGFα. 
Binding of EGF to both domains I and III causes a severe rearrangement of the subdomains in the 
extracellular domain and relief of the auto-inhibited conformation, as revealed by comparison of the 
set of ErbB structures presently available (26,34,36). The relative orientation of domains I and II and 
domains III and IV seems mostly preserved, and domains I/II appear to rotate as a rigid body with the 
domain II/III junction figuring as hinge. How ligands initiate this large conformational change is 
currently unresolved. Since NRG-1β can bind an ErbB-3 proteolytic fragment containing domain I, 
while EGF can directly bind an ErbB-1 fragment encompassing domain III with affinity in the 
micromolar range, it appears that the binding site of primary importance may be different between 
cognate ErbB-3 ligands and ErbB-1 ligands (40,41). In line with this assumption, NRG-1 binding to 
chimeric ErbB-1/ErbB-4 receptors requires the presence of ErbB-4 subdomain I in an ErbB-1 context 
(42). NRG-1β was able to displace radiolabelled EGF from these receptors, demonstrating that this 
chimeric receptor could not simultaneously bind NRG-1β to domain I and EGF to domain III. Overall 
it appears that in the case of NRG-1, domain I interactions contribute mostly to the specificity of 
ligands for ErbB-3 and ErbB-4.  
 
 
Comparison of the ErbB-1 and ErbB-3 binding determinants of EGF-like ligands 
We compared the sequence conservation between the human ErbB-1 and ErbB-3 receptors with 
respect to the residues that are part of the EGF·ErbB-1 or TGFα·ErbB-1 interface (Table I) (26,34). 
The structural alignment of the binding domains of ErbB-1 and ErbB-3 is hindered by the absence of 
the first 35 residues, which in ErbB-1 contribute to a large extent to the binding interface, in the 
crystal structure of the ErbB-3 extracellular domain (35). Although it is well realised that a direct 
extrapolation of the ligand binding site is not feasible, the presence of homologuous residues provides 
some insight on the common features of ErbB receptor-ligand interactions. At first, residues 15-18 of 
ErbB-1 form a β-strand in an anti-parallel fashion with the major β-sheet of the ligand in both crystal 
structures. This interaction mostly concerns main-chain interactions, and ErbB-3 or ErbB-4 could 
equally well mediate such an interaction as both receptors lack residues with large side-chains in the 
corresponding region. Furthermore, the acidic character of Glu90 in ErbB-1 is conserved in Asp93 of 
ErbB-3 within domain I, while in the ligands a basic residue is consistently found in the B-loop region 
(Lys28 in EGF, Arg31 in NRG-1). Likewise, within domain III the important Asp355 is conserved 
among all ErbB receptor members across species. This residue forms a salt-bridge with Arg41 in 
EGF, that is equally strong conserved among EGF-like ligands, which side-chain is held in place by 
the conserved Tyr13 and Leu15 in EGF. These electrostatic interactions within the ligand·ErbB-1 
interface thus appear to be conserved, and may aid to project the ligand in the proper orientation in the 
cleft between the two domains (chapter 4). Also many hydrophobic residues seem generally 
conserved between ErbB-1 and ErbB-3. Intriguingly, Tyr101 in ErbB-1 which interacts with His4 in 
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the N-terminus of TGFα but not with EGF residues, corresponds to Tyr104 in ErbB-3. This residue 
could be part of the ligand binding-site that contacts the aromatic residue that confers ErbB-3 
specificity in ligands. In addition, the hydrophobic pocket in ErbB-1 domain III for Leu47 in EGF is 
mostly conserved, except for Leu382, which has a non-conserved Asn substitution in ErbB-3 and 
ErbB-4. In ErbB-3 this pocket is less pronounced than in ErbB-1 as a result of an amino acid insertion 
(e.g. Met414) close to the center of the hydrophobic cluster.  
 
TABLE I 
Comparison of the ErbB-1 receptor-ligand interface with the corresponding sequences in ErbB-3 
ErbB-3 ErbB-1 EGF TGFα 
Domain I Site 1 
Asn15 Asn12  Gly40 
Leu17 Leu14 Ile23, Leu26 Leu24, His4, Phe5 
Ser18 Thr15  Ala31, Ala41 
Val19 Gln16 Asn32, Cys31 Arg22, Cys32 
Thr20 Leu17 Asn32 Val33 
Gly21 Gly18 Cys33 Cys34 
Leu48 Tyr45 Met21, Ile23 Arg22, Leu24 
Met72 Leu69 Ile23, Leu26 Phe5 
Tyr92 Tyr89  Arg22 
Asp93 Glu90 Lys28 Lys29 
Met101 Leu98 Leu26 Phe5 
Tyr104 Tyr101  His4, Gln26 
Tyr129 Arg125  Glu27 
Lys132 Asn128  Gln26 
    
Domain III Site 2 
Gln322 Leu325 Leu15 Phe17 
Asp343 His346 His16 His18 
Leu345 Leu348  Phe17, Glu44 
Thr347 Val350 Leu15 Phe17 
Asp352 Asp355 Arg41 Arg42 
Pro353 Ser356  Ser11, Thr13 
Trp354 Phe357 His10, Tyr13 His12, Phe15 
Ser379 Leu382 Leu47 Ala46, Leu48 
Gln382 Gln384 Gln43, Arg45 Tyr38 
Tyr405 Gln408  Leu48, Glu44 
Asn406 His409  His45, Leu49 
Phe409 Phe412 Leu47 Leu48 
Met414 Val417 Leu47 Leu48 
Tyr436 Ile438 Leu47 Leu48 
Asp464 Lys465 COOH-end  
 
 
Heterodimerisation with ErbB-2 
We propose that quantitative differences in ErbB-3 binding affinity between ligands ultimately 
determine which dimeric complex can be formed and activated, by which ligands specify qualitatively 
different biological responses. Selectivity between the formation of inactive ErbB-3 homodimers and 
active ErbB-2/ErbB-3 heterodimers will be achieved through the intrinsic property of a ligand to bind 
the ErbB-3 receptor and promote domain rearrangements within its extracellular domain (Figure 3). 
Ligands with high affinity for domain I and/or III of ErbB-3, including NRG-1β and some of the 
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optimised T1E variants, have a high potency to induce domain rearrangements and stabilise ErbB-3 
into the dimerisation state, and thus mediate the formation of both ErbB-3 homodimers and ErbB-
2/ErbB-3 heterodimers. Ligands with relatively low affinity for ErbB-3 due to suboptimal interaction 
with domain I or III, including T1E and NRG-1α, only ineffectively induce domain rearrangements 
and relief of the autoinhibited conformation. ErbB-2 can directly stabilise the ErbB-3 dimerisation 
arm upon exposure and prevents ligand dissociation, and thereby drives the equilibrium towards the 
formation of ErbB-2/ErbB-3 complexes. From an evolutionary point of view such a model would be a 
sensible mechanism to enhance the formation of active ErbB-2/ErbB-3 complexes and to avoid 
biologically inactive ErbB-3 homodimers. In conditions where ErbB-2 is present in excess over ErbB-
3, NRG-1β would be the optimal agonist, while the low affinity NRG-1α isoform would be more 
effective under conditions that ErbB-3 is present in excess over ErbB-2. A switch in isoform 
production thus offers the cell a subtile method of control over cellular functions.  
This model presumes that the dimerisation site of ErbB-2 is maintained constitutively in the extended 
dimerisation configuration. Indeed, the recent publication of the crystal structures of the rat and 
human ErbB-2 extracellular domain and a truncated human ErbB-2 ectodomain indicated a fixed 
conformation for ErbB-2 that resembles the ligand-activated form of ErbB-1 (43,44). The structure 
shows ErbB-2 as monomer in a closed conformation with subdomain I and III residues contacting 
each other, which would explain why ligands fail to bind this receptor. The lack of an auto-inhibited 
conformation in ErbB-2 may be due to non-conserved substitutions of three amino acids that mediate 
the domain II-IV contact (43-45). The function as preferential coreceptor for other ErbB members and 
the transforming potential of ErbB-2 may thus result from the permanent availability of the ErbB-2 
dimerisation arm. Interestingly, the dimerisation interface within ErbB-2 appears to have a 
electronegatively charged surface potential, which may prevent the formation of ErbB-2 homodimers 
(44). In addition, overexpression of ErbB-2 in conjunction with ErbB-3 may alter the membrane 
localisation of the receptors, and thereby influence the availability of ErbB-2 for heterodimerisation. 
 
 
Figure 3:  Kinetic model for T1E-induced heterodimerisation between ErbB-2 and ErbB-3 receptors. Ligand 
binding to ErbB-3 is thought to induce a conformational change that stabilises the receptor in an open 
conformation for dimerisation. Dimerisation is primarily mediated by the dimerisation loop that projects from
domain II, which is occluded by intramolecular interactions in the autoinhibited unliganded state. The affinity of the
ligand critically determines whether the ligand-bound ErbB-3 can be stabilised by ErbB-2 or in addition by a 
second liganded ErbB-3. For reasons of clarity only the subdomains I, II, III and IV of the extracellular domain of
ErbB-3 (in white) and ErbB-2 (in grey) are depicted. The linear terminal regions are indicated within the ligand with
N (NH2-terminal end) and C (COOH-terminal end), respectively.  
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The colocalisation of certain membrane proteins may form a barrier to uncontrolled ErbB-2 activation 
under normal conditions. Notably, the accumulation of ErbB-2 receptors in specific lipid raft domains 
in human breast cancer cells positively affects their availability for heterodimer formation with ErbB-
3 (46). The inverse situation has also been demonstrated, as the sialomucin glycoprotein ASGP-2 was 
found to facilitate ErbB-2 activation in rat mammary carcinoma cells (47).  
Differential receptor binding kinetics may also provide a likely explanation for the ligand-induced 
formation of heterodimeric complexes with ErbB members other than ErbB-2, for instance ligand-
induced ErbB-1/ErbB-3 heterodimers. The intrinsic flexibility of an ErbB receptor, defined by the 
steady-state equilibrium between the autoinhibited locked state and the extended open state in the 
absence of ligand, may determine whether it can serve as coreceptor in its unliganded form. Since 
NRG-1β but not EGF can activate heterodimers of ErbB-3 and ErbB-1, the NRG-1β-bound ErbB-3 
receptor can recruit unliganded ErbB-1 in an heterodimeric complex. Only the high affinity ErbB-3 
ligands seem to be able to signal through this heterodimer, while ErbB-1 ligands preferentially induce 
ErbB-1 homodimers ((30,48) and chapter 4). It will be interesting to learn if dual-specific ligands that 
exert high affinity for both ErbB-1 and ErbB-3 receptors will be able to efficiently activate these 
heterodimers, or wheather the low probability of ErbB-1/ErbB-3 dimerisation may be due to 
incompatibility of their dimerisation loops. Ferguson and coworkers postulate that the estimated 
dissociation constant for the domain II-IV interaction predicts the conformation of the receptor at 
equilibrium (36). It is argued that 80-93% of all surface-expressed unliganded ErbB-1 will be present 
in the auto-inhibited state at equilibrium while 3-20% will be in the extended configuration. The high 
intrinsic flexibility of ErbB-1 may also underlie the occurrence of preformed, inactive ErbB-1 
oligomers, that have been implicated by several in vivo studies using fluorescence techniques (49,50).  
 
 
Implications for the design of ErbB antagonists 
Understanding of the mechanism by which ligands mediate ErbB dimerisation provides several entries 
for interference with aberrant ErbB receptor activation. At first, ErbB activity can be antagonised by 
molecules that lock the receptor into the auto-inhibited conformation. One can think of agents that 
directly crosslink the domain II/IV intramolecular interaction, conformation-selective antibodies that 
target the hinge region between domain II and III, or molecules that stabilise the orientation of 
domains I and III in the unliganded receptor. For instance, a protein that can fill the large gap that is 
observed between domain I and III in the autoinhibited structures of ErbB-1 and ErbB-3 could 
achieve this. Secondly, the loops involved in receptor dimerisation and intramolecular interactions 
may directly serve as targets for anti-cancer agents. Soluble ErbB ectodomains or fragments 
encompassing the dimerisation loop of domain II can bind cell-expressed ErbB receptors with nM 
affinity and inhibit their activation (51-53). Morever, mimetic peptides of the domain IV residues 
mediate effective steric blocking of ErbB interactions (54). The antigen-binding fragment of  
Herceptin, that is in use as treatment for metastatic breast cancer, was found to bind the same 
juxtamembrane region in domain IV of ErbB-2 (43). Herceptin may crosslink two ErbB-2 molecules 
in an orientation that prevents interaction of the transmembrane and kinase domains.  
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Finally, modified ligands that strongly bind only one of the ligand-binding domains but fail to induce 
a domain rearrangement would represent effective competitors of endogeneous EGF-like growth 
factors. This type of ligand-based antagonists has been succesfully generated for the bivalent human 
growth hormone, where one receptor binding site was crippled and the second binding site 
subsequently optimised for high affinity binding by phage display (55,56). However, this approach 
may prove less effective for ErbB ligands for the reason that high affinity binding of EGF-like ligands 
depends on dimerisation, as targeted disruption of residues in the dimerisation loop of ErbB-1 
invariably reduced the binding affinity of the ligand (26,34). As EGF-like ligands seem to have 
optimal folds for binding to both domains I and III, the optimisation of other protein modules for high 
affinity binding to only domain I or III may be more prone to success. The only EGF-like peptide 
with antagonistic activity identified to date is Argos, but it is inclear how it binds to the Drosophila 
EGF receptor (57). The critical regions implicated in the antagonistic activity of Argos are the 20-
amino acid B-loop region, which contains a cluster of basic residues located opposite of acidic 
residues, and the extended C-terminal linear ending (58,59). As one report stated that Argos may even 
inhibit signalling in mammalian cells, it would make a logical template molecule for the engineering 
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Ligands of the epidermal growth factor (EGF) family of growth factors activate their respective ErbB 
receptor by inducing receptor dimerisation, by which both homo- and heterodimers can be formed. 
The ErbB-2 receptor is an orphan (ligand-less) receptor, it can serve as dimerisation partner to the 
other three ErbB receptors. In fact, most EGF-like growth factors preferentially signal through 
heterodimers of their cognate ErbB receptor with ErbB-2, which affects their potency and kinetics of 
signalling, but how ligands mediate ErbB heterodimerisation is unclear. Overexpression of ErbB-2 is 
frequently observed in numeral human cancers of epithelial origin, including those in the breast and 
lung, and is associated with an aggressive tumour phenotype and poor patient prognosis and survival. 
The design of novel anti-cancer agents requires a thorough understanding of the molecular mechanism 
underlying ligand-induced ErbB activation and the specificity of ligand-receptor interactions. This 
thesis addressed the identification of sequences in EGF-like ligands involved in selective ErbB 
receptor binding and heterodimerisation, using the ErbB-2/ErbB-3 heterodimer as model system. 
ErbB-2 is a ligand-less receptor, whereas ErbB-3 lacks tyrosine kinase activity. Hence, both ErbB-2 
and ErbB-3 are active only in the context of ErbB heterodimers, and ErbB-2/ErbB-3 heterodimers, 
which are driven by NRG-1, are the most prevalent and potent ErbB complexes in terms of mitogenic 
and transforming activity.  
Earlier studies revealed that cells that express ErbB-2 and ErbB-3 receptors show a low mitogenic 
response to the ErbB-1 ligand EGF, but not to the ErbB-1 agonist TGFα. We have exploited this 
difference by exchanging domains between EGF and TGFα to identify the sequence determinants of 
ligands for ErbB-2/ErbB-3 interaction (chapter 2). Interestingly, various EGF/TGFα chimeras were 
far more potent activators of cells expressing ErbB-2/ErbB-3 than EGF itself. The chimera T1E, in 
which the linear N-terminal region of EGF has been replaced by TGFα residues, binds with high 
affinity to ErbB-2/ErbB-3 heterodimers, while its binding to the ErbB-1 receptor was retained. 
However, T1E binds only weakly to cells expressing ErbB-3 alone, indicating that the additional 
presence of ErbB-2 is required for high affinity interaction. Analysis of chimeras showed that the 
combination of two different regions conferred specificity towards ErbB-2/ErbB-3, the linear N-
terminal tail and the so-called B-loop region. Further exchange studies identified specific residues in 
the N-terminus (His2 and Phe3 present in TGFα) as important determinants for this gain-of-function. 
Within the B-loop region of EGF Leu26 facilitates interaction, while the negatively charged Glu27 at 
the equivalent position in TGFα impedes its binding to ErbB-2/ErbB-3 heterodimers, arguing that 
selective ErbB interaction of ligands involves both residues that mediate receptor contacts as well as 
negative determinants that prevent binding to other receptors.  
Since the linear N-terminal tail plays a major role in conferring EGF specificity towards ErbB-
2/ErbB-3 heterodimers, we further analysed the sequence requirements within this region for receptor 
interaction using the phage display method. From a library of EGF
234
 variants we selected for EGF
234 
variants with high affinity binding to MDA-MB-453 cells that highly express ErbB-2 and ErbB-3 
receptors (chapter 3). The consensus sequence for optimal ErbB-2/ErbB-3 interaction in EGF was 
EGF/W2V3R4. The thus optimised EGF
234
 variants not only exerted enhanced affinities for cells 
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expressing ErbB-2/ErbB-3 heterodimers, but also for ErbB-3 homodimers, thereby strongly 
suggesting that the linear N-terminus of ligands is directly involved in binding to ErbB-3. The 
residues present in the N-terminus of the chimera T1E appear only sub-optimal for ErbB-3 binding, 
which may explain its dependency on ErbB-2 for high affinity interaction.  
Besides the EGF/TGFα chimera T1E, also distinct NRG isoforms differ in their ability to bind and 
activate distinct ErbB combinations. This differential recruitment of a coreceptor suggests that ligands 
may have a bivalent character and interact with both ErbB-3 and ErbB-2 through independent 
receptor binding sites. Since NRG isoforms vary only in their C-terminal sequences, we evaluated the 
role of the linear C-terminal region of EGF-like ligands for selective dimer formation by phage 
display (chapter 5). A library of T1E
46-50
 variants was subjected to selection for altered receptor 
selectivity and affinity, e.g. the ability to discriminate between ErbB-2 and ErbB-3 as dimerisation 
partners in ErbB-3 complexes. Our findings show that T1E can be strongly optimised for binding to 
ErbB-3 homodimers, indicating that residues in the linear C-terminal region contribute to the ability 
of ligands to bind ErbB-3. Despite negative selection protocols, these T1E
46-50
 variants were still 
potent ligands for ErbB-2/ErbB-3 heterodimers. In contrast, no sequences selective for ErbB-2 versus 
ErbB-3 could be identified, and T1E variants all retained a minimum level of ErbB-3 binding. 
Apparently the ErbB-3 affinity of a ligand determines whether it can form only ErbB-2/ErbB-3 
complexes (low affinity ligands) or also ErbB-3 homodimers (high affinity ligands), thereby coupling 
quantitative differences to a qualitative functional outcome. Our findings imply that ligands interact 
with ErbB-3 through a multi-domain interaction, involving both linear endings of the ligand, and 
argue against an independent binding site for ErbB-2.  
These results underscore a receptor-mediated dimerisation mechanism recently revealed by the crystal 
structure of the ligand-bound ErbB-1 homodimer, where the ligand induces a conformational change 
in the extracellular domain, leading to relief of an auto-inhibited state and exposure of a dimerisation 
loop. The multi-domain interaction with ErbB-3 suggests that ErbB-3 ligands bind their receptor in a 
similar manner as ErbB-1 ligands, where the ligand simultaneously contacts domain I and III of the 
same receptor. The affinity for both domains in ErbB-3 determines the ability of a ligand to induce the 
proper dimerisation conformation, and as ErbB-2 does not need prior ligand-binding it can readily 
stabilise ErbB-3 and drive the equilibrium towards ErbB-2/ErbB-3 heterodimers.  
Since T1E interacts with both ErbB-1 and ErbB-2/ErbB-3, we attempted to selectively impair only its 
ErbB-1 binding ability by mutation of critical residues (Leu15 and Leu47) that mediate domain III 
contacts within the EGF/ErbB-1 interface (chapter 4). However, in the context of the T1E molecule 
these residues do not contribute much to ErbB-1 binding nor ErbB specificity, since replacement for 
the equivalent NRG residues did not affect the binding properties of T1E. This suggests that T1E may 
bind domain III of ErbB-1 in a different manner compared to EGF. It thus seems that the relative 
orientation of a ligand binding domain I and III of a single receptor may differ between distinct EGF-
like ligands.  
In short, this thesis reveals which sequences in EGF-like ligands contribute to specific interaction with 
the ErbB-3 receptor, and provides insight how the relative binding affinity of ligands can determine 




Elke cel heeft een steeds veranderende omgeving. Om hierop te kunnen reageren heeft een cel de 
beschikking over een groot aantal receptoren, moleculaire antennes die worden gebruikt om 
signaalstoffen buiten de cel op te vangen. Binding van een signaalstof (een ligand) aan zijn specifieke 
receptor op het celoppervlak brengt een cascade van biochemische reacties binnen de cel op gang, 
welke uiteindelijk leiden tot veranderingen in het gedrag van de cel. Welke veranderingen dat zijn, 
hangt af van het type ligand en de daarbijbehorende receptor. Dit proces noemen we 
signaaltransductie: signalen van buiten de cel worden doorgegeven en vertaald naar de celkern. Een 
specifiek type liganden zijn groeifactoren. Zij kunnen de cel aanzetten tot bijvoorbeeld celdeling, 
vormverandering en verandering in migratiegedrag. Ontregeling van de signaaltransductie van 
groeifactor-receptoren kan leiden tot ongeremde celdeling, wat een karakteristieke eigenschap is van 
tumorcellen.  
Bij de groeifactoren onderscheiden we verschillende families. Eén daarvan is de familie van 
epidermale groeifactoren (EGF). Groeifactoren van de EGF-familie activeren hun bijpassende ErbB 
receptor door het vormen van paren of dimeren met een tweede receptor, waarbij zowel combinaties 
van dezelfde receptoren (zogenaamde homodimeren) als combinaties van twee verschillende 
receptoren (zogenaamde heterodimeren) mogelijk zijn. ErbB-2 is een ligand-loze receptor, en kan 
alleen geactiveerd worden door het vormen van heterodimeren met de drie andere ErbB receptoren. 
De meeste EGF-gerelateerde liganden hebben een sterke voorkeur voor het vormen van ErbB-2 
heterodimeren van hun receptor met ErbB-2. Dit resulteert in een sterkere en veelal langer durende 
signaaltransductie binnen de cel maar de wijze waarop de EGF-gerelateerde liganden specifiek deze 
ErbB-2 heterodimeren vormen is onduidelijk. In verschillende vormen van kanker van epitheliale 
origine, zoals borst- en longkanker, is het aantal ErbB-2 receptoren op het celoppervlak sterk 
verhoogd. Deze zogenaamde ErbB-2 overexpressie houdt verband met een agressief tumorfenotype 
en een slechte prognose voor de patient. Het ontwikkelen van nieuwe medicijnen tegen deze vorm van 
kanker behoeft een beter begrip van de moleculaire mechanismen die aan de basis liggen van de 
specifiek activatie van deze ErbB-2 receptor door een ligand.  
In dit proefschrift wordt onderzocht welk mechanisme ten grondslag ligt aan ErbB heterodimerisatie 
zoals veroorzaakt door EGF-gerelateerde liganden, en in het bijzonder welke aminozuren in liganden 
betrokken zijn bij selectieve ErbB receptorbinding en de daaropvolgende dimerisatie. Hierbij fungeert 
de ErbB-2/ErbB-3 heterodimer als model systeem. Omdat ErbB-2 geen ligand bindt, terwijl ErbB-3 
geen actieve kinase heeft, zijn beide receptoren alleen actief als ErbB heterodimeren. Bovendien zijn 
ErbB-2/ErbB-3 heterodimeren de meest voorkomende en mitogene receptoren die door neuregulin 
(NRG) geactiveerd worden.  
Eerdere studies wezen uit dat EGF in afwezigheid van zijn ErbB-1 receptor ook cellen die ErbB-2 en 
ErbB-3 receptoren hebben kan activeren. Om de bindings determinanten in EGF te identificeren die 
bijdragen aan deze eigenschap, hebben we domeinen binnen het EGF-molecuul uitgewisseld met 
delen van de verwante groeifactor TGFα. (hoofdstuk 2) Opmerkelijk genoeg bleken sommige van 
deze chimere liganden krachtiger dan EGF in het activeren van normale en borsttumorcellen met een 
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hoog expressie niveau van ErbB-2 en ErbB-3 receptoren. Het chimere ligand T1E, waarin het lineaire 
N-terminale uiteinde van EGF vervangen is voor die van TGFα, bindt met hoge affiniteit aan ErbB-
2/ErbB-3 receptoren, terwijl de binding met ErbB-1 eveneens behouden blijft. T1E bindt echter 
relatief zwak  aan cellen die alleen de ErbB-3 receptoren bevatten, wat aangeeft dat de aanwezigheid 
van ErbB-2 receptoren een voorwaarde is voor binding met een hoge affiniteit. Analyse van de 
diverse EGF/TGFα chimeren toont aan dat de combinatie van twee domeinen in een ligand bepalend 
is voor de specifieke binding aan ErbB-2/ErbB-3: het lineaire N-terminale uiteinde en de zogenaamde 
B-loop. Verdere analyse identificeert specifieke residuen in de N-terminus (His2 en Phe3, zoals 
aanwezig in TGFα) als belangrijke determinanten interactie met ErbB-2 en ErbB-3. In de B-loop van 
EGF blijkt de aanwezigheid van Leu26 binding te faciliteren, terwijl het negatief geladen Glu27 in de 
B-loop van TGFα juist de binding van deze groeifactor aan ErbB-2/ErbB-3 verstoort. Deze 
bevindingen tonen aan dat de selectiviteit in de interactie tussen ligand en receptor niet alleen wordt 
bepaald door aminozuren die contact maken met de receptor, maar eveneens door aminozuren die 
binding aan andere ErbB receptoren voorkomen. 
Gezien het belang van de linaire N-terminale staart voor de toegenomen specificiteit van EGF voor 
ErbB-2/ErbB-3 heterodimeren, is nader onderzocht welke aminozuur volgorde in dit domein 
noodzakelijk en optimaal is voor interactie met de receptor. Door gebruik te maken van phage display 
zijn varianten van EGF geoptimaliseerd voor binding met hoge affiniteit aan ErbB-2 en ErbB-3 
receptoren door te selecteren op borst tumor cellen die deze receptoren tot expressie brengen 
(hoofdstuk 3). De geselecteerde EGF
234
 varianten bleken niet alleen een verhoogde affiniteit voor 
ErbB-2/ErbB-3 heterodimeren te vertonen, maar deden dit ook voor ErbB-3 homodimeren. Dit is een 
sterke aanwijzing dat het lineaire N-terminale uiteinde van EGF-gerelateerde liganden direct 
betrokken is bij binding aan ErbB-3. De consensus sequentie voor optimale ErbB-2/ErbB-3 interactie 
in de geisoleerde EGF
234
 varianten was EGF/W2V3R4. De residuen aanwezig in het N-terminale 
uiteinde van de chimera T1E bleken suboptimaal voor binding met ErbB-3. Dit verklaart mogelijk de 
afhankelijkheid van ErbB-2 voor binding met een hoge affiniteit. 
Behalve de EGF/TGFα chimera T1E hebben ook de diverse NRG isoformen nogal verschillende 
voorkeuren en bindings affiniteiten voor bepaalde ErbB combinaties. Dit verschil in potentie om te 
dimeriseren met een bepaalde co-receptor suggereert dat deze liganden mogelijk een bivalent karakter 
hebben, en dat de interactie met ErbB-2 en ErbB-3 plaatsvindt via twee onafhankelijke bindings 
domeinen. Omdat de NRG-isovormen enkel varieren in sequentie van hun C-terminale domein, is het 
lineaire C-terminale uiteinde geanalyseerd met betrekking tot een rol in de formatie van selectieve 
dimeren met ErbB-2 danwel ErbB-3 in ErbB-3 complexen. Hiervoor is wederom de phage display 
techniek toegepast, ditmaal voor het optimaliseren van T1E voor affiniteit én selectiviteit voor 
verschillende ErbB combinaties. Zo is bijvoorbeeld gekeken naar hun vermogen om onderscheid te 
maken tussen ErbB-2 en ErbB-3 als dimerisatiepartners in ErbB-3 complexen. Onze resultaten 
toonden aan dat T1E nog sterk geoptimaliseerd kan worden voor binding met ErbB-3 homodimeren. 
Dit wijst erop dat residuen in het lineaire C-terminale uiteinde eveneens direct kunnen bijdragen aan 
het vermogen van liganden om te binden aan ErbB-3. Ondanks negatieve selectie strategieën bleken 
deze T1E varianten krachtige liganden voor ErbB-2/ErbB-3 heterodimeren. Daarentegen zijn geen 
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sequenties gevonden in T1E varianten die selectiviteit voor ErbB-2 waarborgen. Deze bevindingen 
impliceren dat de interactie tussen liganden en ErbB-3 plaats heeft via interactie op meerdere 
domeinen. Hierbij zijn beide uiteinden van het ligand betrokken. Onafhankelijke bindingsdomeinen 
voor ErbB-2 lijken niet te bestaan. Klaarblijkelijk bepaalt de affiniteit van een ligand voor ErbB-3 of 
het ErbB-2/ErbB-3 heterodimeren kan vormen (liganden met lage affiniteit) of ook ErbB-3 
homodimeren (liganden met hoge affiniteit), waardoor kwantitatieve verschillen gekoppeld worden 
aan een kwalitatieve functionele uitkomst. 
Deze resultaten onderstrepen een receptor-gemedieerd mechanisme voor ErbB dimerisatie, zoals 
onlangs is gebleken uit de opheldering van de kristalstructuur van ligand gebonden ErbB-1 
homodimeren. Doordat het ligand bindt aan domein I en III van hetzelfde ErbB-1 molecuul 
veroorzaakt het een vormverandering in het extracellulaire domein van de receptor, waardoor een 
loop vrijgemaakt wordt die kan fungeren als dimerisatie-arm. De interactie op meerdere domeinen 
met ErbB-3 suggereert dat ErbB-3 liganden op een gelijke manier met hun receptor binden als ErbB-1 
liganden. Immers, het ErbB-1 ligand maakt op meerdere plekken contact met de domeinen I en III van 
dezelfde receptor. De affiniteit voor beide domeinen in ErbB-3 bepaalt het vermogen van een ligand 
om dimerisatie tot stand te brengen. En omdat ErbB-2 geen eerdere binding met het ligand nodig 
heeft, kan het ErbB-3 stabiliseren en het evenwicht van ErbB-2/ErbB-3 heterodimeren in stand helpen 
houden. 
Gezien het feit dat T1E zowel ErbB-1 als ErbB-2/ErbB-3 kan binden, is getracht het vermogen van 
T1E om met ErbB-1 te binden selectief weg te nemen. Dit is gedaan door cruciale residuen (Leu15 en 
Leu47) te muteren die in EGF contact maken met het domein III in ErbB-1 (hoofdstuk 4) Deze 
individuele residuen blijken echter in het T1E molecuul niet erg van belang voor binding met ErbB-1, 
of voor de ErbB receptor specificiteit, want deze residuen kunnen zonder meer vervangen worden 
door de equivalente NRG-1β residuen. Dit suggereert dat T1E op een andere manier dan EGF bindt 
met domein III van ErbB-1. Het lijkt daarmee dat de relatieve oriëntatie van een ligand voor de 
bindingsdomeinen I en III van een individuele receptor voor specifieke EGF-gerelateerde liganden 
van elkaar verschillen. 
Resumerend, dit proefschrift laat zien welke sequenties in EGF-gerelateerde liganden bijdragen aan 
specifieke interactie met de ErbB-3 receptor, en draagt bij aan het inzicht hoe de relatieve 
bindingsaffiniteit van een ligand voor een receptor bepalend is voor welke ErbB-dimeer combinaties 
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